Tricyclic compound and application thereof

CN118900841APending Publication Date: 2024-11-05CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380009530.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-02-20
Filing Date
2023-06-26
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

Existing MAT2A inhibitors suffer from insufficient selectivity and efficacy in the treatment and prevention of MAT2A-mediated diseases, symptoms, and conditions, particularly in tumors lacking MTAP, where their application is limited.

Method used

A novel class of MAT2A inhibitor compounds has been developed. These compounds possess specific chemical structures that can effectively inhibit the activity of the MAT2A enzyme, thereby reducing the concentration of the methyl donor S-adenosylmethionine, affecting mRNA splicing in tumor cells and causing DNA damage. This can be used to treat and prevent MAT2A-mediated diseases.

Benefits of technology

This novel MAT2A inhibitor compound exhibits high selectivity and efficacy, particularly in MTAP-deficient tumors, where it significantly inhibits tumor cell growth and migration, offering potential therapeutic and preventative benefits for MAT2A-mediated diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118900841A_ABST
    Figure CN118900841A_ABST
Patent Text Reader

Abstract

The invention provides a compound as shown in a formula (I), or a tautomer, a stereoisomer or a pharmaceutically acceptable salt thereof. The compound disclosed by the invention has a relatively strong MAT2A inhibition effect, and has medical application of treating and / or preventing MAT2A-mediated diseases, symptoms and conditions, such as tumors and the like. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Tricyclic compounds and uses thereof

[0001] This application claims priority to Chinese patent applications with application number 202210734328.0 filed with the China Patent Office on June 27, 2022, application number 202211120467.0 filed with the China Patent Office on September 15, 2022, and application number 202310135765.5 filed with the China Patent Office on February 20, 2023, the entire contents of which are incorporated by reference into this application. Technical Field

[0002] The present invention relates to the field of medical technology, and in particular, to a class of novel compounds having MAT2A inhibitory effects and their use in treating and preventing diseases, disorders and conditions mediated by MAT2A, such as tumors. Background Art

[0003] MAT2A stands for Methionine adenosyltransferase 2A, also known as S-Adenosylmethionine Synthase Isoform Type.

[0004] MAT2A is expressed in all tissues, including red blood cells, brain, fetal liver, kidney, and pancreas, but is less abundant in adult liver. Higher expression of MAT2A and MAT2B contributes to cancer cell growth, migration, and invasion. Overall, lower expression of MAT2A and MAT2B leads to increased apoptosis and decreased cell growth, migration, and metastasis.

[0005] MTAP is a methionine transferase that catalyzes the transfer of adenylate and plays an important role in the salvage synthesis of ATP. MTAP deficiency accounts for approximately 15% of all solid tumors. MTAP is deficient to varying degrees in many types of tumors. MTAP deficiency leads to the accumulation of the enzyme substrate methylthioadenosine (MTA). Increased MTA concentrations partially inhibit the activity of PRMT5, while other methyltransferases are relatively unaffected. Inhibiting MAT2A reduces the methyl donor S-adenosylmethionine (SAM), which is a substrate of PRMT5, thereby further inhibiting PRMT5, affecting tumor cell mRNA splicing and causing DNA damage. Therefore, MAT2A inhibitors can benefit tumors with MTAP deficiency.

[0006] Several patents have disclosed MAT2A inhibitors, such as WO2018039972, WO2019191470, WO2020139991, WO2020139992, WO2020243376, and WO2020123395.

[0007] Summary of the Invention

[0008] The present invention provides a class of MAT2A inhibitor compounds with novel structures, or their tautomers, stereoisomers, or pharmaceutically acceptable salts, and also provides the use of such compounds, or their tautomers, stereoisomers, or pharmaceutically acceptable salts, for treating and preventing diseases, disorders, and conditions mediated by MAT2A.

[0009] Specifically, in a first aspect, the present invention provides a compound represented by formula (I), or a tautomer, stereoisomer, or pharmaceutically acceptable salt thereof, which has the following structure:

[0010] in,

[0011] Ring A is selected from C 5-10 Carbocyclic group, C 6-14 Aryl, 5-12 membered heteroaryl, 5-12 membered heterocyclyl;

[0012] R 1 Selected from optionally substituted C 3-12 Carbocyclic group, C 6-14 Aryl, 5-14 membered heteroaryl, 5-14 membered heterocyclic group; the carbocyclic group, aryl, heteroaryl, heterocyclic group are optionally replaced by one or more R a replaced by;

[0013] L is selected from a bond, -O-, -S-, -C 1-4 Alkylene-, -OC 1-4 Alkylene-, -C(O)-, -C(O)O-, -OC(O)-, -N(R a1 )C(O)-、-C(O)N(R a1 )-or-N(R a1 )-; the alkylene group is optionally replaced by one or more R a1 replaced by;

[0014] R a Each occurrence is independently selected from deuterium, halogen, oxo, -CN, -OH, -SH, -NO2, -NH2, -W-OR a1 、-W-SR a1 、-WC(O)R a4 、-WC(O)OR a1 、-W-OC(O)R a1 、-W-OC(O)OR a1 、-WC(O)NR a2 R a3 、-WC(O)NR a2 OR a1 、-W-OC(O)NRa2 R a3 、-W-NR a2 R a3 、-W-NR a2 C(O)R a4 、-W-NR a2 C(O)OR a1 、-W-NR a2 C(O)NR a2 R a3 、-WS(O)R a4 、-WS(O)2R a4 、-W-SO2NR a2 R a3 、-W-NR a2 S(O)2R a4 、-W-OS(O)2R a4 、-W-NR a2 S(O)2NR a2 R a3 、-W-OS(O)2NR a2 R a3 、C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-10 Cycloalkyl, C 3-10 Cycloalkenyl, C 6-14 Aryl, 3-12 membered heterocyclic group, 5-16 membered heteroaryl; the alkyl, alkenyl, alkynyl, alkoxy, alkylthio, cycloalkyl, cycloalkenyl, aryl, heterocyclic group, heteroaryl are optionally substituted by one or more selected from deuterium, halogen, oxo, oxime, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, C 6-14 Aryl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Substituted by a halogenated alkoxy group or a halogenated phenyl group;

[0015] R a1 Each occurrence is independently hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-10 Cycloalkyl, C 6-14 Aryl, 5-12 membered heteroaryl, 3-20 membered heterocyclic group, wherein alkyl, alkoxy, cycloalkyl, aryl, heteroaryl, heterocyclic group are optionally substituted by one or more selected from halogen, deuterium, cyano, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 6-14 Aryl, C1-6 Halogenated alkyl, C 1-6 Substituted by a halogenated alkoxy group or a halogenated phenyl group;

[0016] R a2 and R a3 Each occurrence is independently hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Alkoxy, wherein alkyl, alkoxy is optionally substituted by one or more selected from halogen, deuterium, cyano, hydroxyl, amino, carboxyl, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkyl, C 3-8 Cycloalkyl, phenyl, C 1-6 Halogenated alkyl, C 1-6 substituted by a halogenated alkoxy or halogenated phenyl group; or when R a2 and R a3 When connected to the same nitrogen atom, R a2 and R a3 Together with the nitrogen atoms to which they are attached, they form groups that are substituted by halogen, hydroxyl, amino, nitro, mercapto, cyano, oxo, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-10 Cycloalkyl, 3-10 membered heterocycloalkyl, C 6-14 aryl, 5-12 membered heteroaryl, or one or more optionally substituted 3-10 membered heterocycloalkyl or 5-12 membered heteroaryl;

[0017] R a4 Each occurrence is independently hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, C 6-14 Aryl, 5-12 membered heteroaryl, 3-20 membered heterocyclic group, wherein alkyl, alkoxy, cycloalkyl, aryl, heteroaryl, heterocyclic group are optionally substituted by one or more selected from halogen, deuterium, cyano, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, phenyl, C 1-6 Halogenated alkyl, C 1-6 Substituted by a halogenated alkoxy group or a halogenated phenyl group;

[0018] X is N or CR 6 ;

[0019] R 2 、R 3 and R 6 Each independently selected from hydrogen, deuterium, halogen, -CN, -OH, -SH, -NO2, -NH2, -W-OR b1 、-W-SR b1、-WC(O)R b4 、-WC(O)OR b1 、-W-OC(O)R b1 、-W-OC(O)OR b1 、-WC(O)NR b2 R b3 、-WC(O)NR b2 OR b1 、-W-OC(O)NR b2 R b3 、-W-NR b2 R b3 、-W-NR b2 C(O)R b4 、-W-NR b2 C(O)OR b1 、-W-NR b2 C(O)NR b2 R b3 、-WS(O)R b4 、-WS(O)2R b4 、-W-SO2NR b2 R b3 、-W-NR b2 S(O)2R b4 、-W-OS(O)2R b4 、-W-NR b2 S(O)2NR b2 R b3 、-W-OS(O)2NR b2 R b3 、C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-10 Cycloalkyl, C 3-10 Cycloalkenyl, C 6-14 Aryl, 3-12 membered heterocyclic group, 5-16 membered heteroaryl; the alkyl, alkenyl, alkynyl, alkoxy, alkylthio, cycloalkyl, cycloalkenyl, aryl, heterocyclic group, heteroaryl are optionally substituted by one or more selected from deuterium, halogen, oxo, oxime, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, C 6-14 Aryl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Substituted by a halogenated alkoxy group or a halogenated phenyl group;

[0020] R b1 Each occurrence is independently hydrogen, deuterium, C1-6 Alkyl, C 1-6 Alkoxy, C 3-10 Cycloalkyl, C 6-14 Aryl, 3-20 membered heterocyclic group, wherein alkyl, alkoxy, cycloalkyl, aryl, heterocyclic group is optionally substituted by one or more selected from halogen, deuterium, cyano, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 6-14 Aryl, C 1-6 Halogenated alkyl, C 1-6 Substituted by a halogenated alkoxy group or a halogenated phenyl group;

[0021] R b2 and R b3 Each occurrence is independently hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Alkoxy, wherein alkyl, alkoxy is optionally substituted by one or more selected from halogen, deuterium, cyano, hydroxyl, amino, carboxyl, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkyl, C 3-8 Cycloalkyl, phenyl, C 1-6 Halogenated alkyl, C 1-6 substituted by a halogenated alkoxy or halogenated phenyl group; or when R b2 and R b3 When connected to the same nitrogen atom, R b2 and R b3 Together with the nitrogen atoms to which they are attached, they form groups that are substituted by halogen, hydroxyl, amino, nitro, mercapto, cyano, oxo, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-10 Cycloalkyl, 3-10 membered heterocycloalkyl, C 6-14 aryl, 5-12 membered heteroaryl, or one or more optionally substituted 3-10 membered heterocycloalkyl or 5-12 membered heteroaryl;

[0022] R b4 Each occurrence is independently hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, C 6-14 Aryl, 3-20 membered heterocyclic group, wherein alkyl, alkoxy, cycloalkyl, aryl, heterocyclic group is optionally substituted by one or more selected from halogen, deuterium, cyano, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 6-14 Aryl, C 1-6 Halogenated alkyl, C 1-6 Substituted by a halogenated alkoxy group or a halogenated phenyl group;

[0023] R 4 and R 5 Each independently selected from hydrogen, deuterium, halogen, oxime, -CN, -OH, -SH, -NO2, -NH2, -W-OR c1 、-W-SR c1 、-WC(O)R c4 、-WC(O)OR c1 、-W-OC(O)R c1 、-W-OC(O)OR c1 、-WC(O)NR c2 R c3 、-WC(O)NR c2 OR c1 、-W-OC(O)NR c2 R c3 、-W-NR c2 R c3 、-W-NR c2 C(O)R c4 、-W-NR c2 C(O)OR c1 、-W-NR c2 C(O)NR c2 R c3 、-WS(O)R c4 、-WS(O)2R c4 、-W-SO2NR c2 R c3 、-W-NR c2 S(O)2R c4 、-W-OS(O)2R c4 、-W-NR c2 S(O)2NR c2 R c3 、-W-OS(O)2NR c2 R c3 、C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-10 Cycloalkyl, C 3-10 Cycloalkenyl, C 6-14 Aryl, 3-12 membered heterocyclic group, 5-16 membered heteroaryl; the alkyl, alkenyl, alkynyl, haloalkyl, haloalkoxy, alkoxy, alkylthio, cycloalkyl, cycloalkenyl, heterocyclic group, aryl, heteroaryl are optionally substituted with one or more R c replaced by; or R 4 and R 5Attached to the same, adjacent or separated by one atom ring atoms, and the carbon or nitrogen atom to which it is attached together form an optionally substituted C 3-10 Cycloalkyl, C 6-14 Aryl, 5-12 membered heteroaryl, 5-12 membered heterocyclic group; the optional substitution means that the hydrogen on the substituted group is not replaced or one or more substitutable sites of the substituted group are independently selected from R c substituted by a substituent;

[0024] R c independently selected from deuterium, halogen, oxime, -CN, -OH, -SH, -NO2, -NH2, -W-OR c1 、-W-SR c1 、-WC(O)R c4 、-WC(O)OR c1 、-W-OC(O)R c1 、-W-OC(O)OR c1 、-WC(O)NR c2 R c3 、-WC(O)NR c2 OR c1 、-W-OC(O)NR c2 R c3 、-W-NR c2 R c3 、-W-NR c2 C(O)R c4 、-W-NR c2 C(O)OR c1 、-W-NR c2 C(O)NR c2 R c3 、-WS(O)R c4 、-WS(O)2R c4 、-W-SO2NR c2 R c3 、-W-NR c2 S(O)2R c4 、-W-OS(O)2R c4 、-W-NR c2 S(O)2NR c2 R c3 、-W-OS(O)2NR c2 R c3 、C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-10 Cycloalkyl, C 3-10Cycloalkenyl, 3-12 membered heterocyclyl, 5-16 membered heteroaryl; the alkyl, alkenyl, alkynyl, alkoxy, alkylthio, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl are optionally substituted by one or more selected from deuterium, halogen, oxo, oxime, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, C 6-14 Aryl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Substituted by a halogenated alkoxy group or a halogenated phenyl group;

[0025] R c1 Each occurrence is independently hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-10 Cycloalkyl, C 6-14 Aryl, 3-20 membered heterocyclic group, wherein alkyl, alkoxy, cycloalkyl, aryl, heterocyclic group is optionally substituted by one or more selected from halogen, deuterium, cyano, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 6-14 Aryl, C 1-6 Halogenated alkyl, C 1-6 Substituted by a halogenated alkoxy group or a halogenated phenyl group;

[0026] R c2 and R c3 Each occurrence is independently hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Alkoxy, wherein alkyl, alkoxy is optionally substituted by one or more selected from halogen, deuterium, cyano, hydroxyl, amino, carboxyl, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkyl, C 3-8 Cycloalkyl, phenyl, C 1-6 Halogenated alkyl, C 1-6 substituted by a halogenated alkoxy or halogenated phenyl group; or when R c2 and R c3 When connected to the same nitrogen atom, R c2 and R c3 Together with the nitrogen atoms to which they are attached, they form groups that are substituted by halogen, hydroxyl, amino, nitro, mercapto, cyano, oxo, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-10 Cycloalkyl, 3-10 membered heterocycloalkyl, C 6-14 aryl, 5-12 membered heteroaryl, or one or more optionally substituted 3-10 membered heterocycloalkyl or 5-12 membered heteroaryl;

[0027] Rc4 Each occurrence is independently hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, C 6-14 Aryl, 3-20 membered heterocyclic group, wherein alkyl, alkoxy, cycloalkyl, aryl, heterocyclic group is optionally substituted by one or more selected from halogen, deuterium, cyano, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 6-14 Aryl, C 1-6 Halogenated alkyl, C 1-6 Substituted by a halogenated alkoxy group or a halogenated phenyl group;

[0028] W is selected from a bond, C 1-3 Alkylene, -OC 1-3 Alkylene, -SC 1-3 Alkylene, wherein the alkylene is optionally substituted with one or more substituents selected from deuterium, halogen, oxo, -CN, -OH, -NH2;

[0029] Unless otherwise specified, the heteroatoms in the heterocyclic group and heteroaryl group are independently selected from O, N or S, and the number of heteroatoms is 1, 2 or 3.

[0030] In a further preferred embodiment, wherein Ring A is selected from C 5-10 Cycloalkyl, C 6-10 Aryl, 5-10 membered heteroaryl, 5-10 membered heterocyclyl;

[0031] In a further preferred embodiment, wherein Ring A is selected from C 5-10 Cycloalkyl, C6 aryl, 5-8 membered heteroaryl, 5-10 membered heterocyclyl;

[0032] In a further preferred embodiment, wherein Ring A is selected from C 5-10 Cycloalkyl, 5-10 membered heterocyclic group;

[0033] In a further preferred embodiment, wherein Ring A is selected from a 5-10 membered heterocyclyl;

[0034] In a further preferred embodiment, wherein Ring A is selected from a 5-8 membered heterocyclic group;

[0035] In a further preferred embodiment, wherein, Ring A is selected from a 5-7 membered heterocyclic group, the heteroatoms are independently selected from O or N, and the number of heteroatoms is 1 or 2;

[0036] In a further preferred embodiment, wherein ring A is selected from a 5-6 membered heterocyclic group, the heteroatoms are independently selected from O or N, and the number of heteroatoms is 1 or 2;

[0037] In a further preferred embodiment, wherein, Ring A is selected from a 5-6 membered heterocyclic group, the heteroatom is selected from N, and the number of heteroatoms is 1 or 2;

[0038] In a further preferred embodiment, wherein, Ring A is selected from a 5-membered heterocyclic group, the heteroatoms are independently selected from O or N, and the number of heteroatoms is 1 or 2;

[0039] In a further preferred embodiment, wherein, Ring A is selected from a 5-membered heterocyclic group, the heteroatom is selected from N, and the number of heteroatoms is 1 or 2;

[0040] In a further preferred embodiment, wherein ring A is selected from

[0041] In a further preferred embodiment, wherein ring A is selected from

[0042] In a further preferred embodiment, wherein ring A is selected from

[0043] In a further preferred embodiment, wherein ring A is selected from

[0044] In a further preferred embodiment, wherein X is selected from N or CH;

[0045] In a further preferred embodiment, wherein X is selected from N;

[0046] In a further preferred embodiment, wherein X is selected from CH.

[0047] In a further preferred embodiment, wherein R 1 Selected from optionally substituted C 3-10 Cycloalkyl, C 5-10 Bridged cycloalkyl, C 5-10 Condensed cycloalkyl, C 5-10 Spiroalkyl, C 6-10 aryl, 5-10 membered heteroaryl, 5-10 membered monocyclic heterocyclic group, 5-10 membered bridged heterocyclic group, 5-10 membered fused heterocyclic group, 5-10 membered spiro heterocyclic group; the cycloalkyl, bridged cycloalkyl, fused cycloalkyl, spiro cycloalkyl, aryl, heteroaryl, monocyclic heterocyclic group, bridged heterocyclic group, fused heterocyclic group and spiro heterocyclic group are optionally replaced by one or more R a replaced by;

[0048] In a further preferred embodiment, wherein R 1 Selected from optionally substituted C 3-6 Cycloalkyl, C 5-10 Condensed cycloalkyl, C 5-10 Spiroalkyl, C 6-10Aryl, 5-10 membered heteroaryl, 5-10 membered monocyclic heterocyclic group, 5-10 membered bridged heterocyclic group, 5-10 membered fused heterocyclic group, 5-10 membered spiro heterocyclic group; the cycloalkyl, fused cycloalkyl, spiroalkyl, aryl, heteroaryl, monocyclic heterocyclic group, bridged heterocyclic group, fused heterocyclic group and spiro heterocyclic group are optionally replaced by one or more R a replaced by;

[0049] In a further preferred embodiment, wherein R 1 Selected from optionally substituted C 6-10 Aryl, 5-10 membered heteroaryl, 5-10 membered monocyclic heterocyclic group, 5-10 membered bridged heterocyclic group, 5-10 membered fused heterocyclic group, 5-10 membered spiro heterocyclic group; the aryl, heteroaryl, monocyclic heterocyclic group, bridged heterocyclic group, fused heterocyclic group and spiro heterocyclic group are optionally substituted by one or more R a replaced by;

[0050] In a further preferred embodiment, wherein R 1 Selected from optionally substituted C 6-10 Aryl, 5-8 membered heteroaryl, 5-8 membered monocyclic heterocyclic group, 5-8 membered bridged heterocyclic group, 5-8 membered fused heterocyclic group, 5-8 membered spiro heterocyclic group; the aryl, heteroaryl, monocyclic heterocyclic group, bridged heterocyclic group, fused heterocyclic group and spiro heterocyclic group are optionally substituted by one or more R a replaced by;

[0051] In a further preferred embodiment, wherein R 1 Selected from optionally substituted C6 aryl, 5-8 membered heteroaryl, 5-8 membered monocyclic heterocyclic group; the aryl, heteroaryl, monocyclic heterocyclic group is optionally substituted by one or more R a replaced by;

[0052] In a further preferred embodiment, wherein R 1 is selected from optionally substituted C6 aryl, 5-6 membered heteroaryl, 5-6 membered monocyclic heterocyclic group; the aryl, heteroaryl, monocyclic heterocyclic group is optionally substituted by one or more R a substituted; heteroatoms are independently selected from O, N, and the number of heteroatoms is 1 or 2;

[0053] In a further preferred embodiment, wherein R 1 Selected from optionally substituted C6 aryl, 5-6 membered heteroaryl; the aryl, heteroaryl are optionally substituted by one or more R a substituted; heteroatoms are independently selected from N, and the number of heteroatoms is 1 or 2;

[0054] In a further preferred embodiment, wherein R 1 Selected from optionally one or more R a substituted phenyl, pyridyl or imidazolyl;

[0055] In a further preferred embodiment, wherein R 1 Selected from optionally one or more R a substituted pyridyl;

[0056] In a further preferred embodiment, wherein R 1 Selected from

[0057] In a further preferred embodiment, wherein R 1 Selected from

[0058] In a further preferred embodiment, wherein L is selected from a bond, -O-, -S-, -C 1-4 Alkylene- or -OC 1-4 Alkylene-; the alkylene group is optionally substituted by one or more substituents selected from deuterium, halogen, oxo, -CN, -OH, -NH2;

[0059] In a further preferred embodiment, wherein L is selected from a bond, -O-, -S-, -C 1-2 Alkylene- or -OC 1-2 Alkylene-; the alkylene group is optionally substituted by one or more substituents selected from deuterium, halogen, oxo, -CN, -OH, -NH2;

[0060] In a further preferred embodiment, wherein L is selected from a bond, -O-, -S-, methylene or ethylene; said methylene or ethylene is optionally substituted with one or more substituents selected from deuterium, halogen, oxo, -CN, -OH, -NH2;

[0061] In a further preferred embodiment, wherein L is selected from a bond, -O-, methylene or ethylene;

[0062] In a further preferred embodiment, wherein L is selected from a bond or a methylene group;

[0063] In a further preferred embodiment, wherein L is selected from a bond.

[0064] In a further preferred embodiment, wherein R a Each occurrence is independently selected from deuterium, halogen, -CN, -OH, -SH, -NO2, -NH2, -W-OR a1 、-W-SR a1 、-WC(O)R a4 、-WC(O)OR a1 、-W-OC(O)R a1 、-WC(O)NRa2 R a3 、-W-OC(O)NR a2 R a3 、-W-NR a2 R a3 、-W-NR a2 C(O)R a4 、-WS(O)R a4 、-WS(O)2R a4 、-W-SO2NR a2 R a3 、-W-NR a2 S(O)2R a4 、-W-OS(O)2R a4 、C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-10 Cycloalkyl, 3-12 membered heterocyclic group, 5-16 membered heteroaryl; the alkyl, alkenyl, alkynyl, alkoxy, alkylthio, cycloalkyl, heterocyclic group, heteroaryl are optionally substituted by one or more selected from deuterium, halogen, oxo, oxime, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, phenyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Substituted by a halogenated alkoxy group or a halogenated phenyl group;

[0065] In a further preferred embodiment, wherein R a Each occurrence is independently selected from deuterium, halogen, -CN, -OH, -SH, -NO2, -NH2, -W-OR a1 、-W-SR a1 、-WC(O)R a4 、-WC(O)OR a1 、-W-OC(O)R a1 、-WC(O)NR a2 R a3 、-W-NR a2 R a3 、 -W-NR a2 C(O)R a4 、-WS(O)R a4 、-WS(O)2R a4 、-W-SO2NR a2 R a3 、-W-NR a2 S(O)2R a4 、C 1-6Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-10 Cycloalkyl, 5-10 membered heterocyclic group, 5-10 membered heteroaryl; the alkyl, alkenyl, alkynyl, alkoxy, alkylthio, cycloalkyl, heterocyclic group, heteroaryl are optionally substituted by one or more selected from deuterium, halogen, oxo, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 substituted by a haloalkoxy substituent;

[0066] In a further preferred embodiment, wherein R a Each occurrence is independently selected from deuterium, halogen, -CN, -OH, -SH, -NO2, -NH2, -W-OR a1 、-W-SR a1 、-WC(O)R a4 、-WC(O)OR a1 、-W-OC(O)R a1 、-WC(O)NR a2 R a3 、-W-NR a2 R a3 、-W-NR a2 C(O)R a4 、-WS(O)2R a4 、-W-SO2NR a2 R a3 、-W-NR a2 S(O)2R a4 、C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy; the alkyl, alkenyl, alkynyl, alkoxy may be optionally substituted with one or more selected from deuterium, halogen, oxo, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 substituted by a haloalkoxy substituent;

[0067] In a further preferred embodiment, wherein R a Each occurrence is independently selected from deuterium, halogen, -CN, -OH, -NH2, -W-OR a1 、-W-SR a1 、-WC(O)Ra4 、-WC(O)OR a1 、-W-OC(O)R a1 、-W-NR a2 C(O)R a4 、-C 1-4 Alkyl, C 1-4 Alkoxy; the alkyl and alkoxy groups are optionally substituted by one or more selected from deuterium, halogen, oxo, -CN, -OH, -NO2, -NH2, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent;

[0068] In a further preferred embodiment, wherein R a Each occurrence is independently selected from deuterium, halogen, -OH, -NH2, -W-NR a2 C(O)R a4 、C 1-4 Alkyl, C 1-4 Alkoxy; the alkyl and alkoxy groups are optionally substituted by one or more groups selected from deuterium, halogen, oxo, -OH, -NH2, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl, C 1-4 substituted by a haloalkoxy substituent;

[0069] In a further preferred embodiment, wherein R a Each occurrence is independently selected from deuterium, halogen, C 1-4 Alkyl, -W-NR a2 C(O)R a4 、C 1-4 Haloalkyl; said alkyl or haloalkyl is optionally substituted with one or more deuterium;

[0070] In a further preferred embodiment, wherein R a Each occurrence is independently selected from deuterium, halogen, C 1-4 Alkyl, C 1-4 Alkoxy, -W-NR a2 C(O)R a4 ; The alkyl or haloalkyl group is optionally substituted with one or more deuterium groups;

[0071] In a further preferred embodiment, wherein R a Each occurrence is independently selected from deuterium, halogen, C 1-4 Alkyl, C 1-4 Alkoxy, -NHC(O)R a4 ; The alkyl group is optionally substituted with one or more deuterium groups;

[0072] In a further preferred embodiment, wherein R a Each occurrence is independently selected from halogen, C 1-4 Alkyl, C 1-4 alkoxy;

[0073] In a further preferred embodiment, wherein R a is independently selected at each occurrence from deuterium, F, Cl, Br, methyl, ethyl, propyl, methoxy, ethoxy, trifluoromethyl, trifluoroethyl, or -NHC(O)-phenyl;

[0074] In a further preferred embodiment, wherein R a Each occurrence is independently selected from Cl, methyl, methoxy, or -NHC(O)-phenyl;

[0075] In a further preferred embodiment, wherein R a Each occurrence is independently selected from Cl, methyl or -NHC(O)-phenyl.

[0076] In a further preferred embodiment, wherein R a1 Each occurrence is independently hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 6-10 Aryl, 3-10 membered heterocyclic group, wherein alkyl, alkoxy, cycloalkyl, aryl, heterocyclic group is optionally substituted by one or more selected from halogen, deuterium, cyano, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 The substituents of the haloalkoxy group are substituted; the heteroatoms are independently selected from O, N or S, and the number of heteroatoms is 1, 2 or 3;

[0077] In a further preferred embodiment, wherein R a1 Each occurrence is independently hydrogen, deuterium, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 6-10 Aryl, 3-8 membered heterocyclic group, wherein alkyl, alkoxy, cycloalkyl, aryl, heterocyclic group is optionally substituted by one or more selected from halogen, deuterium, cyano, hydroxyl, amino, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl, C 1-4 The substituent is substituted by a haloalkoxy group; the heteroatoms are independently selected from O and N, and the number of heteroatoms is 1 or 2;

[0078] In a further preferred embodiment, wherein Ra1 Each occurrence is independently hydrogen, deuterium, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C6 aryl, 5-6 membered heterocyclic group, wherein alkyl, alkoxy, cycloalkyl, aryl, heterocyclic group is optionally substituted by one or more selected from halogen, deuterium, hydroxyl, amino, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl, C 1-4 The substituent is substituted by a haloalkoxy group; the heteroatoms are independently selected from O and N, and the number of heteroatoms is 1 or 2;

[0079] In a further preferred embodiment, wherein R a1 Each occurrence is independently hydrogen, deuterium, methyl, ethyl, propyl, methoxy, ethoxy or propoxy, wherein methyl, ethyl, propyl, methoxy, ethoxy or propoxy is optionally replaced by one or more selected from halogen, deuterium, hydroxy, amino, C 1-4 substituted by an alkyl substituent;

[0080] In a further preferred embodiment, wherein R a1 Each occurrence is independently hydrogen, methyl, ethyl, propyl, wherein methyl, ethyl, propyl is optionally substituted by one or more selected from halogen, deuterium, hydroxyl, amino, C 1-4 substituted by an alkyl substituent.

[0081] In a further preferred embodiment, wherein R a2 and R a3 Each occurrence is independently hydrogen, deuterium, C 1-4 Alkyl, C 1-4 Alkoxy, wherein alkyl, alkoxy is optionally substituted by one or more selected from halogen, deuterium, hydroxyl, amino, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl, C 1-4 substituted by a haloalkoxy substituent;

[0082] In a further preferred embodiment, wherein R a2 and R a3 Each occurrence is independently hydrogen, deuterium, C 1-4 Alkyl, C 1-4 Alkoxy, wherein alkyl, alkoxy is optionally substituted by one or more selected from halogen, deuterium, hydroxyl, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent;

[0083] In a further preferred embodiment, wherein R a2 and Ra3 Each occurrence is independently hydrogen, deuterium, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, wherein methyl, ethyl, propyl, methoxy, ethoxy, propoxy is optionally replaced by one or more selected from halogen, deuterium, hydroxyl, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent;

[0084] In a further preferred embodiment, wherein R a2 and R a3 Each occurrence is independently hydrogen, methyl, ethyl, propyl, wherein methyl, ethyl, propyl is optionally substituted by one or more selected from halogen, deuterium, hydroxyl, amino, C 1-4 substituted by an alkyl substituent.

[0085] In a further preferred embodiment, wherein R a4 Each occurrence is independently hydrogen, deuterium, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-8 Cycloalkyl, C 6-10 Aryl, 3-10 membered heterocyclic group, wherein alkyl, alkoxy, cycloalkyl, aryl, heterocyclic group is optionally substituted by one or more selected from halogen, deuterium, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, phenyl, C 1-6 Halogenated alkyl, C 1-6 The substituents are substituted by halogenated alkoxy or halogenated phenyl; the heteroatoms are independently selected from O, N or S, and the number of heteroatoms is 1, 2 or 3;

[0086] In a further preferred embodiment, wherein R a4 Each occurrence is independently hydrogen, deuterium, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C6 aryl, 3-8 membered heterocyclic group, wherein alkyl, alkoxy, cycloalkyl, aryl, heterocyclic group is optionally substituted by one or more selected from halogen, deuterium, hydroxyl, amino, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl, C 1-4 The substituent is substituted by a haloalkoxy group; the heteroatoms are independently selected from O and N, and the number of heteroatoms is 1 or 2;

[0087] In a further preferred embodiment, wherein R a4 Each occurrence is independently hydrogen, deuterium, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6Cycloalkyl, C6 aryl, wherein alkyl, alkoxy, cycloalkyl, aryl are optionally substituted by one or more selected from halogen, deuterium, hydroxyl, amino, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent;

[0088] In a further preferred embodiment, wherein R a4 Each occurrence is independently hydrogen, deuterium, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, cyclopropane, cyclobutane or phenyl; wherein methyl, ethyl, propyl, methoxy, ethoxy, propoxy, cyclopropane, cyclobutane or phenyl is optionally replaced by one or more selected from halogen, deuterium, hydroxy, amino, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent;

[0089] In a further preferred embodiment, wherein R a4 Each occurrence is independently hydrogen, deuterium, methyl, ethyl, propyl, methoxy, ethoxy, propoxy or phenyl; wherein methyl, ethyl, propyl, methoxy, ethoxy, propoxy or phenyl is optionally replaced by one or more selected from halogen, deuterium, hydroxy, amino, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent.

[0090] In a further preferred embodiment, wherein R 2 Selected from hydrogen, deuterium, halogen, -CN, -OH, -SH, -NO2, -NH2, -W-OR b1 、-W-SR b1 、-WC(O)R b4 、-WC(O)OR b1 、-W-OC(O)R b1 、-W-OC(O)OR b1 、-WC(O)NR b2 R b3 、-WC(O)NR b2 OR b1 、-W-NR b2 R b3 、-W-NR b2 C(O)R b4 、-W-NR b2 C(O)NR b2 R b3 、-WS(O)R b4 、-WS(O)2R b4 、-W-SO2NR b2 R b3 、-W-NR b2 S(O)2R b4、-W-OS(O)2R b4 、C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-6 Cycloalkyl, C 6-12 Aryl, 3-6 membered heterocyclic group, 5-12 membered heteroaryl; the alkyl, alkenyl, alkynyl, haloalkyl, haloalkoxy, alkoxy, alkylthio, cycloalkyl, aryl, heterocyclic group, heteroaryl are optionally substituted by one or more selected from deuterium, halogen, oxo, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 substituted by a haloalkoxy substituent;

[0091] In a further preferred embodiment, wherein R 2 Selected from hydrogen, deuterium, halogen, -CN, -OH, -SH, -NO2, -NH2, -W-OR b1 、-W-SR b1 、-WC(O)R b4 、-WC(O)OR b1 、-W-OC(O)R b1 、-W-OC(O)OR b1 、-WC(O)NR b2 R b3 、-WC(O)NR b2 OR b1 、-W-NR b2 R b3 、-W-NR b2 C(O)R b4 、-W-NR b2 C(O)NR b2 R b3 、-WS(O)R b4 、-WS(O)2R b4 、-W-SO2NR b2 R b3 、-W-NR b2 S(O)2R b4 、-W-OS(O)2R b4 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, C 1-6 Alkoxy, C1-6 Alkylthio, C 3-6 Cycloalkyl, C 6-12 Aryl, 5-6 membered heterocyclic group, 5-6 membered heteroaryl; the alkyl, alkenyl, alkynyl, haloalkyl, haloalkoxy, alkoxy, alkylthio, cycloalkyl, aryl, heterocyclic group, heteroaryl are optionally substituted by one or more selected from deuterium, halogen, oxo, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 The substituent is substituted by a haloalkoxy group; the heteroatoms are independently selected from O and N, and the number of heteroatoms is 1 or 2;

[0092] In a further preferred embodiment, wherein R 2 Selected from hydrogen, deuterium, halogen, -CN, -OH, -SH, -NO2, -NH2, -W-OR b1 、-W-SO2NR b2 R b3 、-W-NR b2 S(O)2R b4 、C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C6 aryl; the alkyl, alkoxy, cycloalkyl, aryl are optionally substituted by one or more selected from deuterium, halogen, oxo, -CN, -OH, -NO2, -NH2, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl, C 1-4 substituted by a haloalkoxy substituent;

[0093] In a further preferred embodiment, wherein R 2 Selected from hydrogen, deuterium, halogen, -CN, -OH, -SH, -NO2, -NH2, methyl, ethyl, isopropyl, methoxy, ethoxy, propoxy, -W-SO2NR b2 R b3 、-W-NR b2 S(O)2R b4 The methyl, ethyl, isopropyl, methoxy, ethoxy, propoxy group may be replaced by one or more selected from deuterium, halogen, oxo, -CN, -OH, -NO2, -NH2, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl, C 1-4 substituted by a haloalkoxy substituent;

[0094] In a further preferred embodiment, wherein R 2is selected from hydrogen, deuterium, halogen, -CN, -OH, -NH2, methyl, ethyl, isopropyl, -SO2NH2, -NHSO2H;

[0095] In a further preferred embodiment, wherein R 2 Selected from hydrogen.

[0096] In a further preferred embodiment, wherein R 6 Selected from hydrogen.

[0097] In a further preferred embodiment, wherein R 3 Selected from hydrogen, deuterium, halogen, -CN, -OH, -SH, -NO2, -NH2, -W-OR b1 、-W-SR b1 、-WC(O)R b4 、-WC(O)OR b1 、-W-OC(O)R b1 、-W-OC(O)OR b1 、-WC(O)NR b2 R b3 、-WC(O)NR b2 OR b1 、 -W-NR b2 R b3 、-W-NR b2 C(O)R b4 、-W-NR b2 C(O)NR b2 R b3 、-WS(O)R b4 、-WS(O)2R b4 、-W-SO2NR b2 R b3 、-W-NR b2 S(O)2R b4 、-W-OS(O)2R b4 、C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-6 Cycloalkyl, C 6-12 Aryl, 3-6 membered heterocyclic group, 5-10 membered heteroaryl; the alkyl, alkenyl, alkynyl, haloalkyl, haloalkoxy, alkoxy, alkylthio, cycloalkyl, aryl, heterocyclic group, heteroaryl are optionally substituted by one or more selected from deuterium, halogen, oxo, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, C1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 The substituent is substituted by a haloalkoxy group; the heteroatoms are independently selected from O and N, and the number of heteroatoms is 1 or 2;

[0098] In a further preferred embodiment, wherein R 3 Selected from hydrogen, deuterium, halogen, -CN, -OH, -SH, -NO2, -NH2, -W-OR b1 、-W-SR b1 、-WC(O)R b4 、-WC(O)OR b1 、-W-OC(O)R b1 、-W-OC(O)OR b1 、-WC(O)NR b2 R b3 、-WC(O)NR b2 OR b1 、-W-NR b2 R b3 、-W-NR b2 C(O)R b4 、-W-NR b2 C(O)NR b2 R b3 、-WS(O)R b4 、-WS(O)2R b4 、-W-SO2NR b2 R b3 、-W-NR b2 S(O)2R b4 、-W-OS(O)2R b4 、C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkoxy, C 1-4 Alkylthio, C 3-6 Cycloalkyl, C 6- Aryl, 3-6 membered heterocyclic group, 5-6 membered heteroaryl; the alkyl, alkenyl, alkynyl, alkoxy, alkylthio, cycloalkyl, aryl, heterocyclic group, heteroaryl are optionally substituted by one or more selected from deuterium, halogen, oxo, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 The substituent is substituted by a haloalkoxy group; the heteroatoms are independently selected from O and N, and the number of heteroatoms is 1 or 2;

[0099] In a further preferred embodiment, wherein R3 Selected from hydrogen, deuterium, halogen, -CN, -OH, -NH2, -W-OR b1 、-W-SR b1 、-WC(O)R b4 、-WC(O)OR b1 、-W-OC(O)R b1 、-WC(O)NR b2 R b3 、-W-NR b2 R b3 、-W-NR b2 C(O)R b4 、-W-NR b2 C(O)NR b2 R b3 、-WS(O)R b4 、-WS(O)2R b4 、C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 6- Aryl, 3-6 membered heterocyclic group, 5-6 membered heteroaryl; the alkyl, alkoxy, cycloalkyl, aryl, heterocyclic group, heteroaryl are optionally substituted by one or more selected from deuterium, halogen, oxo, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 The substituent is substituted by a haloalkoxy group; the heteroatoms are independently selected from O and N, and the number of heteroatoms is 1 or 2;

[0100] In a further preferred embodiment, wherein R 3 Selected from hydrogen, deuterium, halogen, -OH, -NH2, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, 5-6 membered heterocyclic group; the alkyl, alkoxy, cycloalkyl, heterocyclic group may be substituted by one or more selected from deuterium, halogen, oxo, -CN, -OH, -NO2, -NH2, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl, C 1-4 The substituent is substituted by a haloalkoxy group; the heteroatoms are independently selected from O and N, and the number of heteroatoms is 1 or 2;

[0101] In a further preferred embodiment, wherein R 3 Selected from F, Cl, Br, -CF3, -CHF2-CH2, -CH2FCH3, -OCF3 or cyclopropane;

[0102] In a further preferred embodiment, wherein R 3 Selected from Cl or -CF3;

[0103] In a further preferred embodiment, wherein R 3 is selected from halogen, C optionally substituted by one or more halogens 1-4 alkyl;

[0104] In a further preferred embodiment, wherein R 3 selected from halogen;

[0105] In a further preferred embodiment, wherein R 3 Selected from Cl.

[0106] In a further preferred embodiment, wherein R b1 Each occurrence is independently hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 6-10 Aryl, 3-10 membered heterocyclic group, wherein alkyl, alkoxy, cycloalkyl, aryl, heterocyclic group is optionally substituted by one or more selected from halogen, deuterium, cyano, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 substituted by a haloalkoxy substituent;

[0107] In a further preferred embodiment, wherein R b1 Each occurrence is independently hydrogen, deuterium, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 6-10 Aryl, 3-8 membered heterocyclic group, wherein alkyl, alkoxy, cycloalkyl, aryl, heterocyclic group is optionally substituted by one or more selected from halogen, deuterium, cyano, hydroxyl, amino, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl, C 1-4 substituted by a haloalkoxy substituent;

[0108] In a further preferred embodiment, wherein R b1 Each occurrence is independently hydrogen, deuterium, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C6 aryl, 5-6 membered heterocyclic group, wherein alkyl, alkoxy, cycloalkyl, aryl, heterocyclic group is optionally substituted by one or more selected from halogen, deuterium, hydroxyl, amino, C 1-4 Alkyl, C1-4 Alkoxy, C 1-4 Halogenated alkyl, C 1-4 The substituent is substituted by a haloalkoxy group; the heteroatoms are independently selected from O and N, and the number of heteroatoms is 1 or 2;

[0109] In a further preferred embodiment, wherein R b1 Each occurrence is independently hydrogen, deuterium, methyl, ethyl, propyl, methoxy, ethoxy or propoxy, wherein methyl, ethyl, propyl, methoxy, ethoxy or propoxy is optionally replaced by one or more selected from halogen, deuterium, hydroxy, amino, C 1-4 substituted by an alkyl substituent;

[0110] In a further preferred embodiment, wherein R b1 Each occurrence is independently hydrogen, methyl, ethyl, propyl, wherein methyl, ethyl, propyl is optionally substituted by one or more selected from halogen, deuterium, hydroxyl, amino, C 1-4 substituted by an alkyl substituent.

[0111] In a further preferred embodiment, wherein R b2 and R b3 Each occurrence is independently hydrogen, deuterium, C 1-4 Alkyl, C 1-4 Alkoxy, wherein alkyl, alkoxy is optionally substituted by one or more selected from halogen, deuterium, hydroxyl, amino, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl, C 1-4 substituted by a haloalkoxy substituent;

[0112] In a further preferred embodiment, wherein R b2 and R b3 Each occurrence is independently hydrogen, deuterium, C 1-4 Alkyl, C 1-4 Alkoxy, wherein alkyl, alkoxy is optionally substituted by one or more selected from halogen, deuterium, hydroxyl, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent;

[0113] In a further preferred embodiment, wherein R b2 and R b3 Each occurrence is independently hydrogen, deuterium, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, wherein methyl, ethyl, propyl, methoxy, ethoxy, propoxy is optionally replaced by one or more selected from halogen, deuterium, hydroxyl, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent;

[0114] In a further preferred embodiment, wherein R b2 and R b3 Each occurrence is independently hydrogen, methyl, ethyl, propyl, wherein methyl, ethyl, propyl is optionally substituted by one or more selected from halogen, deuterium, hydroxyl, amino, C 1-4 substituted by an alkyl substituent.

[0115] In a further preferred embodiment, wherein R b4 Each occurrence is independently hydrogen, deuterium, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-8 Cycloalkyl, C 6-10 Aryl, 3-10 membered heterocyclic group, wherein alkyl, alkoxy, cycloalkyl, aryl, heterocyclic group is optionally substituted by one or more selected from halogen, deuterium, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, phenyl, C 1-6 Halogenated alkyl, C 1-6 The substituents are substituted by halogenated alkoxy or halogenated phenyl; the heteroatoms are independently selected from O, N or S, and the number of heteroatoms is 1, 2 or 3;

[0116] In a further preferred embodiment, wherein R b4 Each occurrence is independently hydrogen, deuterium, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C6 aryl, 3-8 membered heterocyclic group, wherein alkyl, alkoxy, cycloalkyl, aryl, heterocyclic group is optionally substituted by one or more selected from halogen, deuterium, hydroxyl, amino, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl, C 1-4 The substituent is substituted by a haloalkoxy group; the heteroatoms are independently selected from O and N, and the number of heteroatoms is 1 or 2;

[0117] In a further preferred embodiment, wherein R b4 Each occurrence is independently hydrogen, deuterium, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C6 aryl, wherein alkyl, alkoxy, cycloalkyl, aryl are optionally substituted by one or more selected from halogen, deuterium, hydroxyl, amino, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent;

[0118] In a further preferred embodiment, wherein R b4Each occurrence is independently hydrogen, deuterium, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, cyclopropane, cyclobutane or phenyl; wherein methyl, ethyl, propyl, methoxy, ethoxy, propoxy, cyclopropane, cyclobutane or phenyl is optionally replaced by one or more selected from halogen, deuterium, hydroxy, amino, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent;

[0119] In a further preferred embodiment, wherein R b4 Each occurrence is independently hydrogen, deuterium, methyl, ethyl, propyl, methoxy, ethoxy or propoxy; wherein methyl, ethyl, propyl, methoxy, ethoxy, propoxy, optionally substituted by one or more selected from halogen, deuterium, hydroxy, amino, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent.

[0120] In a further preferred embodiment, wherein R 4 and R 5 Each independently selected from hydrogen, deuterium, halogen, -CN, -OH, -SH, -NO2, -NH2, -W-OR c1 、-W-SR c1 、-WC(O)R c4 、-WC(O)OR c1 、-W-OC(O)R c1 、-W-OC(O)OR c1 、-WC(O)NR c2 R c3 、-WC(O)NR c2 OR c1 、-W-OC(O)NR c2 R c3 、-W-NR c2 R c3 、-W-NR c2 C(O)R c4 、-W-NR c2 C(O)NR c2 R c3 、-WS(O)R c4 、-WS(O)2R c4 、-W-SO2NR c2 R c3 、-W-NR c2 S(O)2R c4 、-W-OS(O)2R c4 、C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-8Cycloalkyl, C 3-8 Cycloalkenyl, C 6-12 Aryl, 4-12 membered heterocyclic group, 5-12 membered heteroaryl; the alkyl, alkoxy, alkylthio, cycloalkyl, cycloalkenyl, aryl, heterocyclic group, heteroaryl are optionally replaced by one or more R c replaced by; or R 4 and R 5 Attached to the same, adjacent or separated by one atom ring atoms, and the carbon or nitrogen atom to which it is attached together form an optionally substituted C 3-10 Cycloalkyl, C 6-12 Aryl, 5-12 membered heteroaryl, 5-12 membered heterocyclic group; the optional substitution means that the hydrogen on the substituted group is not replaced or one or more substitutable sites of the substituted group are independently selected from R c substituted by a substituent;

[0121] In a further preferred embodiment, wherein R 4 and R 5 Each independently selected from hydrogen, deuterium, halogen, -CN, -OH, -SH, -NO2, -NH2, -W-OR c1 、-W-SR c1 、-WC(O)R c4 、-WC(O)OR c1 、-W-OC(O)R c1 、-W-OC(O)OR c1 、-WC(O)NR c2 R c3 、-WC(O)NR c2 OR c1 、-W-OC(O)NR c2 R c3 、-W-NR c2 R c3 、-W-NR c2 C(O)R c4 、-W-NR c2 C(O)NR c2 R c3 、-WS(O)R c4 、-WS(O)2R c4 、-W-SO2NR c2 R c3 、-W-NR c2 S(O)2R c4 、-W-OS(O)2R c4 、C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Alkylthio, C 3-6 Cycloalkyl, C4-6 Cycloalkenyl, C 6-12 Aryl, 4-10 membered heterocyclic group, 5-12 membered heteroaryl; the alkyl, alkoxy, alkylthio, cycloalkyl, cycloalkenyl, aryl, heterocyclic group, heteroaryl are optionally replaced by one or more R c replaced by; or R 4 and R 5 Attached to the same, adjacent or separated by one atom ring atoms, and the carbon or nitrogen atom to which it is attached together form an optionally substituted C 3-10 Cycloalkyl, C 6-12 Aryl, 5-12 membered heteroaryl, 5-12 membered heterocyclic group; the optional substitution means that the hydrogen on the substituted group is not replaced or one or more substitutable sites of the substituted group are independently selected from R c The heteroatoms are independently selected from O, N or S, and the number of heteroatoms is 1, 2 or 3;

[0122] In a further preferred embodiment, wherein R 4 and R 5 Each independently selected from hydrogen, deuterium, halogen, -CN, -OH, -NH2, -W-OR c1 、-W-SR c1 、-WC(O)R c4 、-WC(O)OR c1 、-W-OC(O)R c1 、-WC(O)NR c2 R c3 、-W-OC(O)NR c2 R c3 、-W-NR c2 R c3 、-W-NR c2 C(O)R c4 、-WS(O)R c4 、-WS(O)2R c4 、-W-SO2NR c2 R c3 、-W-NR c2 S(O)2R c4 、-W-OS(O)2R c4 、C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Alkylthio, C 3-6 Cycloalkyl, C 4-6 Cycloalkenyl, C6 aryl, 4-10 membered heterocyclic group, 5-12 membered heteroaryl; the alkyl, alkoxy, alkylthio, cycloalkyl, cycloalkenyl, aryl, heterocyclic group, heteroaryl are optionally replaced by one or more R csubstituted; heteroatoms are independently selected from O, N or S, and the number of heteroatoms is 1, 2 or 3;

[0123] In a further preferred embodiment, wherein R 4 and R 5 Each independently selected from hydrogen, deuterium, halogen, -CN, -OH, -NH2, -W-OR c1 、-W-SR c1 、-WC(O)R c4 、-WC(O)OR c1 、-W-OC(O)R c1 、-WC(O)NR c2 R c3 、-W-OC(O)NR c2 R c3 、-W-NR c2 R c3 、-W-NR c2 C(O)R c4 、-WS(O)R c4 、-WS(O)2R c4 、-W-SO2NR c2 R c3 、-W-NR c2 S(O)2R c4 、-W-OS(O)2R c4 、C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Alkylthio, C 3-6 Cycloalkyl, C 4-6 Cycloalkenyl, C6 aryl, 4-10 membered heterocyclic group, 5-6 membered heteroaryl; the alkyl, alkoxy, alkylthio, cycloalkyl, cycloalkenyl, aryl, heterocyclic group, heteroaryl are optionally replaced by one or more R c substituted; heteroatoms are independently selected from O, N or S, and the number of heteroatoms is 1, 2 or 3;

[0124] In a further preferred embodiment, wherein R 4 and R 5 Each independently selected from hydrogen, deuterium, halogen, -OH, -WC(O)NR c2 R c3 、-W-NR c2 R c3 、-W-SO2NR c2 R c3 、-WC(O)R c4 、-WS(O)2R c4 、C 1-4 Alkyl, C 3-6Cycloalkyl, 4-10 membered heterocyclic group, C 6-12 Aryl or 5-10 membered heteroaryl; the alkyl, cycloalkyl, heterocyclic, phenyl or heteroaryl group is optionally replaced by one or more R c replaced by; or R 4 and R 5 The carbon or nitrogen atom to which it is attached together forms an optionally substituted C 3-10 Cycloalkyl, 5-12 membered heterocyclic group; the optional substitution means that the hydrogen on the substituted group is not replaced or one or more substitutable sites of the substituted group are independently selected from R c The heteroatoms are independently selected from O, N or S, and the number of heteroatoms is 1, 2 or 3;

[0125] In a further preferred embodiment, wherein R 4 and R 5 Each independently selected from hydrogen, deuterium, halogen, -OH, -WC(O)NR c2 R c3 、-W-NR c2 R c3 、-W-SO2NR c2 R c3 、-WC(O)R c4 、-WS(O)2R c4 、C 1-4 Alkyl, C 3-6 Cycloalkyl, 4-10 membered heterocyclic group, C 6-12 Aryl or 5-6 membered heteroaryl; the alkyl, cycloalkyl, heterocyclic, phenyl or heteroaryl group is optionally replaced by one or more R c replaced by; or R 4 and R 5 The carbon or nitrogen atom to which it is attached together forms an optionally substituted C 3-10 Cycloalkyl, 5-12 membered heterocyclic group; the optional substitution means that the hydrogen on the substituted group is not replaced or one or more substitutable sites of the substituted group are independently selected from R c The heteroatoms are independently selected from O, N or S, and the number of heteroatoms is 1, 2 or 3;

[0126] In a further preferred embodiment, wherein R 4 For hydrogen, deuterium, halogen, -OH, C 1-4 Alkyl, C 1-4 Alkoxy, 4-6 membered heterocyclic group; the alkyl, alkoxy or heterocyclic group is optionally replaced by R c Replaced by; R 5 Selected from hydrogen, deuterium, halogen, -OH, -WC(O)NR c2 R c3 、-W-NRc2 R c3 、-W-SO2NR c2 R c3 、-WC(O)R c4 、-WS(O)2R c4 、C 1-4 Alkyl, C 3-6 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl; the alkyl, cycloalkyl, heterocyclic, aryl or heteroaryl group is optionally replaced by one or more R c substituted; heteroatoms are independently selected from O, N, and the number of heteroatoms is 1 or 2;

[0127] In a further preferred embodiment, wherein R 4 For hydrogen, deuterium, halogen, -OH, C 1-4 Alkyl, C 1-4 Alkoxy, 4-6 membered heterocyclic group; the alkyl, alkoxy or heterocyclic group is optionally replaced by R c Replaced by; R 5 Selected from hydrogen, deuterium, halogen, -OH, -WC(O)NR c2 R c3 、-W-NR c2 R c3 、-W-SO2NR c2 R c3 、-WC(O)R c4 、-WS(O)2R c4 、C 1-4 Alkyl, C 3-6 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 Aryl or 5-6 membered heteroaryl; the alkyl, cycloalkyl, heterocyclic, aryl or heteroaryl group is optionally replaced by one or more R c substituted; heteroatoms are independently selected from O, N, and the number of heteroatoms is 1 or 2;

[0128] In a further preferred embodiment, wherein R 4 For hydrogen, deuterium, halogen, -OH, C 1-4 Alkyl, C 1-4 Alkoxy, 4-6 membered heterocycloalkyl; the alkyl, alkoxy, heterocycloalkyl are optionally replaced by one or more R c Replaced by; R 5 Selected from hydrogen, deuterium, halogen, -OH, -WC(O)NR c2 R c3 、-W-NR c2 R c3 、-W-SO2NR c2 R c3 、-WC(O)Rc4 、-WS(O)2R c4 、C 1-4 Alkyl, C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, phenyl or 9-10 membered heteroaryl; the alkyl, cycloalkyl, heterocycloalkyl, phenyl or heteroaryl is optionally replaced by one or more R c replaced by;

[0129] In a further preferred embodiment, wherein R 4 For hydrogen, deuterium, halogen, -OH, C 1-4 Alkyl, C 1-4 Alkoxy, 4-6 membered heterocycloalkyl; the alkyl, alkoxy, heterocycloalkyl are optionally replaced by one or more R c Replaced by; R 5 Selected from hydrogen, deuterium, halogen, -OH, -WC(O)NR c2 R c3 、-W-NR c2 R c3 、-W-SO2NR c2 R c3 、-WC(O)R c4 、-WS(O)2R c4 、C 1-4 Alkyl, C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, phenyl or 5-6 membered heteroaryl; the alkyl, cycloalkyl, heterocycloalkyl, phenyl or heteroaryl is optionally replaced by one or more R c replaced by;

[0130] In a further preferred embodiment, wherein R 4 is hydrogen, deuterium, halogen, -OH, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, azetidinyl or pyrrolidinyl; said methyl, ethyl, propyl, methoxy, ethoxy, propoxy, azetidinyl or pyrrolidinyl is optionally replaced by one or more R c Replaced by; R 5 Selected from hydrogen, deuterium, halogen, -OH, -WC(O)NR c2 R c3 、-W-NR c2 R c3 、-W-SO2NR c2 R c3 、-WC(O)R c4 、-WS(O)2R c4, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, pyrrolidinyl, phenyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, benzopyrazolyl; the methyl, ethyl, propyl, methoxy, ethoxy, propoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, pyrrolidinyl, phenyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, benzopyrazolyl is optionally replaced by one or more R c replaced by;

[0131] In a further preferred embodiment, wherein R 4 is hydrogen, deuterium, halogen, -OH, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, azetidinyl or pyrrolidinyl; said methyl, ethyl, propyl, methoxy, ethoxy, propoxy, azetidinyl or pyrrolidinyl is optionally replaced by one or more R c Replaced by; R 5 Selected from hydrogen, deuterium, halogen, -OH, -WC(O)NR c2 R c3 、-W-NR c2 R c3 、-W-SO2NR c2 R c3 、-WC(O)R c4 、-WS(O)2R c4 , methyl, ethyl, propyl, methoxy, ethoxy, propoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, pyrrolidinyl, phenyl, imidazolyl, pyrazolyl, pyridyl or pyrimidinyl; the methyl, ethyl, propyl, methoxy, ethoxy, propoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, pyrrolidinyl, phenyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl is optionally replaced by one or more R c replaced by;

[0132] In a further preferred embodiment, wherein R 4 is hydrogen, halogen, -OH, methyl, ethyl, propyl, methoxy, ethoxy, azetidinyl or pyrrolidinyl; said methyl, ethyl, propyl, methoxy, ethoxy, azetidinyl or pyrrolidinyl is optionally replaced by one or more R c Replaced by; R 5 Selected from hydrogen, halogen, -OH, -C 1-3 Alkylene-C(O)NR c2 R c3 、-C 1-3 Alkylene-NR c2 R c3 、-C 1-3 Alkylene-SO2NR c2 Rc3 、-C(O)R c4 、-S(O)2R c4 , methyl, ethyl, phenyl, cyclopropyl, cyclobutyl, phenyl, pyridyl, benzopyrazolyl; the methyl, ethyl, phenyl, cyclopropyl, cyclobutyl, phenyl, pyridyl, benzopyrazolyl are optionally replaced by one or more R c replaced by;

[0133] In a further preferred embodiment, wherein R 4 For hydrogen, deuterium, halogen, -OH, methyl, R 5 Selected from hydrogen, methyl, phenyl, benzoyl, -SO2CH3,

[0134] In a further preferred embodiment, wherein R 4 is hydrogen, halogen, -OH or methyl; R 5 Selected from hydrogen, methyl, phenyl, benzoyl, -SO2CH3,

[0135] In a further preferred embodiment, wherein R 4 For hydrogen, deuterium, halogen, -OH, methyl, R 5 Selected from hydrogen, methyl, phenyl, benzoyl, -SO2CH3,

[0136] In a further preferred embodiment, wherein R 4 is hydrogen, deuterium, halogen, -OH or methyl; R 5 Selected from hydrogen, methyl, phenyl, benzoyl, -SO2CH3,

[0137] In a further preferred embodiment, wherein R 4 is hydrogen; R 5 Selected from hydrogen, C 1-6 Alkyl, optionally substituted by one or more R c substituted phenyl, 9-10 membered bicyclic heteroaryl;

[0138] In a further preferred embodiment, wherein R 4 is hydrogen; R 5 Selected from hydrogen, C 1-4 Alkyl, optionally substituted by one or more halogen, -OH, C 1-4 Alkyl-substituted phenyl, 9-10 membered bicyclic heteroaryl;

[0139] In a further preferred embodiment, wherein R 4 is hydrogen; R 5 Selected from hydrogen, C 1-4 Alkyl, phenyl optionally substituted by one or more -F, -Cl, -Br, -OH, methyl, ethyl, n-propyl, isopropyl, 9-10 membered bicyclic heteroaryl; the heteroatom in the heteroaryl is selected from N, and the number of heteroatoms is 1, 2, or 3.

[0140] In a further preferred embodiment, wherein R c independently selected from deuterium, halogen, oxime, -CN, -OH, -SH, -NO2, -NH2, -W-OR c1 、-W-SR c1 、-WC(O)R c4 、-WC(O)OR c1 、-W-OC(O)R c1 、-W-OC(O)OR c1 、-WC(O)NR c2 R c3 、-WC(O)NR c2 OR c1 、-W-OC(O)NR c2 R c3 、-W-NR c2 R c3 、-W-NR c2 C(O)R c4 、-W-NR c2 C(O)OR c1 、-W-NR c2 C(O)NR c2 R c3 、-WS(O)R c4 、-WS(O)2R c4 、-W-SO2NR c2 R c3 、-W-NR c2 S(O)2R c4 、-W-OS(O)2R c4 、-W-NR c2 S(O)2NR c2 R c3 、-W-OS(O)2NR c2 R c3 、C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, C1-6 Alkoxy, C 1-6 Alkylthio, C 3-10 Cycloalkyl, C 3-10 Cycloalkenyl, C 6-12 Aryl, 3-12 membered heterocyclic group, 5-16 membered heteroaryl; the alkyl, alkenyl, alkynyl, haloalkyl, haloalkoxy, alkoxy, alkylthio, cycloalkyl, cycloalkenyl, heterocyclic group, heteroaryl are optionally substituted by one or more selected from deuterium, halogen, oxo, oxime, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, C 6-14 Aryl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Substituted by a halogenated alkoxy group or a halogenated phenyl group;

[0141] In a further preferred embodiment, wherein R c independently selected from deuterium, halogen, oxime, -CN, -OH, -SH, -NO2, -NH2, -W-OR c1 、 -W-SR c1 、-WC(O)R c4 、-WC(O)OR c1 、-W-OC(O)R c1 、-W-OC(O)OR c1 、-WC(O)NR c2 R c3 、-WC(O)NR c2 OR c1 、-W-OC(O)NR c2 R c3 、-W-NR c2 R c3 、-W-NR c2 C(O)R c4 、-W-NR c2 C(O)OR c1 、-W-NR c2 C(O)NR c2 R c3 、-WS(O)R c4 、-WS(O)2R c4 、-W-SO2NR c2 R c3 、-W-NR c2 S(O)2R c4 、-W-OS(O)2R c4 、-W-NR c2 S(O)2NR c2 R c3 、-W-OS(O)2NRc2 R c3 、C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-10 Cycloalkyl, C 3-10 Cycloalkenyl, C 6-12 Aryl, 3-12 membered heterocyclic group, 5-16 membered heteroaryl; the alkyl, alkenyl, alkynyl, haloalkyl, haloalkoxy, alkoxy, alkylthio, cycloalkyl, cycloalkenyl, heterocyclic group, heteroaryl are optionally substituted by one or more selected from deuterium, halogen, oxo, oxime, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, C 6-14 Aryl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Substituted by a halogenated alkoxy group or a halogenated phenyl group;

[0142] In a further preferred embodiment, wherein R c independently selected from deuterium, halogen, oxime, -CN, -OH, -SH, -NO2, -NH2, -W-OR c1 、-W-SR c1 、-WC(O)R c4 、-WC(O)OR c1 、-W-OC(O)R c1 、-W-OC(O)OR c1 、-WC(O)NR c2 R c3 、-WC(O)NR c2 OR c1 、-W-OC(O)NR c2 R c3 、-W-NR c2 R c3 、-W-NR c2 C(O)R c4 、-W-NR c2 C(O)OR c1 、-W-NR c2 C(O)NR c2 R c3 、-WS(O)R c4 、-WS(O)2R c4 、-W-SO2NR c2 R c3 、-W-NR c2S(O)2R c4 、-W-OS(O)2R c4 、-W-NR c2 S(O)2NR c2 R c3 、-W-OS(O)2NR c2 R c3 、C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-10 Cycloalkyl, C 3-10 Cycloalkenyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl; the alkyl, alkenyl, alkynyl, haloalkyl, haloalkoxy, alkoxy, alkylthio, cycloalkyl, cycloalkenyl, heterocyclic, heteroaryl may be substituted with one or more selected from deuterium, halogen, oxo, oxime, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, C 6-14 Aryl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Substituted by a halogenated alkoxy group or a halogenated phenyl group;

[0143] In a further preferred embodiment, wherein R c Independently selected from deuterium, halogen, -CN, -OH, -SH, -NH2, -W-OR c1 、-W-SR c1 、-WC(O)R c4 、-WC(O)OR c1 、-W-OC(O)R c1 、-WC(O)NR c2 R c3 、-W-NR c2 R c3 、-W-NR c2 C(O)R c4 、-WS(O)2R c4 、-W-SO2NR c2 R c3 、-W-NR c2 S(O)2R c4 、C 1-4 Alkyl, C 1-4 Alkoxy, C 3-8 Cycloalkyl, 4-8 membered heterocyclic group, C 6-12Aryl, 5-8 membered heteroaryl; the alkyl, alkenyl, alkynyl, alkoxy, alkylthio, cycloalkyl, cycloalkenyl, heterocyclic, heteroaryl may be substituted with one or more selected from deuterium, halogen, oxo, oxime, -CN, -OH, -NO2, -NH2, C 1-4 Alkyl, C 6-12 Aryl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl, C 1-4 substituted by a haloalkoxy substituent;

[0144] In a further preferred embodiment, wherein R c Independently selected from deuterium, halogen, -CN, -OH, -SH, -NH2, -W-OR c1 、-W-SR c1 、-WC(O)R c4 、-WC(O)OR c1 、-W-OC(O)R c1 、-WC(O)NR c2 R c3 、-W-NR c2 R c3 、-W-NR c2 C(O)R c4 、-WS(O)2R c4 、-W-SO2NR c2 R c3 、-W-NR c2 S(O)2R c4 、C 1-4 Alkyl, C 1-4 Alkoxy, C 3-8 Cycloalkyl, 4-8 membered heterocyclyl, C6 aryl, 5-6 membered heteroaryl; the alkyl, alkenyl, alkynyl, alkoxy, alkylthio, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl are optionally substituted by one or more selected from deuterium, halogen, oxo, oxime, -CN, -OH, -NO2, -NH2, C 1-4 Alkyl, C 6-12 Aryl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl, C 1-4 The substituent is substituted by a haloalkoxy group; the heteroatoms are independently selected from O and N, and the number of heteroatoms is 1 or 2;

[0145] In a further preferred embodiment, wherein R c Independently selected from deuterium, halogen, -CN, -OH, -W-OR c1 、-WC(O)NR c2 R c3 、-W-NR c2 Rc3 、-W-SO2NR c2 R c3 、C 1-4 Alkyl, 4-8 membered heterocyclic group; the heterocyclic group is optionally substituted by one or more selected from deuterium, halogen, -OH, C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 The substituent is substituted by a haloalkoxy group; the heteroatoms are independently selected from O and N, and the number of heteroatoms is 1 or 2;

[0146] In a further preferred embodiment, wherein R c Independently selected from deuterium, halogen, -CN, -OH, -W-OR c1 、-WC(O)NR c2 R c3 、-W-NR c2 R c3 、-W-SO2NR c2 R c3 , 4-8 membered heterocyclic group; the heterocyclic group is optionally substituted by one or more selected from deuterium, halogen, -OH, C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 The substituent is substituted by a haloalkoxy group; the heteroatoms are independently selected from O and N, and the number of heteroatoms is 1 or 2;

[0147] In a further preferred embodiment, wherein R c Independently selected from -F, -Cl, -Br, -CH2-OH, -OH, -C(O)NH-CH3, -N(CH3)2, -SO2CH3, -SO2N(CH3)2, morpholinyl, methyl, ethyl, n-propyl, isopropyl;

[0148] In a further preferred embodiment, wherein R c Independently selected from -F, -Cl, -Br, -CH2-OH, -OH, -C(O)NH-CH3, -N(CH3)2, -SO2CH3, -SO2N(CH3)2, morpholinyl.

[0149] In a further preferred embodiment, wherein R c1 Each occurrence is independently hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 6-10 Aryl, 3-10 membered heterocyclic group, wherein alkyl, alkoxy, cycloalkyl, aryl, heterocyclic group is optionally substituted by one or more selected from halogen, deuterium, cyano, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C1-6 Halogenated alkyl, C 1-6 substituted by a haloalkoxy substituent;

[0150] In a further preferred embodiment, wherein R c1 Each occurrence is independently hydrogen, deuterium, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 6-10 Aryl, 3-8 membered heterocyclic group, wherein alkyl, alkoxy, cycloalkyl, aryl, heterocyclic group is optionally substituted by one or more selected from halogen, deuterium, cyano, hydroxyl, amino, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl, C 1-4 substituted by a haloalkoxy substituent;

[0151] In a further preferred embodiment, wherein R c1 Each occurrence is independently hydrogen, deuterium, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C6 aryl, 5-6 membered heterocyclic group, wherein alkyl, alkoxy, cycloalkyl, aryl, heterocyclic group is optionally substituted by one or more selected from halogen, deuterium, hydroxyl, amino, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl, C 1-4 The substituent is substituted by a haloalkoxy group; the heteroatoms are independently selected from O and N, and the number of heteroatoms is 1 or 2;

[0152] In a further preferred embodiment, wherein R c1 Each occurrence is independently hydrogen, deuterium, methyl, ethyl, propyl, methoxy, ethoxy or propoxy, wherein methyl, ethyl, propyl, methoxy, ethoxy or propoxy is optionally replaced by one or more selected from halogen, deuterium, hydroxy, amino, C 1-4 substituted by an alkyl substituent;

[0153] In a further preferred embodiment, wherein R c1 Each occurrence is independently hydrogen, methyl, ethyl, propyl, wherein methyl, ethyl, propyl is optionally substituted by one or more selected from halogen, deuterium, hydroxyl, amino, C 1-4 substituted by an alkyl substituent.

[0154] In a further preferred embodiment, wherein R c2 and R c3 Each occurrence is independently hydrogen, deuterium, C 1-4 Alkyl, C 1-4Alkoxy, wherein alkyl, alkoxy is optionally substituted by one or more selected from halogen, deuterium, hydroxyl, amino, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl, C 1-4 substituted by a haloalkoxy substituent;

[0155] In a further preferred embodiment, wherein R c2 and R c3 Each occurrence is independently hydrogen, deuterium, C 1-4 Alkyl, C 1-4 Alkoxy, wherein alkyl, alkoxy is optionally substituted by one or more selected from halogen, deuterium, hydroxyl, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent;

[0156] In a further preferred embodiment, wherein R c2 and R c3 Each occurrence is independently hydrogen, deuterium, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, wherein methyl, ethyl, propyl, methoxy, ethoxy, propoxy is optionally replaced by one or more selected from halogen, deuterium, hydroxyl, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent;

[0157] In a further preferred embodiment, wherein R c2 and R c3 Each occurrence is independently hydrogen, methyl, ethyl, propyl, wherein methyl, ethyl, propyl is optionally substituted by one or more selected from halogen, deuterium, hydroxyl, amino, C 1-4 substituted by an alkyl substituent.

[0158] In a further preferred embodiment, wherein R c4 Each occurrence is independently hydrogen, deuterium, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-8 Cycloalkyl, C 6-10 Aryl, 3-10 membered heterocyclic group, wherein alkyl, alkoxy, cycloalkyl, aryl, heterocyclic group is optionally substituted by one or more selected from halogen, deuterium, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, phenyl, C 1-6 Halogenated alkyl, C 1-6 Substituted by a halogenated alkoxy group or a halogenated phenyl group;

[0159] In a further preferred embodiment, wherein R c4 Each occurrence is independently hydrogen, deuterium, C 1-4 Alkyl, C1-4 Alkoxy, C 3-6 Cycloalkyl, C6 aryl, 3-8 membered heterocyclic group, wherein alkyl, alkoxy, cycloalkyl, aryl, heterocyclic group is optionally substituted by one or more selected from halogen, deuterium, hydroxyl, amino, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl, C 1-4 The substituent is substituted by a haloalkoxy group; the heteroatoms are independently selected from O and N, and the number of heteroatoms is 1 or 2;

[0160] In a further preferred embodiment, wherein R c4 Each occurrence is independently hydrogen, deuterium, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C6 aryl, wherein alkyl, alkoxy, cycloalkyl, aryl are optionally substituted by one or more selected from halogen, deuterium, hydroxyl, amino, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent;

[0161] In a further preferred embodiment, wherein R c4 Each occurrence is independently hydrogen, deuterium, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, cyclopropane, cyclobutane or phenyl; wherein methyl, ethyl, propyl, methoxy, ethoxy, propoxy, cyclopropane, cyclobutane or phenyl is optionally replaced by one or more selected from halogen, deuterium, hydroxy, amino, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent;

[0162] In a further preferred embodiment, wherein R c4 Each occurrence is independently hydrogen, deuterium, methyl, ethyl, propyl, methoxy, ethoxy or propoxy; wherein methyl, ethyl, propyl, methoxy, ethoxy, propoxy, optionally substituted by one or more selected from halogen, deuterium, hydroxy, amino, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent.

[0163] In a further preferred embodiment, wherein W is selected from a bond, C 1-3 Alkylene, wherein the alkylene is optionally substituted with one or more substituents selected from deuterium, halogen, oxo, -CN, -OH, -NH2;

[0164] In a further preferred embodiment, wherein W is selected from a bond, C 1-3 Alkylene, wherein the alkylene is optionally substituted with one or more substituents selected from deuterium, halogen, oxo, -CN, -OH, -NH2;

[0165] In a further preferred embodiment, wherein W is selected from a bond, methylene or ethylene, said methylene or ethylene being optionally substituted with one or more substituents selected from deuterium, halogen, oxo, -CN, -OH, -NH2.

[0166] In a second aspect, the present invention provides a compound represented by formula (II), or a tautomer, stereoisomer or a pharmaceutically acceptable salt thereof:

[0167] Wherein, Ring A is a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic group; R 1 、R 2 、R 3 、R 4 、R 5 , L and X are defined as those for the compound represented by formula (I) of the present invention.

[0168] In a further preferred embodiment, wherein L is a bond.

[0169] In a further preferred embodiment, wherein R 5 The substitution position is the N atom on the ring.

[0170] In a further preferred embodiment, wherein ring A is selected from

[0171] In a further preferred embodiment, wherein ring A is selected from

[0172] In a further preferred embodiment, wherein ring A is selected from

[0173] In a further preferred embodiment, wherein ring A is selected from

[0174] In a third aspect, the present invention provides a compound represented by formula (III), or a tautomer, stereoisomer, or pharmaceutically acceptable salt thereof, which has the following structure:

[0175] where X 1 Selected from C, N, O or S; n 1 Selected from 0, 1, 2, 3; R 1 、R 2 、R 3 、R 4 、R 5 , L and X are as defined for the compound represented by formula (I) of the present invention.

[0176] In a further preferred embodiment, wherein n1 Selected from 0, 1 or 2;

[0177] In a further preferred embodiment, wherein L is selected from a bond;

[0178] In a further preferred embodiment, wherein X 1 is selected from C, N or O;

[0179] In a further preferred embodiment, wherein, Selected from

[0180] In a further preferred embodiment, wherein ring A is selected from

[0181] In a fourth aspect, the present invention provides a compound represented by formula (III-a), (III-b), (III-c), (III-d) or (III-e), or a tautomer, stereoisomer or pharmaceutically acceptable salt thereof, which has the following structure:

[0182] where R 1 、R 2 、R 3 、R 4 、R 5 、R 6 , L and X are as defined for the compound represented by formula (I).

[0183] In a further preferred embodiment, wherein L is selected from a bond;

[0184] In a further preferred embodiment, wherein R 5 The substitution position is the N atom on the ring.

[0185] In a further preferred embodiment, wherein ring A is selected from

[0186] In a further preferred embodiment, wherein X is selected from N or CH;

[0187] In a further preferred embodiment, wherein L is a bond;

[0188] In a further preferred embodiment, wherein R 3 Selected from -Cl or -CF3;

[0189] In a further preferred embodiment, wherein R 2 selected from hydrogen;

[0190] In a further preferred embodiment, wherein R 6 selected from hydrogen;

[0191] In a further preferred embodiment, wherein R 4 is hydrogen; R 5 Selected from hydrogen, methyl, phenyl,

[0192] In a further preferred embodiment, wherein R 1 Selected from optionally one or more R a substituted pyridyl;

[0193] In a further preferred embodiment, wherein R a Each occurrence is independently selected from Cl, methyl, methoxy;

[0194] In a further preferred embodiment, wherein R 1 Selected from

[0195] In a fifth aspect, the present invention provides an atropisomer of a compound represented by Formula (III-a), (III-b), (III-c), (III-d) or (III-e), or a pharmaceutically acceptable salt thereof:

[0196] where R 1 、R 2 、R 3 、R 4 、R 5 、R 6 , L and X are as described for the compound represented by formula (III-a), (III-b), (III-c), (III-d) or (III-e), wherein L is a bond, R 1 At least one R a replaced.

[0197] Atropisomers are stereoisomers resulting from hindered rotation about a single bond axis, where the barriers to rotation are sufficiently high to allow separation of the individual rotamers. (LaPlante et al., J. Med. Chem., 54:7005 (2011)). Compounds of formula (III-a), (III-b), (III-c), (III-d), or (III-e), wherein R 1 By one or more R a Substituted in the quinazolinone ring with the group R 1The bond between the two rings has a chiral axis (stereogenic axis). Due to the asymmetric nature of the substitutions on the rings connected by this bond, and due to the restricted rotation of this bond caused by steric hindrance, such compounds can form rotamers. Therefore, these compounds of formula (III-a), (III-b), (III-c), (III-d) or (III-e) can form two rotamers, which can be separated into individual atropisomers in certain circumstances, such as chromatography on a chiral stationary phase.

[0198] In further preferred embodiments, the compound of formula (III-a), (III-b), (III-c), (III-d) or (III-e) can be provided as a mixture of two atropisomers or as a single atropisomer. They are separable and stable in solution at ambient and physiological temperatures. The absolute spatial structure of the atropisomers can be determined by single crystal X-ray crystallography.

[0199] In a further preferred embodiment, the compound of formula (III-a), (III-b), (III-c), (III-d) or (III-e) may be provided as an individual atropisomer or as a mixture comprising two atropisomers of formula (III-a), (III-b), (III-c), (III-d) or (III-e) in any ratio.

[0200] In a further preferred embodiment, the compound of formula (III-a), (III-b), (III-c), (III-d) or (III-e), or a salt thereof, wherein only one atropisomer is provided, or wherein only one atropisomer is provided in admixture with minor amounts of other atropisomers. If no absolute configuration is assigned, the atropisomer provided can be defined by the order of elution relative to the other atropisomer during chromatography on a chiral stationary phase under specific conditions.

[0201] In further preferred embodiments, atropisomers of compounds of Formula (III-a), (III-b), (III-c), (III-d) or (III-e), wherein each atropisomer of a compound of Formula (III-a), (III-b), (III-c), (III-d) or (III-e) is provided substantially free of its complementary atropisomer. As used herein, "substantially free" means providing a compound of Formula (I) having at least 95% atropisomer purity, preferably at least 99% atropisomer purity, and more preferably at least 99.5% atropisomer purity.

[0202] On the basis of conforming to the common sense in this field, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present invention.

[0203] Preferably, the compound provided by the present invention or its tautomer, stereoisomer, atropisomer or pharmaceutically acceptable salt, wherein the compound has the following structure:

[0204] In a sixth aspect, the present invention also aims to provide a method for preparing the compound represented by the above general formula or its tautomers, stereoisomers, or pharmaceutically acceptable salts thereof.

[0205] The method can be prepared, for example, using the method shown in the following scheme.

[0206] Method 1:

[0207] The methyl group of 1.9 is removed to give intermediate 1.10, which is then subjected to a ring closure reaction to give the target compound 1.11. Alternatively, the methyl group of intermediate 1.9 is removed and an in situ ring closure reaction is performed to give the target compound 1.11.

[0208] In a further preferred embodiment, wherein compound 1.9 can be prepared by the following steps:

[0209] Starting from a fluorinated aryl formic acid (1.1), an ester is formed with methanol to obtain intermediate 1.2, followed by bromination at the benzyl position of the aromatic ring to obtain intermediate 1.3, and then the bromine atom is replaced by a methoxy group to obtain compound 1.4, which undergoes esterification under alkaline conditions to obtain intermediate 1.5 containing a carboxyl group, and then the carboxyl group is converted into an amide to obtain intermediate 1.6, which is then reacted with R under the action of oxalyl chloride. 1 -L-NH2 reacts to give intermediate 1.7, which is then subjected to ring closure reaction under alkaline conditions to give intermediate 1.8, which reacts with phosphorus oxychloride and then with R 5 Reaction with NH2 affords intermediate 1.9.

[0210] where R 1 、R 2 、R 3 、R 4 、R 5 , L and X are as described for the compound represented by formula (III-a).

[0211] Method 2:

[0212] 2.8 is cyclized with methanesulfonyl chloride to give the target compound 2.9.

[0213] In a further preferred embodiment, wherein compound 2.8 can be prepared by the following steps:

[0214] Starting from fluorinated and brominated aryl formic acid (2.1), the carboxylic acid is converted into the amide intermediate 2.2, which is then reacted with R 1 -L-NH2 was reacted to give intermediate 2.3, followed by a ring-closure reaction under alkaline conditions to give intermediate 2.4. 2.4 reacted with isobutyl acrylate to give compound 2.5 via a Heck reaction, and then the double bond was reduced with sodium borohydride to give intermediate 2.6. This was then reacted with phosphorus oxychloride and subsequently R5NH2 was added to give intermediate 2.7, which was then reduced with lithium aluminum hydride to give the hydroxyl-containing intermediate 2.8.

[0215] where R 1 、R 2 、R 3 、R 5 , L and X are as described for the compound represented by formula (III-b).

[0216] Method 3:

[0217] 3.5 undergoes substitution reaction under alkaline conditions to give the target compound 3.6.

[0218] In a further preferred embodiment, wherein compound 3.5 can be prepared by the following steps:

[0219] Starting from substituted 2,6-difluorobenzoic acid (3.1), the carboxylic acid was converted to the amide intermediate 3.2, which was then reacted with R 1 -L-NH2 reacts to give intermediate 3.3, followed by ring closure under alkaline conditions to give intermediate 3.4, 3.4 reacts with phosphorus oxychloride, and then an amine compound substituted with a terminal hydroxyl group is added to give intermediate 3.5.

[0220] where R 1 、R 2 、R 3 、R 4 、R 5 、R 6 and L are as described for the compound represented by formula (III-c).

[0221] Method 4:

[0222] 4.2 is subjected to dealkylation and ring closure reaction under acidic conditions to give the target compound 4.3.

[0223] In a further preferred embodiment, wherein compound 4.2 can be prepared by the following steps:

[0224] Where alkyl represents C 1-6 alkyl.

[0225] Starting from 3.4, a substitution reaction with an acetal substituted with a terminal amino group is carried out to give intermediate 4.1, which is then reacted with phosphorus oxychloride and subsequently an amine compound is added to give intermediate 4.2.

[0226] where R 1 、R 2 、R 3 、R 4 、R 5 、R 6 and L are as described for the compound represented by formula (III-d).

[0227] Method 5:

[0228] The hydroxyl group of 5.12 was converted into the MsO fragment with strong leaving ability, and finally an intramolecular ring-closure reaction occurred under alkaline conditions to obtain the target compound 5.14.

[0229] In a further preferred embodiment, wherein compound 5.12 can be prepared by the following steps:

[0230] Starting from 5.1, it reacts with phosphorus oxychloride to obtain intermediate 5.2, which is then reacted with potassium vinyl boron trifluoride to obtain intermediate 5.3. Subsequently, it is hydrolyzed under alkaline conditions to obtain compound 5.4 containing a carboxyl fragment. The carboxyl group is then converted into an amide, which is then reacted with p-toluenesulfonyl chloride to obtain intermediate 5.6. Then, under the action of oxalyl chloride, it reacts with R 1 The NH2 reaction gave intermediate 5.7, which then underwent intramolecular ring closure under alkaline conditions to give intermediate 5.8. The vinyl group of 5.8 was then oxidized to a formic acid fragment, and the carboxyl group of 5.9 was subsequently converted to a methyl ester. The methyl ester was then reacted with R in the presence of phosphorus oxychloride. 5 NH2 reaction affords intermediate 5.11, which is then reduced to the methyl ester fragment to afford intermediate 5.12.

[0231] where R 1 、R 2 、R 3 、R 5 , L and X are as described for the compound represented by formula (III-a).

[0232] Method 6:

[0233] 6.4 react with phosphorus oxychloride and then with R 5 NH2 reaction gave intermediate 6.5, which was then reacted with the corresponding aldehyde R 4 The target compound 6.6 was obtained by CHO reaction.

[0234] In a further preferred embodiment, wherein compound 6.4 can be prepared by the following steps:

[0235] Starting from 6.1, the carboxyl group was converted to amide to give intermediate 6.2, which was then reacted with R 1 -L-NH2 reaction to give intermediate 6.3, followed by ring closure under basic conditions to give intermediate 6.4.

[0236] where R 1 、R 2 、R 3 、R 5 、R 6 , L are as described for the compound represented by formula (III-c).

[0237] Method 7:

[0238] Using intermediate 5.8 as the starting material, under the action of PyBop and DBU, it reacted with R 5 NH2 reaction gave the target compound 7.1.

[0239] where R 1 、R 2 、R 3 、R 5 , L and X are as described for the compound represented by formula (III-e).

[0240] Note: The protection and deprotection reaction steps involved in this step have been omitted. The substituents are defined as in the above general formula.

[0241] The present invention also aims to provide the following intermediates for preparing compounds of the general formula:

[0242] Among them, R 1 、R 2 、R 3 、R 4 、R 5 、R 6 , L and X are defined as those for the compound represented by formula (I) of the present invention, wherein alkyl represents C 1-6 alkyl.

[0243] Another aspect of the present invention provides a pharmaceutical composition comprising the compound of the present invention or its tautomer, stereoisomer or pharmaceutically acceptable salt.

[0244] Furthermore, the pharmaceutical composition of the present invention comprises the compound of the present invention or its tautomer, stereoisomer or pharmaceutically acceptable salt, and pharmaceutically acceptable excipients.

[0245] The administration of the compound of the present invention or its tautomer, stereoisomer or pharmaceutically acceptable salt thereof can be carried out in pure form or in the form of a suitable pharmaceutical composition by any acceptable mode of administration for providing drugs of similar use. The pharmaceutical composition of the present invention can be prepared by combining the compound of the present invention with a suitable pharmaceutically acceptable excipient.

[0246] Another aspect of the present invention also provides use of the compound of the present invention or its tautomer, stereoisomer, or pharmaceutically acceptable salt or pharmaceutical composition of the present invention in the preparation of a medicament for preventing and / or treating diseases, disorders and conditions mediated by MAT2A.

[0247] Furthermore, the present invention provides uses, wherein the diseases, disorders and conditions are MTAP-deficient tumors.

[0248] Another aspect of the present invention provides use of the compound of the present invention or its tautomers, stereoisomers, or the pharmaceutical composition of the present invention in the preparation of a drug for preventing and / or treating tumors.

[0249] Furthermore, in the use provided by the present invention, the tumor includes solid tumors and hematological tumors; preferably, the solid tumor includes a digestive tract tumor, and more preferably colorectal cancer. In certain contexts in the art, the cancer may also be referred to as a malignant tumor.

[0250] In another aspect, the present invention provides a method for preventing and / or treating diseases, disorders and conditions mediated by MAT2A, comprising administering to an individual in need thereof a compound of the present invention or its tautomer, stereoisomer or pharmaceutically acceptable salt, or a pharmaceutical composition of the present invention; preferably, the disease, disorder and condition is a tumor; preferably, the disease, disorder and condition is a tumor with MTAP deficiency; more preferably, the tumor includes solid tumors and hematological tumors.

[0251] In another aspect, the present application provides compounds of the present invention, or tautomers, stereoisomers, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions of the present invention for use in preventing and / or treating diseases, disorders, and conditions mediated by MAT2A; preferably, the diseases, disorders, and conditions are tumors in which MTAP is deleted; preferably, the diseases, disorders, and conditions are tumors; more preferably, the tumors include solid tumors and hematological tumors. Furthermore, the present invention provides uses or methods in which the compounds of the present invention, or tautomers, stereoisomers, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions of the present invention are used in combination with one, two, or more drugs having tumor-suppressing activity.

[0252] The present invention also provides a pharmaceutical composition comprising the compound of the present invention or its tautomers, stereoisomers or pharmaceutically acceptable salts thereof and another, two or more drugs having tumor-inhibiting activity.

[0253] definition

[0254] The terms "optional," "optionally," "optionally," or "optionally" mean that the subsequently described event or circumstance may but need not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.

[0255] Unless otherwise specified, the term "optionally substituted" or "arbitrarily substituted" means that the substituents are independently selected from one or more hydroxyl, halogen, hydroxyl, amino, nitro, thiol, cyano, azido, carboxyl, -C(O)C 1-6 Alkyl, -C(O)OC 1-6 Alkyl, -OC(O)-C 1-6 Alkyl, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)(C 1-6 alkyl), -C(O)NH-C 1-6 Alkyl, -NHC(O)-C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-10 Cycloalkyl, C 3-10 Cycloalkylsulfonyl, 3-10 membered heterocycloalkyl, C 6-14 Aryl, 5-12 membered heteroaryl group; wherein, the C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-10 Cycloalkyl, C 3-10Cycloalkylsulfonyl, 3-10 membered heterocycloalkyl, C 6-14 The aryl or 5-12 membered heteroaromatic ring group may be optionally selected from halogen, hydroxy, amino, cyano, C 1-6 Alkyl or C 1-6 is substituted by one or more alkoxy groups.

[0256] The term "oxo" refers to a group in which two hydrogen atoms at the same substitution position are replaced by the same oxygen atom to form a double bond.

[0257] Unless otherwise specified, the term "carbocyclyl" refers to a saturated or partially unsaturated cyclic carbon-containing group, such as a 4-6 membered (e.g., 5-6 membered) saturated carbocycle and a 5-6 membered partially unsaturated carbocycle. In one embodiment, the carbocyclyl is a 3-4 membered monocycle, a 3-5 membered monocycle, a 3-6 membered monocycle, a 3-8 membered monocycle, a 3-10 membered monocycle, a 5-8 membered monocycle, a 5-6 membered monocycle, a 4-12 membered bicyclic ring, or a 10-15 membered tricyclic ring system. Carbocycles include bridged rings or spirocycles. The limiting examples of carbocyclic radical include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclopentenyl, cyclohexadienyl, cycloheptatrienyl, benzocyclopentyl, bicyclo [3.2.1] octanyl, bicyclo [5.2.0] nonanyl, tricyclo [5.3.1.1] dodecyl, adamantyl or spiral [3.3] heptyl etc.Carbocyclic radical can be optionally substituted.When substituted, substituent is preferably 1 to 5, and described substituent is independently selected from F, Cl, Br, I, =O, alkyl, alkenyl, alkynyl, alkoxy, hydroxyl, nitro, cyano and amino.

[0258] Unless otherwise specified, the term "alkyl" refers to a monovalent saturated aliphatic hydrocarbon group, a straight or branched chain group containing 1 to 20 carbon atoms, preferably containing 1 to 10 carbon atoms (i.e., C 1-10 Alkyl), further preferably containing 1 to 8 carbon atoms (C 1-8 Alkyl), more preferably containing 1-6 carbon atoms (ie C 1-6 Alkyl), such as "C 1-6 "Alkyl" means that the group is an alkyl group and the number of carbon atoms in the carbon chain is between 1 and 6 (specifically 1, 2, 3, 4, 5 or 6). Examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, neopentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, n-heptyl, n-octyl, and the like.

[0259] Unless otherwise specified, the term "alkenyl" refers to a straight or branched unsaturated aliphatic hydrocarbon group consisting of carbon atoms and hydrogen atoms and having at least one double bond. The alkenyl group may contain 2 to 20 carbon atoms, preferably 2 to 10 carbon atoms (i.e., C 2-10 alkenyl), further preferably containing 2 to 8 carbon atoms (C 2-8 alkenyl), more preferably containing 2 to 6 carbon atoms (ie, C 2-6 alkenyl), 2-5 carbon atoms (ie C 2-5 alkenyl), 2-4 carbon atoms (ie C 2-4 alkenyl), 2-3 carbon atoms (ie C 2-3 alkenyl), 2 carbon atoms (i.e., C2 alkenyl), for example, "C 2-6 The term "alkenyl" refers to an alkenyl group, and the number of carbon atoms in the carbon chain is between 2 and 6 (specifically 2, 3, 4, 5 or 6). Non-limiting examples of alkenyl groups include, but are not limited to, ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, isobutenyl and 1,3-butadienyl.

[0260] Unless otherwise specified, the term "alkynyl" refers to a straight or branched unsaturated aliphatic hydrocarbon group consisting of carbon atoms and hydrogen atoms and having at least one triple bond. The alkynyl group may contain 2 to 20 carbon atoms, preferably 2 to 10 carbon atoms (i.e., C 2-10 Alkynyl), further preferably containing 2 to 8 carbon atoms (C 2-8 Alkynyl), more preferably containing 2-6 carbon atoms (ie, C 2-6 Alkynyl), 2-5 carbon atoms (ie C 2-5 Alkynyl), 2-4 carbon atoms (ie C 2-4 Alkynyl), 2-3 carbon atoms (ie C 2-3 alkynyl), 2 carbon atoms (i.e., C2 alkynyl), for example, "C 2-6 "Alkynyl" means that the group is an alkynyl group, and the number of carbon atoms in the carbon chain is between 2 and 6 (specifically 2, 3, 4, 5 or 6). Non-limiting examples of alkynyl groups include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl and 1-butynyl.

[0261] Unless otherwise specified, the term "cycloalkyl" refers to a monocyclic saturated aliphatic hydrocarbon group having the specified number of carbon atoms, preferably containing 3 to 12 carbon atoms (i.e., C 3-12 cycloalkyl), more preferably containing 3 to 10 carbon atoms (C 3-10 cycloalkyl), further preferably 3-7 carbon atoms (C 3-7 Cycloalkyl), 4-6 carbon atoms (C 4-6 Cycloalkyl), 5-6 carbon atoms (C 5-6Examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methylcyclopropyl, 2-ethyl-cyclopentyl, dimethylcyclobutyl, and the like.

[0262] Unless otherwise specified, the term "alkoxy" refers to an -O-alkyl group, wherein the alkyl group is as defined above, i.e., containing 1 to 20 carbon atoms, preferably 1 to 10 carbon atoms, more preferably 1 to 8 carbon atoms, and more preferably 1 to 6 carbon atoms (specifically 1, 2, 3, 4, 5 or 6). Representative examples include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, butoxy, 1-methylpropoxy, 2-methylpropoxy, tert-butoxy, pentyloxy, 1-methylbutoxy, 2-methylbutoxy, 3-methylbutoxy, 1,1-dimethylpropoxy, 1,2-dimethylpropoxy, 2,2-dimethylpropoxy, 1-ethylpropoxy, and the like.

[0263] Unless otherwise specified, the term "alkylthio" refers to an -S-alkyl group, wherein the alkyl group is as defined above, i.e., containing 1 to 20 carbon atoms, preferably 1 to 10 carbon atoms, more preferably 1 to 8 carbon atoms, and more preferably 1 to 6 carbon atoms (specifically 1, 2, 3, 4, 5 or 6). Representative examples include, but are not limited to, methylthio, ethylthio, propylthio, isopropylthio, butylthio, 1-methylpropylthio, 2-methylpropylthio, tert-butylthio, pentylthio, 1-methylbutylthio, 2-methylbutylthio, 3-methylbutylthio, 1,1-dimethylpropylthio, 1,2-dimethylpropylthio, 2,2-dimethylpropylthio, 1-ethylpropylthio, and the like.

[0264] Unless otherwise specified, the term "halogen" or "halo" refers to F, Cl, Br, I. The term "haloalkyl" refers to an alkyl group as defined above in which one, two or more hydrogen atoms or all of the hydrogen atoms are replaced by halogen. Representative examples of haloalkyl include CCl3, CF3, CHCl2, CH2Cl, CH2Br, CH2I, CH2CF3, CF2CF3, and the like.

[0265] Unless otherwise specified, the term "heterocyclyl" or "heterocycle" refers to a saturated or partially unsaturated monocyclic or polycyclic non-aromatic substituent having ring carbon atoms and 1 to 4 ring heteroatoms, containing 3 to 20 ring atoms, of which 1, 2, 3 or more ring atoms are selected from N, O or S, and the remaining ring atoms are C. Preferably, the heterocyclyl contains 3 to 12 ring atoms (3-12 membered heterocyclyl), more preferably 3 to 10 ring atoms (3-10 membered heterocyclyl), or 3 to 8 ring atoms (3-8 membered heterocyclyl), or 3 to 6 ring atoms (3-6 membered heterocyclyl), or 4 to 6 ring atoms (4-6 membered heterocyclyl), or 5 to 6 ring atoms (5-6 membered heterocyclyl). The number of heteroatoms is preferably 1 to 4, more preferably 1 to 3 (i.e., 1, 2 or 3). Examples of monocyclic heterocyclic groups include pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, dihydropyrrolyl, piperidinyl, piperazinyl, pyranyl, etc. Polycyclic heterocyclic groups include spirocyclic, fused ring and bridged heterocyclic groups. "Heterocyclic group" can be a monocyclic ("monocyclic heterocyclic group") or a fused ("fused heterocyclic group" or "heterofused heterocyclic group"), bridged ("heterobridged heterocyclic group" or "bridged heterocyclic group") or spiro-fused ("heterospirocyclic group" or "spirocyclic heterocyclic group") ring system, such as a bicyclic system ("bicyclic heterocyclic group"), and can be saturated or partially unsaturated. Heterocyclic bicyclic systems can include one or more heteroatoms in one or both rings. "Heterocyclyl" also includes ring systems in which the heterocyclyl ring, as defined above, is fused to one or more carbocyclyl groups, wherein the point of attachment is on the carbocyclyl or heterocyclyl ring, or "heterocyclyl" also includes ring systems in which the heterocyclyl ring, as defined above, is fused to one or more aryl or heteroaryl groups, or a cycloalkyl ring, as defined above, is fused to one or more heteroaryl groups, wherein the point of attachment is on the heterocyclyl or cycloalkyl ring, and in such cases, the number of members of the heterocyclyl ring system is the number of atoms in the ring system after fusion. In certain embodiments, each instance of heterocyclyl is independently optionally substituted, e.g., unsubstituted (an "unsubstituted heterocyclyl") or substituted (a "substituted heterocyclyl") with one or more substituents. Exemplary 3-membered heterocyclyl groups containing 1 heteroatom include, but are not limited to, aziridine, oxiranyl, and thiorenyl. Exemplary 4-membered heterocyclyl groups containing one heteroatom include, but are not limited to, azetidinyl, oxetanyl, and thietanyl. Exemplary 5-membered heterocyclyl groups containing one heteroatom include, but are not limited to, tetrahydrofuranyl, dihydrofuranyl, tetrahydrophenylthio, dihydrophenylthio, pyrrolidinyl, dihydropyrrolyl, and pyrrolyl-2,5-dione. Exemplary 5-membered heterocyclyl groups containing two heteroatoms include, but are not limited to, dioxolanyl, oxathiolanyl, dithiolanyl, and oxazolidin-2-one.Exemplary 5-membered heterocyclyl groups containing 3 heteroatoms include, but are not limited to, triazolinyl, oxadiazolinyl, and thiadiazolinyl. Exemplary 6-membered heterocyclyl groups containing 1 heteroatom include, but are not limited to, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl. Exemplary 6-membered heterocyclyl groups containing 2 heteroatoms include, but are not limited to, piperazinyl, morpholinyl, dithianyl, and dioxanyl. Exemplary 6-membered heterocyclyl groups containing 3 heteroatoms include, but are not limited to, triazacyclohexane, oxadiazinyl, thiadiazinyl, oxathiazinyl, and dioxazacyclohexane. Exemplary 7-membered heterocyclyl groups containing 1 heteroatom include, but are not limited to, azepanyl, oxanyl, and thianyl. Exemplary 8-membered heterocyclyl groups containing 1 heteroatom include, but are not limited to, azocanyl, oxacyclooctanyl, and thiocanyl. Exemplary 5-membered heterocyclyl groups fused to a C6 aryl ring (also referred to herein as a 5,6-bicyclic heterocycle) include, but are not limited to, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinyl, and the like. Exemplary 6-membered heterocyclyl groups fused to an aryl ring (also referred to herein as a 6,6-bicyclic heterocycle) include, but are not limited to, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and the like.

[0266] Unless otherwise specified, “heterocycloalkyl” refers to a monocyclic, saturated “heterocyclyl” or “heterocycle” as defined above, with the ring atoms as defined above, i.e., containing 3 to 20 ring atoms (“3-20 membered heterocycloalkyl”), with 1 to 4 heteroatoms (1, 2, 3 or 4), preferably 1 to 3 heteroatoms (1, 2 or 3), wherein each heteroatom is independently selected from N, O or S. Preferably, the group contains 3 to 12 ring atoms (“3-12 membered heterocycloalkyl”), more preferably 3 to 10 ring atoms (“3-10 membered heterocycloalkyl”), even more preferably 3 to 8 ring atoms (“3-8 membered heterocycloalkyl”), even more preferably 4 to 7 ring atoms (“4-7 membered heterocycloalkyl”), even more preferably 5 to 10 ring atoms (“5-10 membered heterocycloalkyl”), even more preferably 5 to 6 ring atoms (“5-6 membered heterocycloalkyl”). In certain embodiments, each example of heterocycloalkyl is independently optionally substituted, e.g., unsubstituted (an "unsubstituted heterocycloalkyl") or substituted with one or more substituents (a "substituted heterocycloalkyl"). Some exemplary "heterocycloalkyl" groups are given above in the "heterocyclyl" or "heterocycle" section, and also include, but are not limited to, aziridine, oxirane, thiirane, azetidinyl, oxetanyl, thietanyl, tetrahydrofuranyl, oxanyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, oxathiolanyl, oxazolidinyl, dioxanyl, dithiolanyl, thiazolidinyl, pyrrolidinyl, pyrazolidinyl, imidazolinyl, and the like.

[0267] Unless otherwise specified, the term "aryl" or "aromatic ring group" refers to a monocyclic, bicyclic, or tricyclic aromatic carbocyclic ring system containing 6 to 16 carbon atoms, or 6 to 14 carbon atoms, or 6 to 12 carbon atoms, or 6 to 10 carbon atoms, preferably 6 to 10 carbon atoms. The term "aryl" can be used interchangeably with the term "aromatic ring group." Examples of aryl groups include, but are not limited to, phenyl, naphthyl, anthracenyl, phenanthrenyl, or pyrenyl.

[0268] Unless otherwise specified, the term "heteroaryl" or "heteroaromatic ring group" means an aromatic monocyclic or polycyclic ring system containing a 5-14 membered structure, or preferably a 5-10 membered structure, or preferably a 5-8 membered structure, more preferably a 5-6 membered structure, wherein 1, 2, 3 or more ring atoms are heteroatoms and the remaining atoms are carbon, the heteroatoms are independently selected from O, N or S, and the number of heteroatoms is preferably 1, 2 or 3. Examples of heteroaryl groups include, but are not limited to, furyl, thienyl, oxazolyl, thiazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, thiodiazolyl, triazinyl, phthalazinyl, quinolyl, isoquinolyl, pteridinyl, purinyl, indolyl, isoindolyl, indazolyl, benzofuranyl, benzothiophenyl, benzopyridinyl, benzopyrimidinyl, benzo pyrazinyl, benzimidazolyl, benzophthalazinyl, pyrrolo[2,3-b]pyridinyl, imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-b]pyridazinyl, [1,2,4]triazolo[4,3-b]pyridazinyl, [1,2,4]triazolo[1,5-a]pyrimidinyl, [1,2,4]triazolo[1,5-a]pyridinyl, etc.

[0269] Unless otherwise specified, the term "pharmaceutically acceptable salt" or "pharmaceutically acceptable salt" refers to a salt that is suitable for use in contact with mammalian tissues, particularly human tissues, without excessive toxicity, irritation, allergic response, etc., and is commensurate with a reasonable benefit / risk ratio, within the scope of sound medical judgment. For example, pharmaceutically acceptable salts of amines, carboxylic acids, and other types of compounds are well known in the art. The salts can be prepared in situ during the final isolation and purification of the compounds of the present invention, or separately by reacting the free base or free acid with a suitable reagent.

[0270] The compounds of the present invention also include their "isotopic derivatives". Unless otherwise specified, the term "isotopic derivative" means that the compounds of the present invention may exist in an isotopically labeled or enriched form, containing one or more atoms whose atomic mass or mass number is different from the atomic mass or mass number of the largest atom found in nature. Isotopes can be radioactive or non-radioactive isotopes. Isotopes commonly used as isotopic labels are: hydrogen isotopes, 2 H and 3 H; Carbon isotope: 13 C and 14 C; Chlorine isotope: 35 Cl and 37 Cl; Fluorine isotope: 18 F; Iodine isotope: 123 I and 125 I; Nitrogen isotopes: 13 N and 15N; oxygen isotopes: 15 O. 17 O and 18 O and sulfur isotopes 35 These isotope-labeled compounds can be used to study the distribution of pharmaceutical molecules in tissues. 3 H and 13 C, because they are easy to label and detect, they are more widely used. Some heavy isotopes, such as deuterium ( 2 H) substitution can enhance metabolic stability, extend half-life, and thus achieve the purpose of reducing dosage and provide therapeutic advantages. Isotope-labeled compounds are generally synthesized from labeled starting materials using known synthetic techniques similar to those for synthesizing non-isotope-labeled compounds. The compounds of the present invention also include "solvates" and "solvates thereof." Unless otherwise specified, the terms "solvate" and "solvate" refer to the physical association of a compound of the present invention with one or more solvent molecules (whether organic or inorganic). This physical association includes hydrogen bonding. In certain cases, such as when one or more solvent molecules are incorporated into the crystal lattice of a crystalline solid, the solvate will be able to be isolated. The solvent molecules in the solvate may exist in a regular and / or disordered arrangement. The solvate may contain stoichiometric or non-stoichiometric amounts of solvent molecules. "Solvate" encompasses both solution-phase and separable solvates. Exemplary solvates include, but are not limited to, hydrates, ethanolates, methanolates, and isopropanolates. Solvation methods are well known in the art.

[0271] Unless otherwise specified, the term "stereoisomer" refers to compounds that have the same chemical constitution but differ in the way the atoms or groups are arranged in space. Stereoisomers include enantiomers, diastereomers, conformers (rotamers), geometric isomers (cis / trans) isomers, atropisomers, etc. Any resulting mixture of stereoisomers can be separated into pure or substantially pure geometric isomers, enantiomers, and diastereomers based on the differences in the physicochemical properties of the components, for example, by chromatography and / or fractional crystallization.

[0272] The term "atropisomer" refers to a conformational stereoisomer that occurs when rotation about a single bond in a molecule is prevented or greatly slowed due to steric interactions with other parts of the molecule. The compounds of the present invention include all atropisomers as single atropisomers or as non-specific mixtures of each. If the barrier to rotation about a single bond is high enough, the interconversion between conformations is slow enough, and separation and isolation of the isomeric species as distinct compounds can be permitted. For example, groups such as, but not limited to, the following R1 groups May exhibit restricted rotation.

[0273] Unless otherwise specified, the term "tautomer" refers to structural isomers of different energies that are interconvertible through a low energy barrier. If tautomerism is possible (e.g., in solution), a chemical equilibrium of the tautomers can be achieved. For example, proton tautomers (also known as prototropic tautomers) include interconversions that occur via proton migration, such as keto-enol isomerization and imine-enamine isomerization. Valence tautomers include interconversions that occur via reorganization of some of the bonding electrons.

[0274] Unless otherwise indicated, the structural formulas described herein include all isomeric forms (e.g., enantiomers, diastereomers, and geometric isomers (or conformers)): for example, R and S configurations containing asymmetric centers, (Z) and (E) isomers of double bonds, and (Z) and (E) conformers. Therefore, single stereochemical isomers of the compounds of the present invention or mixtures of their enantiomers, diastereomers, or geometric isomers (or conformers) are within the scope of the present invention.

[0275] The compounds of the present invention also include "prodrugs" thereof. Unless otherwise specified, the term "prodrug" refers to a drug that is converted into the parent drug in vivo. Prodrugs are generally useful because they can improve certain, undesirable physical or biological properties. Physical properties are often related to solubility (excessive or insufficient lipid or water solubility) or stability, while problematic biological properties include rapid metabolism or poor bioavailability, which may themselves be related to physicochemical properties. For example, they may be bioavailable orally, whereas the parent drug is not. Prodrugs also have improved solubility in pharmaceutical compositions compared to the parent drug. An example, but not limited to, of a prodrug is any compound of the present invention administered as an ester ("prodrug") to facilitate transport across cell membranes, where water solubility is detrimental to mobility, but once inside the cell, water solubility is beneficial, which is then metabolically hydrolyzed to the carboxylic acid, the active entity. Another example of a prodrug is a short peptide (polyamino acid) conjugated to an acid group, where the peptide is metabolized to reveal the active moiety.

[0276] Abbreviations used in the Preparation Examples, Examples, and elsewhere herein are:

[0277] DMF N,N-dimethylformamide

[0278] DBU 1,8-diazabicyclo[5.4.0]undec-7-ene

[0279] DIEA N,N-Diisopropylethylamine

[0280] SPhos 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl

[0281] PyBop 1H-Benzotriazol-1-yloxytripyrrolidino hexafluorophosphate

[0282] The beneficial effects of the present invention are:

[0283] The present invention designs a class of novel compounds, providing a new approach for treating diseases such as tumors. Enzyme assays demonstrate that the compounds of the present invention have a strong inhibitory effect on MAT2A. They exhibit strong cell proliferation activity against HCT116 MTAP knockout cells and weaker cell proliferation activity against HCT116 cells with wild-type MTAP, demonstrating good selectivity. They also exhibit excellent in vivo efficacy. Furthermore, human UGT1A1 enzyme activity assays demonstrate that the compounds of the present invention have a low risk of inhibiting UGT1A1. Pharmacokinetic studies demonstrate high oral bioavailability and good dose-exposure correlation. Human endogenous ergosterol (hERG) assays demonstrate low cardiotoxicity. Furthermore, the present invention investigates a specific synthesis method that is simple, easy to operate, and suitable for large-scale industrial production and application. DETAILED DESCRIPTION

[0284] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. Experimental methods in the following examples where specific conditions are not specified are generally performed under conventional conditions or according to the conditions recommended by the manufacturer. Unless otherwise defined, all professional and scientific terms used herein have the same meanings as those familiar to professionals in the field. In addition, any methods and materials similar or equivalent to those described herein can be applied to the present invention. The preferred embodiments and materials shown herein are for demonstration purposes only.

[0285] The following are preparation examples of exemplary compounds of the present invention.

[0286] Example 1: 7-Chloro-1-(2-methylpyridin-3-yl)-4,5-dihydropyrrolo[2,3,4-de]quinazolin-2(1H)-one (A1)

[0287] Step 1: Synthesis of methyl 4-chloro-2-fluoro-6-methylbenzoate

[0288] To a 250 mL round-bottom flask, 4-chloro-2-fluoro-6-methylbenzoic acid (8.44 g, 44.70 mmol) and dichloromethane (100 mL) were added. Oxalyl chloride (8.51 g, 67.10 mmol) and DMF (0.2 mL) were then added and stirred at room temperature. After completion of the reaction as monitored by TLC, the solvent was removed under reduced pressure, methanol (200 mL) and 5M sodium methoxide (13.41 mL, 67.05 mmol) were added, and the reaction was allowed to proceed for 0.5 h. After completion of the reaction, the solvent was removed under reduced pressure, 100 mL of water was added, and the mixture was extracted twice with 80 mL of ethyl acetate. The organic phases were combined, washed sequentially with water and saturated sodium chloride solution, and concentrated to obtain the desired product, methyl 4-chloro-2-fluoro-6-methylbenzoate (8.43 g, 93% yield).

[0289] Step 2: Synthesis of methyl 2-(bromomethyl)-4-chloro-6-fluorobenzoate

[0290] The product of the previous step, methyl 4-chloro-2-fluoro-6-methylbenzoate (8.43 g, 41.70 mmol), NBS (9.66 g, 54.27 mmol), azobisisobutyronitrile (2.05 g, 12.50 mmol) and carbon tetrachloride (160 mL) were added to a 250 mL round-bottom flask and heated to 85 degrees Celsius. The reaction was completed after 8 h, and the mixture was concentrated and used directly in the next step.

[0291] Step 3: Synthesis of methyl 4-chloro-2-fluoro-6-(methoxymethyl)benzoate

[0292] The concentrated product of the previous step, methyl 2-(bromomethyl)-4-chloro-6-fluorobenzoate, 5M sodium methoxide (12.51 mL, 62.55 mmol) and methanol (50 mL) were added to a 250 mL round-bottom flask and stirred at room temperature. The reaction was completed after 1 h, and the solvent was removed under reduced pressure. 100 mL of water was added and the mixture was extracted twice with 80 mL of ethyl acetate. The organic phases were combined, washed sequentially with water and saturated sodium chloride solution, concentrated, and purified by column chromatography to obtain methyl 4-chloro-2-fluoro-6-(methoxymethyl)benzoate (5.1 g, two-step yield 53%).

[0293] Step 4: Synthesis of 4-chloro-2-fluoro-6-(methoxymethyl)benzoic acid

[0294] The product from the previous step, methyl 4-chloro-2-fluoro-6-(methoxymethyl)benzoate (4.60 g, 19.70 mmol), sodium hydroxide (3.10 g, 79.09 mmol), methanol (40 mL), and water (10 mL) were added to a 100 mL round-bottom flask and stirred at room temperature for 2 hours. After the reaction, 100 mL of water was added, the pH was adjusted to 4-5 with concentrated hydrochloric acid, and extraction was performed twice with 80 mL of ethyl acetate. The organic phases were combined, washed sequentially with water and saturated sodium chloride solution, and concentrated to yield the desired product, 4-chloro-2-fluoro-6-(methoxymethyl)benzoic acid (4.24 g, 98.1% yield). ESI-MS (m / z): 217.0 [MH] - .

[0295] Step 5: Synthesis of 4-chloro-2-fluoro-6-(methoxymethyl)benzamide

[0296] The product from the previous step, 4-chloro-2-fluoro-6-(methoxymethyl)benzoic acid (4.24 g, 19.39 mmol), ammonium chloride (1.35 g, 25.21 mmol), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (11.06 g, 29.09 mmol), and DMF (35 mL) were added to a 100 mL round-bottom flask. N,N-diisopropylethylamine (5.0 g, 38.78 mmol) was then added and the mixture was allowed to react at room temperature overnight. After completion of the reaction, 200 mL of water was added and the mixture was extracted twice with 100 mL of ethyl acetate. The organic phases were combined, washed sequentially with water and saturated sodium chloride solution, concentrated under reduced pressure, and purified by column chromatography to obtain the target compound, 4-chloro-2-fluoro-6-(methoxymethyl)benzamide (2.50 g, 59% yield). ESI-MS (m / z): 218.0 [M+H] + .

[0297] Step 6: Synthesis of 7-chloro-5-(methoxymethyl)-1-(2-methylpyridin-3-yl)quinazoline-2,4(1H,3H)-dione

[0298] The product from the previous step, 4-chloro-2-fluoro-6-(methoxymethyl)benzamide (300 mg, 1.37 mmol), oxalyl chloride (174 μL, 2.06 mmol), and anhydrous tetrahydrofuran (10 mL) were added to a 50 mL round-bottom flask and heated to 80°C. After the reaction, the reaction solution was cooled to room temperature, and 2-methylpyridin-3-amine (149 mg, 1.37 mmol) was added to the reaction solution and reacted at room temperature for 3 hours. After the reaction, 1 M potassium bis(trimethylsilyl)amide (5.48 mL, 5.48 mmol) was added to the reaction solution and stirred at room temperature for 4 hours. After the reaction, 100 mL of water was added, the pH was adjusted to 6-7 with acetic acid, and the mixture was extracted twice with 100 mL of ethyl acetate. The organic phases were combined, washed with water and saturated sodium chloride solution in sequence, concentrated, and purified by column chromatography to obtain the target product, 7-chloro-5-(methoxymethyl)-1-(2-methylpyridin-3-yl)quinazoline-2,4(1H,3H)-dione (310 mg, yield 68%). ESI-MS (m / z): 332.1 [M+H] + .

[0299] Step 7: Synthesis of 4-amino-7-chloro-5-(methoxymethyl)-1-(2-methylpyridin-3-yl)quinazolin-2(1H)-one

[0300] The product from the previous step, 7-chloro-5-(methoxymethyl)-1-(2-methylpyridin-3-yl)quinazoline-2,4(1H,3H)-dione (286 mg, 0.86 mmol), phosphorus oxychloride (262 mg, 2.58 mmol), N,N-diisopropylethylamine (749 μL, 4.31 mmol), and anhydrous dioxane (10 mL) were added to a 50 mL round-bottom flask and heated to 100°C with stirring. After the reaction was complete, the reaction solution was cooled to room temperature, and then aqueous ammonia solution (5 mL) was added to the reaction solution and reacted at room temperature for 0.5 h. After the reaction, 100 mL of water was added to the reaction solution, and the mixture was extracted twice with 100 mL of ethyl acetate. The organic phases were combined, washed with water and a saturated sodium chloride solution in sequence, concentrated, and purified by column chromatography to obtain the target product, 4-amino-7-chloro-5-(methoxymethyl)-1-(2-methylpyridin-3-yl)quinazolin-2(1H)-one (170 mg, yield 60%). ESI-MS (m / z): 331.1 [M+H] + .

[0301] Step 8: Synthesis of 4-amino-7-chloro-5-(hydroxymethyl)-1-(2-methylpyridin-3-yl)quinazolin-2(1H)-one

[0302] The product from the previous step, 4-amino-7-chloro-5-(methoxymethyl)-1-(2-methylpyridin-3-yl)quinazolin-2(1H)-one (150 mg, 0.45 mmol), boron tribromide (750 μL), and dichloromethane (7.5 mL) were added to a 25 mL round-bottom flask and reacted at room temperature overnight. After the reaction, 100 mL of water was added to the reaction solution, and the pH was adjusted to approximately 7 with sodium hydroxide. The solution was extracted three times with 100 mL of dichloromethane. The organic phases were combined, washed sequentially with water and saturated sodium chloride solution, concentrated, and directly purified by column chromatography to obtain the target product, 4-amino-7-chloro-5-(hydroxymethyl)-1-(2-methylpyridin-3-yl)quinazolin-2(1H)-one (100 mg, 70% yield). ESI-MS (m / z): 317.1 [M+H]. + .

[0303] Step 9: Synthesis of 7-chloro-1-(2-methylpyridin-3-yl)-4,5-dihydropyrrolo[2,3,4-de]quinazolin-2(1H)-one

[0304] The product of the previous step, 4-amino-7-chloro-5-(hydroxymethyl)-1-(2-methylpyridin-3-yl)quinazolin-2(1H)-one (100 mg, 0.32 mmol), N-bromosuccinimide (64 mg, 0.38 mmol), triphenylphosphine (124 mg, 0.47 mmol), triethylamine (96 mg, 0.95 mmol) and dichloromethane (5 mL) were added to a 25 mL round-bottom flask, and methylsulfonyl chloride (43 mg, 0.38 mmol) was added and the reaction was allowed to react at room temperature overnight. After the reaction, 100 mL of water was added to the reaction solution, and the mixture was extracted twice with 100 mL of ethyl acetate. The organic phases were combined, washed with water and saturated sodium chloride solution in sequence, concentrated, and directly purified by column chromatography to obtain the target product 7-chloro-1-(2-methylpyridin-3-yl)-4,5-dihydropyrrolo[2,3,4-de]quinazolin-2(1H)-one (40 mg, yield 42%), ESI-MS (m / z): 299.1 [M+H] + ; 1 H NMR(600MHz,DMSO)δ9.39(s,1H),8.57(d,J=3.9Hz,1H),7.73(d,J=7.6Hz,1 H),7.47–7.40(m,1H),7.30(s,1H),6.17(s,1H),4.85(s,2H),2.21(s,3H).

[0305] Two separate atropisomers A1-P1 and A1-P2 were obtained according to the separation method of A16. A1-P1, ESI-MS (m / z): 299.1 [M+H] + ; 1H NMR (600MHz, DMSO) δ9.39(s,1H),8.57(d,J=3.9Hz,1H),7.73(d,J=7.6Hz,1H),7.47–7.40(m ,1H),7.30(s,1H),6.17(s,1H),4.85(s,2H),2.21(s,3H).A1-P2, ESI-MS(m / z): 299.1[M+H] + ; 1 H NMR(600MHz,DMSO)δ9.39(s,1H),8.57(d,J=3.9Hz,1H),7.73(d,J=7.6Hz,1 H),7.47–7.40(m,1H),7.30(s,1H),6.17(s,1H),4.85(s,2H),2.21(s,3H).

[0306] Example 2: 7-Chloro-4-methyl-1-(2-methylpyridin-3-yl)-4,5-dihydropyrrolo[2,3,4-de]quinazolin-2(1H)-one (A2)

[0307] Step 1: Synthesis of 7-chloro-5-(methoxymethyl)-4-(methylamino)-1-(2-methylpyridin-3-yl)quinazolin-2(1H)-one

[0308] 7-Chloro-5-(methoxymethyl)-1-(2-methylpyridin-3-yl)quinazoline-2,4(1H,3H)-dione (100 mg, 0.30 mmol), phosphorus oxychloride (137 mg, 0.90 mmol), N,N-diisopropylethylamine (194 mg, 1.51 mmol), and anhydrous dioxane (5 mL) were added to a 50 mL round-bottom flask and heated to 100°C with stirring. After the reaction was completed, the reaction solution was cooled to room temperature, and then aqueous methylamine solution (5 mL) was added to the reaction solution and reacted at room temperature for 0.5 h. After the reaction, 100 mL of water was added to the reaction solution, and the mixture was extracted twice with 100 mL of ethyl acetate. The organic phases were combined, washed with water and a saturated sodium chloride solution, and concentrated to give the target product, 7-chloro-5-(methoxymethyl)-4-(methylamino)-1-(2-methylpyridin-3-yl)quinazolin-2(1H)-one (104 mg, yield 100%). ESI-MS (m / z): 345.1 [M+H] + .

[0309] Step 2: Synthesis of 7-chloro-4-methyl-1-(2-methylpyridin-3-yl)-4,5-dihydropyrrolo[2,3,4-de]quinazolin-2(1H)-one

[0310] The product from the previous step, 7-chloro-5-(methoxymethyl)-4-(methylamino)-1-(2-methylpyridin-3-yl)quinazolin-2(1H)-one (104 mg, 0.30 mmol), boron tribromide (500 μL), and dichloromethane (5 mL) were added to a 25 mL round-bottom flask and reacted overnight at room temperature. After completion of the reaction, 100 mL of water was added to the reaction solution, and the pH was adjusted to approximately 7 with sodium hydroxide. The solution was extracted twice with 100 mL of ethyl acetate. The organic phases were combined, washed sequentially with water and saturated sodium chloride solution, concentrated, and purified by column chromatography to obtain the desired product, 7-chloro-4-methyl-1-(2-methylpyridin-3-yl)-4,5-dihydropyrrolo[2,3,4-de]quinazolin-2(1H)-one (35 mg, 37% yield). ESI-MS (m / z): 313.1 [M+H]. + . 1 H NMR (600MHz, DMSO) δ8.61–8.54(m,1H),7.73–7.70(m,1H),7.43(dd,J=7.8,4 .8Hz,1H),7.31(s,1H),6.18(s,1H),4.92(s,2H),3.23(s,3H),2.21(s,3H).

[0311] Two separate atropisomers A2-P1 and A2-P2 were obtained according to the separation method of A16. A2-P1, ESI-MS (m / z): 313.1 [M+H] + . 1 H NMR (600MHz, DMSO) δ8.61–8.54(m,1H),7.73–7.70(m,1H),7.43(dd,J=7.8,4.8Hz,1H),7.31( s,1H),6.18(s,1H),4.92(s,2H),3.23(s,3H),2.21(s,3H).A2-P1, ESI-MS(m / z): 313.1[M+H] + . 1 H NMR (600MHz, DMSO) δ8.61–8.54(m,1H),7.73–7.70(m,1H),7.43(dd,J=7.8,4 .8Hz,1H),7.31(s,1H),6.18(s,1H),4.92(s,2H),3.23(s,3H),2.21(s,3H).

[0312] Example 3: 7-Chloro-4-phenyl-1-(2-methylpyridin-3-yl)-4,5-dihydropyrrolo[2,3,4-de]quinazolin-2(1H)-one (A3)

[0313] According to the synthesis method of compound A2, 7-chloro-4-phenyl-1-(2-methylpyridin-3-yl)-4,5-dihydropyrrolo[2,3,4-de]quinazolin-2(1H)-one (15 mg, yield 56%) was obtained using aniline and the like as synthetic raw materials. ESI-MS (m / z): 375.1 [M+H] + . 1 H NMR (600MHz, DMSO) δ8.61(dd,J=4.8,1.3Hz,1H),8.08(d,J=8.0Hz,2H),7.80(dd,J=7.8,1.2Hz,1H),7.51(t,J=8. 0Hz,2H),7.47(dd,J=7.8,4.9Hz,1H),7.41(s,1H),7.25(t,J=7.4Hz,1H),6.29(s,1H),5.51(s,2H),2.25(s,3H).

[0314] Two separate atropisomers A3-P1 and A3-P2 were obtained according to the separation method of A16. A3-P1, ESI-MS (m / z): 375.1 [M+H] + . 1 H NMR (600MHz, DMSO) δ8.61(dd,J=4.8,1.3Hz,1H),8.08(d,J=8.0Hz,2H),7.80(dd,J=7.8,1.2Hz,1H),7.51(t,J=8.0Hz,2H),7.47(d d,J=7.8,4.9Hz,1H),7.41(s,1H),7.25(t,J=7.4Hz,1H),6.29(s,1H),5.51(s,2H),2.25(s,3H).A3-P2, ESI-MS(m / z): 375.1[M+H] + . 1 H NMR (600MHz, DMSO) δ8.61(dd,J=4.8,1.3Hz,1H),8.08(d,J=8.0Hz,2H),7.80(dd,J=7.8,1.2Hz,1H),7.51(t,J=8. 0Hz,2H),7.47(dd,J=7.8,4.9Hz,1H),7.41(s,1H),7.25(t,J=7.4Hz,1H),6.29(s,1H),5.51(s,2H),2.25(s,3H).

[0315] Example 4: 7-Chloro-4-benzoyl-1-(2-methylpyridin-3-yl)-4,5-dihydropyrrolo[2,3,4-de]quinazolin-2(1H)-one (A4)

[0316] Compound A1 (27 mg, 0.09 mmol) and dichloromethane (5 mL) were added to a 25 mL round-bottom flask. Triethylamine (27 mg, 0.27 mmol) and benzoyl chloride (19 mg, 0.14 mmol) were added and reacted at room temperature for 2 h. After the reaction, the product was directly purified by column chromatography to obtain the target product, 7-chloro-4-benzoyl-1-(2-methylpyridin-3-yl)-4,5-dihydropyrrolo[2,3,4-de]quinazolin-2(1H)-one (25 mg, 64% yield). ESI-MS (m / z): 403.1 [M+H] + . 1 H NMR (600MHz, DMSO) δ8.60(d,J=3.7Hz,1H),7.79(d,J=7.3Hz,2H),7.75(d,J=7.3Hz,1H),7 .62(t,J=7.4Hz,1H),7.51(t,J=7.7Hz,2H),7.46-7.45(m,J=7.9,5.0Hz,2H),6.36(s,1H), 5.43(d,J=5.0Hz,2H),2.19(s,3H).

[0317] Example 5: 7-Chloro-4-methyl-1-(2-chloropyridin-3-yl)-4,5-dihydropyrrolo[2,3,4-de]quinazolin-2(1H)-one (A16)

[0318] According to the synthesis method of compound A2, 7-chloro-4-methyl-1-(2-chloropyridin-3-yl)-4,5-dihydropyrrolo[2,3,4-de]quinazolin-2(1H)-one (205 mg, yield 63%) was obtained using methylamine and the like as synthetic raw materials. ESI-MS (m / z): 333.0 [M+H] + ; 1 H NMR(600MHz,DMSO)δ8.56(dd,J=4.8Hz,1.7Hz,1H),8.04(dd,J=7.7Hz,1.7Hz,1H), 7.65(dd,J=7.7Hz,4.8Hz,1H),7.34(s,1H),6.38(s,1H),4.93(s,2H),3.23(s,3H).

[0319] Compound A16 is an axial chiral compound containing two atropisomers, as shown in the figure below:

[0320] Compound A16 was separated by supercritical fluid chromatography (SFC) (instrument: SFC 150, column: Daicel CHIRALCEL AD, 250 mm*30 mm, 10 μM, mobile phase: CO2:EtOH=70:30, flow rate: 80 g / min, wavelength: 214 nm, temperature: 35°C) to obtain compounds A16-P1 (first eluting isomer) and A16-P2 (second eluting isomer). The two compounds were then analyzed by high-performance liquid chromatography (HPLC) (instrument: Waters e2695-2998, column: IG-3 (150 mm*4.6 mm, 3 μm), mobile phase: 0.1% diethylamine in n-hexane:ethanol = 30:70, flow rate: 1.0 mL / min, wavelength: 239 nm, column temperature: 30°C). The retention time of compound A16-P1 was 4.89 min, and the retention time of compound A16-P2 was 7.73 min.

[0321] Compound A16-P1, ESI-MS (m / z): 333.0 [M+H] + ; 1 H NMR (600MHz, DMSO-d6) δ8.56 (dd, J=4.8, 1.8Hz, 1H), 8.05 (dd, J=7.8, 1.8Hz, 1H), 7.65 (dd, J=7.7,4.8Hz,1H),7.34(d,J=1.3Hz,1H),6.38(d,J=1.2Hz,1H),4.93(s,2H),3.23(s,3H).

[0322] Compound A16-P2, ESI-MS (m / z): 333.0 [M+H] + ; 1 H NMR (600MHz, DMSO-d6) δ8.56 (dd, J=4.8, 1.8Hz, 1H), 8.05 (dd, J=7.7, 1.8Hz, 1H), 7.65 (dd, J=7.7,4.8Hz,1H),7.34(d,J=1.2Hz,1H),6.38(d,J=1.2Hz,1H),4.93(s,2H),3.23(s,3H).

[0323] Example 6: 9-chloro-1-(2-methylpyridin-3-yl)-4,5,6,7-tetrahydroazepine 2,3,4-de]quinazoline-2(1H)-one (B1)

[0324] Step 1: 2-Bromo-4-chloro-6-fluorobenzamide

[0325] 2-Bromo-4-chloro-6-fluorobenzoic acid (2.5 g, 10 mmol) was added to dichloromethane (100 mL), and oxalyl chloride (3.2 g, 25 mmol) and two drops of DMF were added under ice bath, and stirred at room temperature for 1 hour. After the reaction was completed, the system was concentrated, and dioxane (100 mL) was added, and ammonia water (2.8 g, 50 mmol) was added dropwise under ice bath, and then the temperature was raised to room temperature and stirred for reaction. After the reaction was completed, the reaction solution was added to water (300 mL), extracted three times with ethyl acetate, the organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated. 2-Bromo-4-chloro-6-fluorobenzamide (2 g, yield 80%) was obtained. ESI-MS (m / z): 251.9 [M+H] + .

[0326] Step 2: 2-Bromo-4-chloro-6-fluoro-N-((2-methylpyridin-3-yl)carbamoyl)benzamide

[0327] 2-Bromo-4-chloro-6-fluorobenzamide (990 mg, 3.9 mmol) was added to tetrahydrofuran (10 mL), followed by oxalyl chloride (541 mg, 4.3 mmol), and the mixture was heated to 70°C and stirred for 1 hour. After cooling, the mixture was added dropwise to a solution of 2-methylpyridin-3-amine (426 mg, 3.9 mmol) in tetrahydrofuran (10 mL), and then stirred at room temperature for reaction. After completion of the reaction, the reaction solution was poured into water (300 mL) and extracted five times with dichloromethane. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. 2-Bromo-4-chloro-6-fluoro-N-((2-methylpyridin-3-yl)carbamoyl)benzamide (1.4 g, yield 93%) was obtained. ESI-MS (m / z): 386.0 [M+H] + .

[0328] Step 3: 5-Bromo-7-chloro-1-(2-methylpyridin-3-yl)quinazoline-2,4(1H,3H)-dione

[0329] 2-Bromo-4-chloro-6-fluoro-N-((2-methylpyridin-3-yl)carbamoyl)benzamide (560 mg, 1.45 mmol) was added to tetrahydrofuran (30 mL). 1M potassium bistrimethylsilylamide (2.9 mL, 2.9 mmol) was added dropwise under ice-cooling, and the mixture was stirred under ice-cooling. After the reaction, water (200 mL) was added to the reaction solution, and the pH was adjusted to approximately 5 with acetic acid. After stirring for several minutes, the mixture was extracted three times with ethyl acetate. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified and dried with ethyl acetate to obtain 5-bromo-7-chloro-1-(2-methylpyridin-3-yl)quinazoline-2,4(1H,3H)-dione (400 mg, 75% yield). ESI-MS (m / z): 366.0 [M+H] + ; 1 H NMR (600MHz, DMSO-d6) δ11.93(s,1H),8.65(dd,J=4.8Hz,J=1.8Hz,1H),7.85(dd,J=8.4Hz,J=1.8H z, 1H), 7.68 (d, J = 1.8Hz, 1H), 7.49 (dd, J = 7.8Hz, J = 4.8Hz, 1H), 6.30 (d, J = 1.8Hz, 1H), 2.28 (s, 3H).

[0330] Step 4: tert-Butyl 3-(7-chloro-1-(2-methylpyridin-3-yl)-2,4-dicarbonyl-1,2,3,4-tetrahydroquinazolin-5-yl)acrylate

[0331] 5-Bromo-7-chloro-1-(2-methylpyridin-3-yl)quinazoline-2,4(1H,3H)-dione (150 mg, 0.41 mmol) was added to DMF (5 mL), followed by tert-butyl acrylate (263 mg, 2.05 mmol), palladium acetate (18 mg, 0.082 mmol), tri-o-methylphenylphosphine (50 mg, 0.164 mmol), and potassium carbonate (113 mg, 0.8 mmol). The system was stirred at 140°C under an argon atmosphere. After the reaction was completed, the temperature was lowered and the reaction solution was added to water (100 mL) and extracted three times with ethyl acetate. The organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was separated and purified by thin-layer chromatography (developing solvent: dichloromethane:methanol = 20:1) to obtain tert-butyl 3-(7-chloro-1-(2-methylpyridin-3-yl)-2,4-dicarbonyl-1,2,3,4-tetrahydroquinazolin-5-yl)acrylate (120 mg, yield 71%). ESI-MS (m / z): 414.1 [M+H] + .

[0332] Step 5: tert-Butyl 3-(7-chloro-1-(2-methylpyridin-3-yl)-2,4-dicarbonyl-1,2,3,4-tetrahydroquinazolin-5-yl)propanoate

[0333] Tert-butyl 3-(7-chloro-1-(2-methylpyridin-3-yl)-2,4-dicarbonyl-1,2,3,4-tetrahydroquinazolin-5-yl)acrylate (120 mg, 0.29 mmol) was added to tetrahydrofuran (5 mL), followed by methanol (1 mL). Sodium borohydride (55 mg, 1.45 mmol) was added under ice-cooling, and the reaction was stirred at room temperature. After completion of the reaction, water (50 mL) was added to the reaction solution, which was then extracted with ethyl acetate (3 x 50 mL). The combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by thin-layer chromatography (developing solvent: dichloromethane:methanol = 20:1) to obtain tert-butyl 3-(7-chloro-1-(2-methylpyridin-3-yl)-2,4-dicarbonyl-1,2,3,4-tetrahydroquinazolin-5-yl)propanoate (100 mg, 83% yield). ESI-MS (m / z): 416.1 [M+H] + .

[0334] Step 6: tert-Butyl 3-(4-amino-7-chloro-1-(2-methylpyridin-3-yl)-2-carbonyl-1,2-dihydroquinazolin-5-yl)propanoate

[0335] tert-Butyl 3-(7-chloro-1-(2-methylpyridin-3-yl)-2,4-dicarbonyl-1,2,3,4-tetrahydroquinazolin-5-yl)propanoate (100 mg, 0.24 mmol) was added to dioxane (10 mL), followed by phosphorus oxychloride (110 mg, 0.72 mmol) and DIEA (155 mg, 1.2 mmol). The mixture was heated to 100°C and stirred for 1 hour. After cooling, aqueous ammonia (0.2 mL) was added dropwise, and the reaction was stirred at room temperature. After completion of the reaction, water (100 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (3 x 50 mL). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was separated and purified by thin-layer chromatography (developing solvent: dichloromethane:methanol = 15:1) to obtain tert-butyl 3-(4-amino-7-chloro-1-(2-methylpyridin-3-yl)-2-carbonyl-1,2-dihydroquinazolin-5-yl)propanoate (50 mg, 50% yield). ESI-MS (m / z): 415.1 [M+H] + .

[0336] Step 7: 4-amino-7-chloro-5-(3-hydroxypropyl)-1-(2-methylpyridin-3-yl)quinazolin-2(1H)-one

[0337] Tert-butyl 3-(4-amino-7-chloro-1-(2-methylpyridin-3-yl)-2-carbonyl-1,2-dihydroquinazolin-5-yl)propanoate (50 mg, 0.12 mmol) was added to tetrahydrofuran (5 mL). Lithium aluminum tetrahydride (13 mg, 0.36 mmol) was added under ice-cooling and the reaction was stirred under ice-cooling. After completion of the reaction, 1 mL of methanol was added to the reaction solution, which was concentrated and purified by thin-layer chromatography (developing solvent: dichloromethane:methanol = 10:1) to obtain 4-amino-7-chloro-5-(3-hydroxypropyl)-1-(2-methylpyridin-3-yl)quinazolin-2(1H)-one (30 mg, 73% yield). ESI-MS (m / z): 345.1 [M+H] + .

[0338] Step 8: 9-chloro-1-(2-methylpyridin-3-yl)-4,5,6,7-tetrahydroazepine 2,3,4-de]quinazoline-2(1H)-one

[0339] 4-Amino-7-chloro-5-(3-hydroxypropyl)-1-(2-methylpyridin-3-yl)quinazolin-2(1H)-one (30 mg, 0.087 mmol) was added to dichloromethane (10 mL). Methanesulfonyl chloride (9 mg, 0.087 mmol), triethylamine (18 mg, 0.18 mmol), and triphenylphosphine (33 mg, 0.132 mmol) were added and stirred at room temperature for 1 hour. Methanesulfonyl chloride (45 mg) and triethylamine (36 mg) were then added portionwise. The reaction mixture was stirred at room temperature overnight. After completion of the reaction, the mixture was quenched with a small amount of methanol, concentrated, and purified by thin-layer chromatography using a developing solvent of dichloromethane:ethyl acetate:methanol = 5:5:1. The product layers were collected, combined, rinsed, and concentrated to yield 9-chloro-1-(2-methylpyridin-3-yl)-4,5,6,7-tetrahydroazepine. [2,3,4-de]quinazolin-2(1H)-one (3.5 mg, yield 12%), ESI-MS (m / z): 327.1 [M+H] + ; 1 H NMR (600MHz, CDCl3) δ9.77(br,1H),8.66(d,J=4.8Hz,1H),7.55(d,J=7.8Hz,1H),7.37(dd,J1=7.8Hz,J2=4.8 Hz,1H),7.00(s,1H),6.24(s,1H),3.65-3.62(m,2H),3.05(t,J=7.2Hz,2H),2.36(s,3H),2.26-2.23(m,2H).

[0340] Two separate atropisomers B1-P1 and B1-P2 were obtained according to the separation method of A16. B1-P1, ESI-MS (m / z): 327.1 [M+H] + ; 1 H NMR (600MHz, CDCl3) δ9.77(br,1H),8.66(d,J=4.8Hz,1H),7.55(d,J=7.8Hz,1H),7.37(dd,J1=7.8H z,J2=4.8Hz,1H),7.00(s,1H),6.24(s,1H),3.65-3.62(m,2H),3.05(t,J=7.2Hz,2H),2.36(s,3H), 2.26-2.23(m,2H). B2-P1,ESI-MS(m / z): 327.1[M+H] + ; 1 H NMR (600MHz, CDCl3) δ9.77(br,1H),8.66(d,J=4.8Hz,1H),7.55(d,J=7.8Hz,1H),7.37(dd,J1=7.8Hz,J2=4.8 Hz,1H),7.00(s,1H),6.24(s,1H),3.65-3.62(m,2H),3.05(t,J=7.2Hz,2H),2.36(s,3H),2.26-2.23(m,2H).

[0341] Example 7: 9-chloro-1-(2-methylpyridin-3-yl)-5,6-dihydro-1H-[1,4]oxazepine [5,6,7-de]quinazolin-2(4H)-one (B2)

[0342] According to the method for synthesizing 5-bromo-7-chloro-1-(2-methylpyridin-3-yl)quinazoline-2,4(1H,3H)-dione, 7-chloro-5-fluoro-1-(2-methylpyridin-3-yl)quinazoline-2,4(1H,3H)-dione was synthesized using 4-chloro-2,6-difluorobenzoic acid and 2-methylpyridin-3-amine as raw materials. ESI-MS (m / z): 306.1 [M+H] + .

[0343] Step 1: 7-Chloro-5-fluoro-4-((2-hydroxyethyl)amino)-1-(2-methylpyridin-3-yl)quinazolin-2(1H)-one

[0344] 7-Chloro-5-fluoro-1-(2-methylpyridin-3-yl)quinazoline-2,4(1H,3H)-dione (200 mg, 0.64 mmol) and dioxane (10 mL) were added to a 100 mL round-bottom flask, and phosphorus oxychloride (292 mg, 1.92 mmol) and diisopropylethylamine (420 mg, 3.27 mmol) were added. The reaction was stirred at 100 ° C for 1 hour. After cooling, aminoethanol (200 mg, 3.27 mmol) was added and the reaction was stirred at room temperature. After the reaction, 100 mL of water was added, and the mixture was extracted three times with 300 mL of ethyl acetate. The organic phases were combined and dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to give 7-chloro-5-fluoro-4-((2-hydroxyethyl)amino)-1-(2-methylpyridin-3-yl)quinazolin-2(1H)-one (100 mg, yield 45%). ESI-MS (m / z): 349.1 [M+H] + ;

[0345] Step 2: 9-chloro-1-(2-methylpyridin-3-yl)-5,6-dihydro-1H-[1,4]oxazepine [5,6,7-de]quinazolin-2(4H)-one

[0346] The product from the previous step, 7-chloro-5-fluoro-4-((2-hydroxyethyl)amino)-1-(2-methylpyridin-3-yl)quinazolin-2(1H)-one (100 mg, 0.29 mmol) and N,N-dimethylformamide (5 mL) were added to a 100 mL round-bottom flask. Sodium hydride (23 mg, 0.57 mmol) was added under ice-bath stirring and the mixture was stirred at room temperature for reaction. After the reaction, 100 mL of water was added and the mixture was extracted twice with 200 mL of ethyl acetate. The organic phases were combined and washed twice with 100 mL of water. The organic phases were dried over anhydrous sodium sulfate, filtered, concentrated, and purified by thin-plate chromatography to obtain 9-chloro-1-(2-methylpyridin-3-yl)-5,6-dihydro-1H-[1,4]oxazepine. [5,6,7-de]quinazolin-2(4H)-one (13 mg, yield 13%), ESI-MS (m / z): 329.1 [M+H] + .

[0347] Example 8: 9-chloro-5-hydroxy-4-methyl-1-(2-methylpyridin-3-yl)-4,5,6,7-tetrahydro-[1,4]diazepine 2-[5,6,7-de]quinazolin-2(1H)-one (B3)

[0348] Step 1: 7-Chloro-5-((2,2-diethoxyethyl)amino)-1-(2-methylpyridin-3-yl)quinazoline-2,4(1H,3H)-dione

[0349] 5-Bromo-7-chloro-1-(2-methylpyridin-3-yl)quinazoline-2,4(1H,3H)-dione (500 mg, 1.37 mmol), aminoacetaldehyde diethyl acetal (364 mg, 2.74 mmol), tris(dibenzylideneacetone)dipalladium (128 mg, 0.14 mmol), 1,1'-binaphthyl-2,2'-bisdiphenylphosphine (174 mg, 0.28 mmol), sodium tert-butoxide (395 mg, 4.1 mmol) and toluene (10 mL) were added to a 100 mL round-bottom flask, the mixture was evacuated with nitrogen, and the reaction was stirred at 100°C. After the reaction, the temperature was lowered and 100 mL of water was added. The mixture was extracted twice with 200 mL of ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. After purification by column chromatography, 7-chloro-5-((2,2-diethoxyethyl)amino)-1-(2-methylpyridin-3-yl)quinazoline-2,4(1H,3H)-dione (500 mg, yield 87%) was obtained. ESI-MS (m / z): 419.1 [M+H] + .

[0350] Step 2: 7-Chloro-5-((2,2-diethoxyethyl)amino)-4-(methylamino)-1-(2-methylpyridin-3-yl)quinazolin-2(1H)-one

[0351] The product of the previous step, 7-chloro-5-((2,2-diethoxyethyl)amino)-1-(2-methylpyridin-3-yl)quinazoline-2,4(1H,3H)-dione (200 mg, 0.48 mmol) and dioxane (10 mL) were added to a 100 mL round-bottom flask, and phosphorus oxychloride (218 mg, 1.44 mmol) and diisopropylethylamine (310 mg, 2.4 mmol) were added. The reaction was stirred at 100 ° C for 1 hour. After cooling, methylamine aqueous solution was added and the reaction was stirred at room temperature. After the reaction, 100 mL of water was added, and the mixture was extracted three times with 300 mL of ethyl acetate. The organic phases were combined and dried over anhydrous sodium sulfate, filtered, and concentrated. After separation and purification by column chromatography, 7-chloro-5-((2,2-diethoxyethyl)amino)-4-(methylamino)-1-(2-methylpyridin-3-yl)quinazolin-2(1H)-one (100 mg, yield 48%) was obtained. ESI-MS (m / z): 432.2 [M+H] + .

[0352] Step 3: 9-chloro-5-hydroxy-4-methyl-1-(2-methylpyridin-3-yl)-4,5,6,7-tetrahydro-[1,4]diazepine 5,6,7-de]quinazolin-2(1H)-one

[0353] The product from the previous step, 7-chloro-5-((2,2-diethoxyethyl)amino)-4-(methylamino)-1-(2-methylpyridin-3-yl)quinazolin-2(1H)-one (100 mg, 0.23 mmol) and acetonitrile (2 mL) were added to a 100 mL round-bottom flask, concentrated hydrochloric acid (0.1 mL) was added, and the mixture was stirred at 80°C under sealed conditions. After the reaction was completed, the mixture was concentrated, 100 mL of ethyl acetate was added, and the mixture was washed twice with 100 mL of sodium bicarbonate aqueous solution. The organic phase was concentrated and purified by thin-plate chromatography to obtain 9-chloro-5-hydroxy-4-methyl-1-(2-methylpyridin-3-yl)-4,5,6,7-tetrahydro-[1,4]diazepine. 2-[5,6,7-de]quinazolin-2(1H)-one, ESI-MS (m / z): 358.1 [M+H] + ; 1 H NMR (600MHz, DMSO-d6) δ8.56(d,J=4.2Hz,1H),7.69-7.68(m,1H),7.65(t,J=7.2Hz,1H),7.419(t,J=6.0Hz,1H),6.35(d, J=1.2Hz,1H),5.25-5.23(m,2H),4.89(br,1H),3.64-3.59(m,1H),3.57-3.52(m,1H),3.16(s,3H),2.18(d,J=30Hz,3H).

[0354] Two separate atropisomers B3-P1 and B3-P2 were obtained according to the separation method of A16. B3-P1, ESI-MS (m / z): 358.1 [M+H] + ; 1 H NMR (600MHz, DMSO-d6) δ8.56(d,J=4.2Hz,1H),7.69-7.68(m,1H),7.65(t,J=7.2Hz,1H),7.419(t,J=6.0Hz,1H),6.35(d, J=1.2Hz,1H),5.25-5.23(m,2H),4.89(br,1H),3.64-3.59(m,1H),3.57-3.52(m,1H),3.16(s,3H),2.18(d,J=30Hz,3H). B3-P2, ESI-MS(m / z):358.1[M+H] + ; 1H NMR (600MHz, DMSO-d6) δ8.56(d,J=4.2Hz,1H),7.69-7.68(m,1H),7.65(t,J=7.2Hz,1H),7.419(t,J=6.0Hz,1H),6.35(d, J=1.2Hz,1H),5.25-5.23(m,2H),4.89(br,1H),3.64-3.59(m,1H),3.57-3.52(m,1H),3.16(s,3H),2.18(d,J=30Hz,3H).

[0355] Compounds A5-A15, A17-A18, A20-A28, and A30-A37 were prepared according to the corresponding synthetic methods using the corresponding intermediates as starting materials.

[0356] Example 39: 2-Methyl-5-(2-methylpyridin-3-yl)-7-(trifluoromethyl)-1,2-dihydro-2,3,5,6-tetraazonaphthalen-4(5H)-one (A19)

[0357] Step 1: Synthesis of ethyl 4-chloro-2-hydroxy-6-(trifluoromethyl)nicotinate

[0358] Ethyl 2,4-dihydroxy-6-(trifluoromethyl)nicotinate (synthesized according to the literature "Org. Process Res. Dev., 2011, 15, 788–796") (50 g, 199.1 mmol) was added to a DMF (62 mL) solution at room temperature. After thorough stirring to dissolve, the reaction flask was placed in ice water. POCl3 (122.10 g, 796 mmol) was slowly added dropwise at 0°C. After completion of the addition, the reaction was placed in an oil bath at 90°C for 1 h. LCMS confirmed the reaction was complete. A saturated solution of K2HPO4 (2.5 L) was prepared and the reaction mixture was slowly poured into it to quench the reaction. The mixture was then extracted with dichloromethane, washed with saturated brine (500 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product. The crude product was purified on a silica gel column (SiO2, DCM:MeOH = 1:0) to obtain ethyl 4-chloro-2-hydroxy-6-(trifluoromethyl)nicotinate (35 g).

[0359] Step 2: Synthesis of ethyl 2-hydroxy-6-(trifluoromethyl)-4-vinylnicotinate

[0360] The product from the previous step (5 g) and potassium vinyl trifluoroborate (4.28 g) were added to a 100 mL tetrafluoroethylene flask. H₂O (10 mL) and dioxane (40 mL) were then added. SPhos (761 mg) and K₃PO₄ (11.81 g) were added with stirring at room temperature, and Pd(OAc)₂ (416 mg) was added under a nitrogen atmosphere. The mixture was heated to 90°C and allowed to react for 48 h. LCMS monitored the reaction for completion. The reaction mixture was then concentrated under reduced pressure to remove the solvent and then purified on a silica gel column (SiO₂, DCM:MeOH = 1:0 to 10:1) to yield ethyl 2-hydroxy-6-(trifluoromethyl)-4-vinylnicotinate (2.57 g).

[0361] Step 3: Synthesis of 2-hydroxy-6-(trifluoromethyl)-4-vinylnicotinic acid

[0362] The product from the previous step (18 g, 1 eq.) was added to a mixture of MeOH (110 mL), THF (110 mL), and H₂O (55 mL) at room temperature. NaOH (6.43 g, 3 eq.) was then added. The reaction mixture was heated to 60°C and allowed to react for 16 h. LCMS confirmed the reaction was complete. The reaction mixture was then decompressed and the solvent removed, and purified to yield 2-hydroxy-6-(trifluoromethyl)-4-vinylnicotinic acid (7 g).

[0363] Step 4: Synthesis of 2-hydroxy-6-(trifluoromethyl)-4-vinylnicotinamide

[0364] The product from the previous step (7 g, 1 eq.) was dissolved in DCM (100 mL), followed by the slow addition of oxalyl chloride (9.46 g) and DMF (0.4 g). The mixture was allowed to react at room temperature for 1 hour. A sample was taken and methanol was added to confirm the reaction was complete by TLC. The reaction system was then spin-dried to dryness, and 500 mL of NH3-dioxane solution was added. The reaction was allowed to react at room temperature for 1 hour. LCMS confirmed the reaction was complete. The reaction solution was then concentrated under reduced pressure to remove the solvent and purified on a silica gel column (SiO2, DCM:MeOH = 1:0 to 5:1) to obtain 2-hydroxy-6-(trifluoromethyl)-4-vinylnicotinamide (7 g).

[0365] Step 5: 3-aminocarbonyl-6-(trifluoromethyl)-4-vinylpyridine-2-methyl p-toluenesulfonate

[0366] The product from the previous step (7 g) was added to DCM (50 mL), followed by p-toluenesulfonyl chloride (TsCl, 8.6 g), triethylamine (TEA, 7.6 g), and DMAP (375 mg). The mixture was stirred at room temperature for 2 hours. LCMS monitored the reaction for completion. The mixture was extracted with water (100 mL) and ethyl acetate. The combined organic phases were concentrated under reduced pressure to afford the crude product, which was then purified on a silica gel column (SiO2, PE:EA = 10:1 to pure DCM) to afford 3-aminocarbonyl-6-(trifluoromethyl)-4-vinylpyridine-2-methyl p-toluenesulfonate (8.5 g).

[0367] Step 6: 3-(((2-methylpyridin-3-yl)aminocarbonyl)aminocarbonyl)-6-(trifluoromethyl)-4-vinylpyridine-2-methyl p-toluenesulfonate

[0368] The product from the previous step (1.0 g) was added to THF (40 mL), followed by oxalyl chloride (0.50 mL). The mixture was then heated to 80°C and stirred for 1 hour. A sample was taken and quenched with methanol to confirm the formation of the reaction intermediate. After cooling to room temperature, 3-amino-2-methylpyridine (400 mg) was added and stirred at room temperature for one hour. LCMS monitored the reaction for completion. Aqueous acetic acid was added to adjust the pH to acidic, and the mixture was extracted with H2O (100 mL) and ethyl acetate. The organic phases were combined and concentrated under reduced pressure to yield crude 3-(((2-methylpyridin-3-yl)aminocarbonyl)aminocarbonyl)-6-(trifluoromethyl)-4-vinylpyridine-2-methyl p-toluenesulfonate (4.5 g).

[0369] Step 7: 1-(2-methylpyridin-3-yl)-7-(trifluoromethyl)-5-vinylpyrido[2,3-d]pyrimidine 2,4-(1H,3H)-dione

[0370] The product from the previous step (4.5 g) was added to acetonitrile (ACN, 50 mL), and DBU (3.9 ml) was added and stirred at room temperature for 1 h. LCMS monitored the reaction to be complete. Acetic acid was added to adjust the pH to acidic, and the mixture was directly concentrated under reduced pressure to obtain a crude product. The product 1-(2-methylpyridin-3-yl)-7-(trifluoromethyl)-5-vinylpyrido[2,3-d]pyrimidine 2,4-(1H,3H)-dione (280 mg) was obtained by purification by prep-TLC (ethyl acetate: dichloromethane = 1:4).

[0371] Step 8: Synthesis of 1-(2-methylpyridin-3-yl)-2,4-dioxo-7-(trifluoromethyl)-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-5-carboxylic acid

[0372] 1-(2-methylpyridin-3-yl)-7-(trifluoromethyl)-5-vinylpyridino[2,3-d]pyrimidine-2,4(1H,3H)-dione (472 mg, 1.356 mmol.) was added to a solution of 1,4-dioxane (20 mL) and water (10 mL) at room temperature. After sufficient stirring to dissolve, 10 drops of 1N sulfuric acid solution were added, potassium permanganate (1.07 g, 6.781 mmol.) was added, and the mixture was placed in an oil bath at 50°C to react for 1 hour. LCMS detected that the reaction was complete. Cooled to room temperature, 20 mL of methanol was added and stirred for 0.5 hours. The filter cake was then filtered through diatomaceous earth and washed with methanol. The filtrate was concentrated to obtain the product, which was directly used in the next step. ESI-MS (m / z): 367.0 [M+H] + .

[0373] Step 9: Synthesis of methyl 1-(2-methylpyridin-3-yl)-2,4-dioxo-7-(trifluoromethyl)-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-5-carboxylate

[0374] The product from the previous step was dissolved in dichloromethane (100 mL), oxalyl chloride (256 mg, 2.034 mmol.) was added, DMF (1 drop) was added, and the mixture was stirred at room temperature for 2 h. TLC showed that the reaction was complete. Methanol (20 mL) was added and stirring was continued for 0.5 h. TLC showed that the reaction was complete, and the reaction mixture was directly concentrated under reduced pressure to remove the solvent, and then passed through a silica gel column ((SiO 2, The mixture was purified by distillation with DCM:MeOH = 1:0 to 50:1) to give 1-(2-methylpyridin-3-yl)-2,4-dioxo-7-(trifluoromethyl)-1,2,3,4-tetrahydropyridine[2,3-d]pyrimidine-5-carboxylic acid methyl ester (428 mg, 83% yield over two steps) ESI-MS (m / z): 381.1 [M+H] + .

[0375] Step 10: Synthesis of methyl 1-(2-methylpyridin-3-yl)-4-(methylamino)-2-oxo-7-(trifluoromethyl)-1,2-dihydropyrido[2,3-d]pyrimidine-5-carboxylate

[0376] 1-(2-methylpyridin-3-yl)-2,4-dioxo-7-(trifluoromethyl)-1,2,3,4-tetrahydropyridine[2,3-d]pyrimidine-5-carboxylic acid methyl ester (209 mg, 0.549 mmol) was dissolved in 1,4-dioxane (10 mL), and N,N-diisopropylethylamine (708 mg, 5.490 mmol) and phosphorus oxychloride (501 mg, 3.294 mmol) were added. The reaction solution was heated to 100 ° C and reacted for 1 hour. LCMS monitoring showed that the reaction was complete. The reaction temperature was lowered to room temperature, and N,N-diisopropylethylamine (708 mg, 105.490 mmol) and methylamine hydrochloride (185 mg, 2.745 mmol) were added. The reaction was allowed to react at room temperature for 2 hours. LCMS monitoring showed that the reaction was complete. The system was directly carried out to the next step without treatment. ESI-MS (m / z): 394.1 [M+H] + .

[0377] Step 11: Synthesis of 1-(2-methylpyridin-3-yl)-5-(hydroxymethyl)-4-(methylamino)-7-(trifluoromethyl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0378] The system from the previous step was added to methanol (10 mL), and sodium borohydride (208 mg, 5.490 mmol) was added portionwise under ice-cooling. The reaction was allowed to react at room temperature for 0.5 h. LCMS monitored the reaction until completion. The product was extracted twice with 100 mL of water and 80 mL of ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure to remove the solvent. The product was purified by silica gel column chromatography (SiO2, DCM:MeOH = 1:0 to 20:1) to afford 1-(2-methylpyridin-3-yl)-5-(hydroxymethyl)-4-(methylamino)-7-(trifluoromethyl)pyrido[2,3-d]pyrimidin-2(1H)-one (28.4 mg, 14% yield over two steps). ESI-MS (m / z): 366.1 [M+H]. + .

[0379] Step 12: Synthesis of 2-methyl-5-(2-methylpyridin-3-yl)-7-(trifluoromethyl)-1,2-dihydro-2,3,5,6-tetraazonaphthalen-4(5H)-one

[0380] 1-(2-Methylpyridin-3-yl)-5-(hydroxymethyl)-4-(methylamino)-7-(trifluoromethyl)pyrido[2,3-d]pyrimidin-2(1H)-one (28 mg, 0.078 mmol) was added to DCM (5 mL), followed by triethylamine (24 mg, 0.233 mmol) and methylsulfonyl chloride (18 mg, 0.155 mmol). The mixture was stirred at room temperature for 0.5 h. LCMS confirmed the reaction was complete and the product was concentrated under reduced pressure to afford the crude product. The product was then purified on a silica gel column (SiO2, DCM:MeOH = 20:1) to afford 5-(2-methylpyridin-3-yl)-2-methyl-7-(trifluoromethyl)-1,2-dihydro-2,3,5,6-tetraazonaphthalen-4(5H)-one (11 mg, 42% yield). ESI-MS (m / z): 348.1 [M+H] + . 1 H NMR (600MHz, DMSO) δ8.53 (d, J = 4.9 Hz, 1H), 7.81 (s, 1H), 7.69 (d, J = 7.7 Hz, 1H), 7.41-7.38 (m, 1H), 5.10 (d, J = 4.5 Hz, 2H), 3.29 (s, 3H), 2.19 (s, 3H).

[0381] Two separate atropisomers, A19-P1 and A19-P2, were obtained according to the separation method of A16. A19-P1, ESI-MS (m / z): 348.1 [M+H] + . 1 H NMR (600MHz, DMSO) δ8.53 (d, J = 4.9 Hz, 1H), 7.81 (s, 1H), 7.69 (d, J = 7.7 Hz, 1H), 7.41-7.38 (m, 1H), 5.10 (d, J = 4.5 Hz, 2H), 3.29 (s, 3H), 2.19 (s, 3H). A19-P2, ESI-MS(m / z): 348.1[M+H] + . 1 H NMR (600MHz, DMSO) δ8.53 (d, J = 4.9 Hz, 1H), 7.81 (s, 1H), 7.69 (d, J = 7.7 Hz, 1H), 7.41-7.38 (m, 1H), 5.10 (d, J = 4.5 Hz, 2H), 3.29 (s, 3H), 2.19 (s, 3H).

[0382] Example 40: 5-(2-chloropyridin-3-yl)-2-methyl-7-(trifluoromethyl)-1,2-dihydro-2,3,5,6-tetraazonaphthalen-4(5H)-one (A29)

[0383] According to the synthesis method of compound A19, 3-amino-2-chloropyridine and methylamine were used as raw materials to obtain the product 5-(2-chloropyridin-3-yl)-2-methyl-7-(trifluoromethyl)-1,2-dihydro-2,3,5,6-tetraazonaphthalen-4(5H)-one (10 mg, yield 36%). ESI-MS (m / z): 368.1 [M+H] + , 1 H NMR (600MHz, CDCl3) δ8.50 (d, J = 5.04, 1H), 7.76 (d, J = 5.16, 1H), 7.51 (s, 1H), 7.44 (t, J = 5.16, 1H), 4.93 (s, 2H), 3.44 (s, 3H).

[0384] Two separate atropisomers A29-P1 and A29-P2 were obtained according to the separation method of A16. A29-P1, ESI-MS (m / z): 368.1 [M+H] + , 1 H NMR (600MHz, CDCl3) δ8.50 (d, J = 5.04, 1H), 7.76 (d, J = 5.16, 1H), 7.51 (s, 1H), 7. 44(t,J=5.16,1H),4.93(s,2H),3.44(s,3H).A29-P2, ESI-MS(m / z): 368.1[M+H] + , 1 H NMR (600MHz, CDCl3) δ8.50 (d, J = 5.04, 1H), 7.76 (d, J = 5.16, 1H), 7.51 (s, 1H), 7.44 (t, J = 5.16, 1H), 4.93 (s, 2H), 3.44 (s, 3H).

[0385] Example 41: 7-Chloro-4-(2-methyl-2H-indazol-5-yl)-1-(2-methylpyridin-3-yl)-4,5-dihydropyrrolo[2,3,4-de]quinazolin-2(1H)-one (A38)

[0386] According to the synthesis method of compound A2, 7-chloro-4-(2-methyl-2H-indazol-5-amine and 3-amino-2-methylpyridine were used as synthetic raw materials to obtain 7-chloro-4-(2-methyl-2H-indazol-5-yl)-1-(2-methylpyridin-3-yl)-4,5-dihydropyrrolo[2,3,4-de]quinazolin-2(1H)-one (5 mg, yield 60%). ESI-MS (m / z): 429.1 [M+H] + . 1H NMR (600MHz, DMSO) δ8.61(d,J=4.8Hz,1H),8.44(s,1H),8.28(d,J=1.8Hz,1H),8.02( dd,J=9.3,2.1Hz,1H),7.79(d,J=6.6Hz,1H),7.74(d,J=9.4Hz,1H),7.47(dd,J=7.8, 4.9Hz,1H),7.41(s,1H),6.28(s,1H),5.55(s,2H),4.20(s,3H),2.26(s,3H).

[0387] Two separate atropisomers were obtained according to the separation method of A16, namely A38-P1 and A38-P2. A38-P1, ESI-MS (m / z): 429.1 [M+H] + . 1 H NMR (600MHz, DMSO) δ8.61(d,J=4.8Hz,1H),8.44(s,1H),8.28(d,J=1.8Hz,1H),8.02(dd,J=9.3,2.1Hz,1H),7.79(d,J=6.6Hz,1H),7.74(d,J= 9.4Hz,1H),7.47(dd,J=7.8,4.9Hz,1H),7.41(s,1H),6.28(s,1H),5.55(s,2H),4.20(s,3H),2.26(s,3H).A38-P2, ESI-MS(m / z): 429.1[M+H] + . 1 H NMR (600MHz, DMSO) δ8.61(d,J=4.8Hz,1H),8.44(s,1H),8.28(d,J=1.8Hz,1H),8.02(dd,J=9.3,2.1Hz,1H),7.79(d,J=6.6H z,1H),7.74(d,J=9.4Hz,1H),7.47(dd,J=7.8,4.9Hz,1H),7.41(s,1H),6.28(s,1H),5.55(s,2H),4.20(s,3H),2.26(s,3H).

[0388] Example 42: 7-Chloro-4-(4-chlorophenyl)-1-(2-methylpyridin-3-yl)-4,5-dihydropyrrolo[2,3,4-de]quinazolin-2(1H)-one (A39)

[0389] According to the synthesis method of compound A2, 7-chloro-4-(4-chlorophenyl)-1-(2-methylpyridin-3-yl)-4,5-dihydropyrrolo[2,3,4-de]quinazolin-2(1H)-one (15 mg, yield 50%) was obtained using p-chloroaniline and 3-amino-2-methylpyridine as synthetic raw materials. ESI-MS (m / z): 409.1 [M+H] + . 1 H NMR (600MHz, DMSO) δ8.61(dd,J=4.8,1.3Hz,1H),8.12(d,J=9.0Hz,2H),7.82–7.77(m,1H),7.58( d,J=9.0Hz,2H),7.47(dd,J=7.8,4.8Hz,1H),7.41(s,1H),6.31(s,1H),5.50(s,2H),2.25(s,3H).

[0390] Two separate atropisomers were obtained according to the separation method of A16, namely A39-P1 and A39-P2. A39-P1, ESI-MS (m / z): 409.1 [M+H] + . 1 H NMR(600MHz, DMSO)δ8.61(dd,J=4.8,1.3Hz,1H),8.12(d,J=9.0Hz,2H),7.82–7.77(m,1H),7.58(d,J=9.0Hz,2H),7 .47(dd,J=7.8,4.8Hz,1H),7.41(s,1H),6.31(s,1H),5.50(s,2H),2.25(s,3H).A39-P2, ESI-MS(m / z): 409.1[M+H] + . 1 H NMR (600MHz, DMSO) δ8.61(dd,J=4.8,1.3Hz,1H),8.12(d,J=9.0Hz,2H),7.82–7.77(m,1H),7.58( d,J=9.0Hz,2H),7.47(dd,J=7.8,4.8Hz,1H),7.41(s,1H),6.31(s,1H),5.50(s,2H),2.25(s,3H).

[0391] Example 43: 7-Chloro-1-(2-methylpyridin-3-yl)-4,5-dihydropyrrolo[2,3,4-de]quinazolin-2(1H)-one (A40)

[0392] According to the synthesis method of compound A1, 7-chloro-1-(2-methoxypyridin-3-yl)-4-methyl-4,5-dihydropyrrolo[2,3,4-de]quinazolin-2(1H)-one (17 mg, yield 50%) was obtained using 2-methoxypyridin-3-amine and methylamine as synthetic raw materials. ESI-MS (m / z): 329.1 [M+H] + . 1 H NMR(600MHz,DMSO)δ8.30(d,J=3.8Hz,1H),7.77(d,J=7.1Hz,1H),7.28(s,1 H),7.19-7.17(m,1H),6.25(s,1H),4.90(s,2H),3.80(s,3H),3.21(s,3H).

[0393] Two separate atropisomers were obtained according to the resolution method of A16, namely A40-P1 and A40-P2. A40-P1, ESI-MS (m / z): 329.1 [M+H] + . 1 H NMR (600MHz, DMSO) δ8.30(d,J=3.8Hz,1H),7.77(d,J=7.1Hz,1H),7.28(s,1H),7.19-7.17(m ,1H),6.25(s,1H),4.90(s,2H),3.80(s,3H),3.21(s,3H).A40-P2, ESI-MS(m / z):329.1[M+H] + . 1 H NMR(600MHz,DMSO)δ8.30(d,J=3.8Hz,1H),7.77(d,J=7.1Hz,1H),7.28(s,1 H),7.19-7.17(m,1H),6.25(s,1H),4.90(s,2H),3.80(s,3H),3.21(s,3H).

[0394] Example 44: 4-Methyl-1-(2-methylpyridin-3-yl)-8-(trifluoromethyl)-5,6-dihydro-1H-pyrimido[4,5,6-ij][2,7]naphthyridin-2(4H)-one (C1)

[0395] 1-(2-methylpyridin-3-yl)-7-(trifluoromethyl)-5-vinylpyrido[2,3-d]pyrimidine 2,4-(1H,3H)-dione (100 mg, 0.287 mmol) was added to DMF (3 mL), and methylamine hydrochloride (58.16 mg, 0.861 mmol) and PyBop (448.26 mg, 0.861 mmol) were added to the reaction solution. Finally, DBU (219 mg, 1.44 mmol) was added, and the reaction solution was stirred at 20 ° C for 16 hours. LC-MS detected that the main peak was the product peak. The reaction solution was purified by preparative liquid phase to obtain the product (11.4 mg, yield 11%). ESI-MS (m / z): 362.1 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ=8.52-8.47(m,1H),7.65-7.55(m,2H),7.40-7.33(m,1H),3.85-3.76(m,2H),3.28-3.19(m,5H),2.14(s,3H).

[0396] Two separate atropisomers were obtained according to the separation method of A16, namely C1-P1 and C1-P2. C1-P1, ESI-MS (m / z): 362.1 [M+H] + . 1 H NMR(400MHz, DMSO-d6)δ=8.52-8.47(m,1H),7.65-7.55(m,2H),7.40-7.33(m,1H),3 .85-3.76(m,2H),3.28-3.19(m,5H),2.14(s,3H).C1-P2, ESI-MS(m / z):362.1[M+H] + . 1 H NMR (400MHz, DMSO-d6) δ=8.52-8.47(m,1H),7.65-7.55(m,2H),7.40-7.33(m,1H),3.85-3.76(m,2H),3.28-3.19(m,5H),2.14(s,3H).

[0397] Compounds B4-B72 and C2-C23 were prepared according to the corresponding synthetic methods using the corresponding intermediates as starting materials.

[0398] The following are the efficacy tests and data of the compounds of the present invention.

[0399] Test Example 1: Enzyme test

[0400] The inhibitory effect of the test compounds on MAT2A enzymatic activity was determined using the MAT2A inhibitor enzymatic screening kit (BPS Bioscience).

[0401] 1) Dissolve the test compound in DMSO and mix thoroughly until completely dissolved. Dilute all compounds to a starting concentration of 2 mM in DMSO. Repeat the dilution series three times to create a total of 10 concentrations. Add the compounds to the reaction at a 1:100 ratio (maximum final concentration of 20 μM) for the assay. Prepare a 100× positive control (1 mM AGI-24512) and a 100× negative control (100% DMSO).

[0402] 2) Using an Echo 550 pipetting system, transfer 200 nL of the diluted compound to each well of a Corning 3702 reaction plate. Seal the plate with a sealing film and centrifuge at 1000 g for 1 minute. The final DMSO concentration is 1%.

[0403] 3) Prepare 1× MAT2A enzyme reaction buffer: Add 1 volume of 5× MAT2A enzyme reaction buffer to 4 volumes of water and mix thoroughly.

[0404] 4) Prepare 2× MAT2A enzyme solution using 1× enzyme reaction buffer.

[0405] 5) Add 10 μL of 2×MAT2A enzyme solution to each well of a 384-well reaction plate (Corning 3702) and seal the plate with a sealing film.

[0406] 6) Centrifuge at 1000 g for 60 seconds and incubate at room temperature for 30 minutes.

[0407] 7) Prepare a 2× L-methionine and ATP mixture using 1× MAT2A enzyme reaction buffer.

[0408] 8) Add 10 μL of 2× L-methionine and ATP mixture to each well of a 384-well reaction plate (Corning 3702) and seal the plate with a sealing film. The total reaction volume is 20 μL.

[0409] 9) Centrifuge at 1000 g for 60 seconds and incubate at room temperature for 60 minutes.

[0410] 10) Prepare Colorimetric Detection Reagent.

[0411] 11) Add 20 μL of detection buffer to each well, centrifuge at 1000 g for 30 seconds, and incubate at room temperature for 15 minutes.

[0412] 12) The fluorescence signal at 630 nm was measured using a multifunctional microplate reader (PerkinElmer, Nivo).

[0413] The experimental results show that the compounds of the present invention have a strong MAT2A inhibitory effect. Exemplary compounds are shown in the table below: A stands for IC 50 ≤50nM, B represents 50nM <IC 50 ≤100nM, C represents IC 50 >100nM.

[0414] Test Example 2. Test for inhibiting cell proliferation

[0415] The specific operation procedure is as follows: treat tumor cells with compounds for 5 days and evaluate the effect of the test compound on tumor cell proliferation. - / - HCT116-WT (colorectal cancer cell) and wild-type control cells were seeded at a density of 600 cells / well in 384-well culture plates and treated with different concentrations of the test compound (starting at 20 μM, 10 concentration gradients). The cells were incubated at 37°C, 5% CO2, and saturated humidity for 5 days.

[0416] Cell proliferation was assessed using an ATP-based cell proliferation assay kit (Cell Titer Glo, Promega Corporation). Cells were equilibrated at room temperature for 30 minutes and then treated with Cell Titer Glo reagent. The culture dish was then covered with aluminum foil and shaken for 15 minutes to allow for thorough mixing and lysis. Chemiluminescence detection was performed using a multi-function microplate reader (Envision 2105, PerkinElmer). Blank wells (no cells) and DMSO control wells were set up.

[0417] The inhibition rate (IR) of the test compound was calculated using the following formula:

[0418] IR (%) = [1-(RLU compound-RLU blank control) / (RLU vehicle control-RLU blank control)] × 100%

[0419] GraphPad Prism was used for graphing, data analysis, and IC 50 calculate.

[0420] The compounds of the invention were tested in the above assays and their IC for inhibition of cell proliferation was determined. 50 , as shown in the following table.

[0421] The results showed that the test compound exhibited strong cell proliferation inhibitory activity against HCT116 MTAP knockout cells and weak cell proliferation inhibitory activity against MTAP wild-type HCT116 cells, that is, it exhibited good selectivity.

[0422] Note: When the maximum inhibition rate is less than 50%, the result is expressed as IC 50 > Maximum starting concentration.

[0423] Test Example 3. Human UGT1A1 enzyme activity test

[0424] The enzyme inhibitory activity of the compound on UGT1A1 was determined by the following procedure:

[0425] 1) Add 1 μL of 2 mM control compound (atazanavir), 1 μL of 440 μM test compound, or 1 μL of dimethyl sulfoxide (solvent control) to the culture plate. Add the main reaction solution containing a final concentration of 0.01 mg / mL UGT1A1 (Corning, 456411), 0.5 μM substrate bilirubin, and Tris buffer. Preincubate in a 37°C water bath for 10 min. The final concentration of the control compound is 10 μM, and the final concentration of the test compound is 2.2 μM.

[0426] 2) The reaction was started by adding 20 μL of UDPGA solution with a final concentration of 2 mM, reacted at 37°C for 5 min, and stopped by adding 400 μL of cold acetonitrile containing an internal standard.

[0427] 3) Vortex the sample for 5 minutes and centrifuge at 3220g for 40 minutes at 4°C. Then, transfer 100 μL of the supernatant to a new 96-well plate and analyze metabolite formation by LC-MS / MS. Calculate the percent inhibition by comparing the reduction in metabolite formation (peak area quantification) between the test drug and the control group.

[0428] UGT1A1 is involved in the metabolism of bilirubin in the body. When UGT1A1 is inhibited, bilirubin metabolism is blocked, which eventually leads to an increase in bilirubin in the body. 50 The results were greater than 50 μM, indicating that the compounds of the present invention have a low risk of inhibiting UGT1A1.

[0429] Experimental Example 4. Pharmacokinetic Study in Mice

[0430] Experimental animals: CD-1 mice (male, 22-25 g) were purchased from Beijing Weitonglihua Laboratory Animal Technology Co., Ltd.

[0431] Experimental procedures: CD-1 mice (male, 22-25 g) were intravenously injected or gavaged with the test compound. Plasma was collected from the mice 5 min, 15 min, 0.5 h, 1 h, 2 h, 4 h, 8 h, and 24 h after administration. The compound concentration was detected by LC-MS / MS to investigate its plasma clearance rate Cl and elimination half-life T 1 / 2 , peak time T max , peak concentration C max , pharmacokinetic parameters such as area under the concentration-time curve AUC, apparent distribution volume Vss, and absolute bioavailability F.

[0432] Assay Method: Analyte stock solutions were diluted in acetonitrile / water (1:1) to obtain the desired working solution concentration series. To 10 μL of blank CD1 mouse plasma, 10 μL of working solution (1, 2, 5, 10, 50, 100, 500, 1000, 5000, 10,000 ng / mL) was added to create a total volume of 20 μL of calibration standards ranging from 1 to 10,000 ng / mL (1, 2, 5, 10, 50, 100, 500, 1000, 5000, 10,000 ng / mL). Five quality control (QC) samples (2 ng / mL, 5 ng / mL, 10 ng / mL, 800 ng / mL, and 8,000 ng / mL) were prepared on the day of analysis in the same manner as the calibration standards. 20 μL of standard, 20 μL of QC sample, and 20 μL of unknown sample (10 μL of unknown sample plasma and 10 μL of blank solution) were added to 200 μL of the IS mixture containing acetonitrile to precipitate proteins. The sample was then vortexed for 3 minutes. After centrifugation at 4700 rpm at 4°C for 15 minutes, the supernatant was diluted with ultrapure water at a 1:2 (v / v) ratio. 10 μL of the diluted supernatant was then injected into the LC / MS / MS system for quantitative analysis.

[0433] Pharmacokinetic results show that the compounds of the present invention have high absolute oral bioavailability (preferred compounds can reach more than 70%), moderate clearance rate, and good dose-exposure correlation.

[0434] Test Example 5: hERG test

[0435] The potential inhibitory effect of the test articles on the hERG channel was evaluated using an automated patch clamp system. This study used a CHO cell line stably expressing the hERG gene and Cisapride as a positive control.

[0436] The CHO-hERG-DUO cell line stably expressing the hERG channel was purchased from B'SYS GmbH. Cells were cultured in F12 (HAM) medium containing 10% FBS, 100 U / mL penicillin-streptomycin, 100 μg / mL hygromycin, and 100 μg / mL G418. Cells were passaged three times weekly and maintained at approximately 80% confluence.

[0437] The test compounds were dissolved in DMSO to a stock solution with a final concentration of 10 mM; the stock solution was then serially diluted with DMSO at a ratio of 1:3 (3.33, 1.11, and 0.37 mM); the final compound concentrations were 30, 10, 3.33, 1.11, and 0.37 μM.

[0438] The blank solvent was used to establish a baseline. After the hERG current had stabilized for at least 5 minutes, the compound working solution was perfused. The hERG current was recorded for no less than 5 minutes to reach steady state, and then 5 scans were captured. If steady state was not reached within 10 minutes, the average peak current of the last 5 scans was used instead of the steady state value. The experiment was performed twice (n=2) to detect hERG current inhibition of the compound at 5 concentrations to determine the IC50.

[0439] Calculate the current inhibition percentage using the following formula.

[0440] IC was calculated using Graphpad Prism 8.0 50 .

[0441] The test results show that the preferred compounds of the present invention have no significant inhibitory effect on hERG channels within the test concentration range of this test. 50 greater than 30 μM, indicating that the compounds of the present invention have a lower risk of cardiotoxicity.

[0442] The above describes the embodiments of the present invention. However, the present invention is not limited to the above embodiments. Any modifications, equivalent replacements, improvements, etc. made within the spirit and principles of the present invention shall be included in the scope of protection of the present invention.

Claims

1. A compound as represented by formula (I), or a tautomer, stereoisomer or pharmaceutically acceptable salt thereof, having the following structure: in, Ring A is selected from C 5-10 Carbocyclic group, C 6-14 Aryl, 5-12 membered heteroaryl, 5-12 membered heterocyclyl; R 1 Selected from optionally substituted C 3-12 Carbocyclic group, C 6-14 Aryl, 5-14 membered heteroaryl, 5-14 membered heterocyclic group; the carbocyclic group, aryl, heteroaryl, heterocyclic group are optionally replaced by one or more R a replaced by; L is selected from a bond, -O-, -S-, -C 1-4 Alkylene-, -OC 1-4 Alkylene-, -C(O)-, -C(O)O-, -OC(O)-, -N(R a1 )C(O)-、-C(O)N(R a1 )-or-N(R a1 )-; the alkylene group is optionally replaced by one or more R a1 replaced by; R a Each occurrence is independently selected from deuterium, halogen, oxo, -CN, -OH, -SH, -NO2, -NH2, -W-OR a1 、-W-SR a1 、-WC(O)R a4 、-WC(O)OR a1 、-W-OC(O)R a1 、-W-OC(O)OR a1 、-WC(O)NR a2 R a3 、-WC(O)NR a2 OR a1 、-W-OC(O)NR a2 R a3 、-W-NR a2 R a3 、-W-NR a2 C(O)R a4 、-W-NR a2 C(O)OR a1 、-W-NR a2 C(O)NR a2 R a3 、-WS(O)R a4 、-WS(O)2R a4 、-W-SO2NR a2 R a3 、-W-NR a2 S(O)2R a4 、-W-OS(O)2R a4 、-W-NR a2 S(O)2NR a2 R a3 、-W-OS(O)2NR a2 R a3 、C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1- 6 alkoxy, C 1-6 Alkylthio, C 3-10 Cycloalkyl, C 3-10 Cycloalkenyl, C 6-14 Aryl, 3-12 membered heterocyclic group, 5-16 membered heteroaryl; the alkyl, alkenyl, alkynyl, alkoxy, alkylthio, cycloalkyl, cycloalkenyl, aryl, heterocyclic group, heteroaryl are optionally substituted by one or more selected from deuterium, halogen, oxo, oxime, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, C 6-14 Aryl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Substituted by a halogenated alkoxy group or a halogenated phenyl group; R a1 Each occurrence is independently hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-10 Cycloalkyl, C 6-14 Aryl, 5-12 membered heteroaryl, 3-20 membered heterocyclic group, wherein alkyl, alkoxy, cycloalkyl, aryl, heteroaryl, heterocyclic group are optionally substituted by one or more selected from halogen, deuterium, cyano, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 6-14 Aryl, C 1-6 Halogenated alkyl, C 1-6 Substituted by a halogenated alkoxy group or a halogenated phenyl group; R a2 and R a3 Each occurrence is independently hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Alkoxy, wherein alkyl, alkoxy is optionally substituted by one or more selected from halogen, deuterium, cyano, hydroxyl, amino, carboxyl, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkyl, C 3-8 Cycloalkyl, phenyl, C 1-6 Halogenated alkyl, C 1-6 substituted by a halogenated alkoxy or halogenated phenyl group; or when R a2 and R a3 When connected to the same nitrogen atom, R a2 and R a3 Together with the nitrogen atoms to which they are attached, they form groups that are substituted by halogen, hydroxyl, amino, nitro, mercapto, cyano, oxo, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-10 Cycloalkyl, 3-10 membered heterocycloalkyl, C 6-14 aryl, 5-12 membered heteroaryl, or one or more optionally substituted 3-10 membered heterocycloalkyl or 5-12 membered heteroaryl; R a4 Each occurrence is independently hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, C 6-14 Aryl, 5-12 membered heteroaryl, 3-20 membered heterocyclic group, wherein alkyl, alkoxy, cycloalkyl, aryl, heteroaryl, heterocyclic group are optionally substituted by one or more selected from halogen, deuterium, cyano, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, phenyl, C 1-6 Halogenated alkyl, C 1-6 Substituted by a halogenated alkoxy group or a halogenated phenyl group; X is N or CR 6 ; R 2 、R 3 and R 6 Each independently selected from hydrogen, deuterium, halogen, -CN, -OH, -SH, -NO2, -NH2, -W-OR b1 、-W-SR b1 、-WC(O)R b4 、-WC(O)OR b1 、-W-OC(O)R b1 、-W-OC(O)OR b1 、-WC(O)NR b2 R b3 、-WC(O)NR b2 OR b1 、-W-OC(O)NR b2 R b3 、-W-NR b2 R b3 、-W-NR b2 C(O)R b4 、-W-NR b2 C(O)OR b1 、 -W-NR b2 C(O)NR b2 R b3 、-WS(O)R b4 、-WS(O)2R b4 、-W-SO2NR b2 R b3 、-W-NR b2 S(O)2R b4 、-W-OS(O)2R b4 、-W-NR b2 S(O)2NR b2 R b3 、-W-OS(O)2NR b2 R b3 、C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1- 6 alkoxy, C 1-6 Alkylthio, C 3-10 Cycloalkyl, C 3-10 Cycloalkenyl, C 6-14 Aryl, 3-12 membered heterocyclic group, 5-16 membered heteroaryl; the alkyl, alkenyl, alkynyl, alkoxy, alkylthio, cycloalkyl, cycloalkenyl, aryl, heterocyclic group, heteroaryl are optionally substituted by one or more selected from deuterium, halogen, oxo, oxime, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, C 6-14 Aryl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Substituted by a halogenated alkoxy group or a halogenated phenyl group; R b1 Each occurrence is independently hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-10 Cycloalkyl, C 6-14 Aryl, 3-20 membered heterocyclic group, wherein alkyl, alkoxy, cycloalkyl, aryl, heterocyclic group is optionally substituted by one or more selected from halogen, deuterium, cyano, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 6-14 Aryl, C 1-6 Halogenated alkyl, C 1-6 Substituted by a halogenated alkoxy group or a halogenated phenyl group; R b2 and R b3 Each occurrence is independently hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Alkoxy, wherein alkyl, alkoxy is optionally substituted by one or more selected from halogen, deuterium, cyano, hydroxyl, amino, carboxyl, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkyl, C 3-8 Cycloalkyl, phenyl, C 1-6 Halogenated alkyl, C 1-6 substituted by a halogenated alkoxy or halogenated phenyl group; or when R b2 and R b3 When connected to the same nitrogen atom, R b2 and R b3 Together with the nitrogen atoms to which they are attached, they form groups that are substituted by halogen, hydroxyl, amino, nitro, mercapto, cyano, oxo, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-10 Cycloalkyl, 3-10 membered heterocycloalkyl, C 6-14 aryl, 5-12 membered heteroaryl, or one or more optionally substituted 3-10 membered heterocycloalkyl or 5-12 membered heteroaryl; R b4 Each occurrence is independently hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, C 6-14 Aryl, 3-20 membered heterocyclic group, wherein alkyl, alkoxy, cycloalkyl, aryl, heterocyclic group is optionally substituted by one or more selected from halogen, deuterium, cyano, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 6-14 Aryl, C 1-6 Halogenated alkyl, C 1-6 Substituted by a halogenated alkoxy group or a halogenated phenyl group; R 4 and R 5 Each independently selected from hydrogen, deuterium, halogen, oxime, -CN, -OH, -SH, -NO2, -NH2, -W-OR c1 、-W-SR c1 、-WC(O)R c4 、-WC(O)OR c1 、-W-OC(O)R c1 、-W-OC(O)OR c1 、-WC(O)NR c2 R c3 、-WC(O)NR c2 OR c1 、-W-OC(O)NR c2 R c3 、-W-NR c2 R c3 、-W-NR c2 C(O)R c4 、-W-NR c2 C(O)OR c1 、-W-NR c2 C(O)NR c2 R c3 、-WS(O)R c4 、-WS(O)2R c4 、-W-SO2NR c2 R c3 、-W-NR c2 S(O)2R c4 、-W-OS(O)2R c4 、-W-NR c2 S(O)2NR c2 R c3 、-W-OS(O)2NR c2 R c3 、C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1- 6 alkoxy, C 1-6 Alkylthio, C 3-10 Cycloalkyl, C 3-10 Cycloalkenyl, C 6-14 Aryl, 3-12 membered heterocyclic group, 5-16 membered heteroaryl; the alkyl, alkenyl, alkynyl, haloalkyl, haloalkoxy, alkoxy, alkylthio, cycloalkyl, cycloalkenyl, heterocyclic group, aryl, heteroaryl are optionally substituted with one or more R c replaced by; or R 4 and R 5 Attached to the same, adjacent or separated by one atom ring atoms, and the carbon or nitrogen atom to which it is attached together form an optionally substituted C 3-10 Cycloalkyl, C 6-14 Aryl, 5-12 membered heteroaryl, 5-12 membered heterocyclic group; the optional substitution means that the hydrogen on the substituted group is not replaced or one or more substitutable sites of the substituted group are independently selected from R c substituted by a substituent; R c independently selected from deuterium, halogen, oxime, -CN, -OH, -SH, -NO2, -NH2, -W-OR c1 、-W-SR c1 、-WC(O)R c4 、-WC(O)OR c1 、-W-OC(O)R c1 、-W-OC(O)OR c1 、-WC(O)NR c2 R c3 、-WC(O)NR c2 OR c1 、-W-OC(O)NR c2 R c3 、-W-NR c2 R c3 、-W-NR c2 C(O)R c4 、-W-NR c2 C(O)OR c1 、-W-NR c2 C(O)NR c2 R c3 、-WS(O)R c4 、-WS(O)2R c4 、-W-SO2NR c2 R c3 、-W-NR c2 S(O)2R c4 、-W-OS(O)2R c4 、-W-NR c2 S(O)2NR c2 R c3 、-W-OS(O)2NR c2 R c3 、C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-10 Cycloalkyl, C 3-10 Cycloalkenyl, 3-12 membered heterocyclyl, 5-16 membered heteroaryl; the alkyl, alkenyl, alkynyl, alkoxy, alkylthio, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl are optionally substituted by one or more selected from deuterium, halogen, oxo, oxime, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, C 6-14 Aryl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Substituted by a halogenated alkoxy group or a halogenated phenyl group; R c1 Each occurrence is independently hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-10 Cycloalkyl, C 6-14 Aryl, 3-20 membered heterocyclic group, wherein alkyl, alkoxy, cycloalkyl, aryl, heterocyclic group is optionally substituted by one or more selected from halogen, deuterium, cyano, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 6-14 Aryl, C 1-6 Halogenated alkyl, C 1-6 Substituted by a halogenated alkoxy group or a halogenated phenyl group; R c2 and R c3 Each occurrence is independently hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Alkoxy, wherein alkyl, alkoxy is optionally substituted by one or more selected from halogen, deuterium, cyano, hydroxyl, amino, carboxyl, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkyl, C 3-8 Cycloalkyl, phenyl, C 1-6 Halogenated alkyl, C 1-6 substituted by a halogenated alkoxy or halogenated phenyl group; or when R c2 and R c3 When connected to the same nitrogen atom, R c2 and R c3 Together with the nitrogen atoms to which they are attached, they form groups that are substituted by halogen, hydroxyl, amino, nitro, mercapto, cyano, oxo, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-10 Cycloalkyl, 3-10 membered heterocycloalkyl, C 6-14 aryl, 5-12 membered heteroaryl, or one or more optionally substituted 3-10 membered heterocycloalkyl or 5-12 membered heteroaryl; R c4 Each occurrence is independently hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, C 6-14 Aryl, 3-20 membered heterocyclic group, wherein alkyl, alkoxy, cycloalkyl, aryl, heterocyclic group is optionally substituted by one or more selected from halogen, deuterium, cyano, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 6-14 Aryl, C 1-6 Halogenated alkyl, C 1-6 Substituted by a halogenated alkoxy group or a halogenated phenyl group; W is selected from a bond, C 1-3 Alkylene, -OC 1-3 Alkylene, -SC 1-3 Alkylene, wherein the alkylene is optionally substituted with one or more substituents selected from deuterium, halogen, oxo, -CN, -OH, and -NH2; Unless otherwise specified, the heteroatoms in the heterocyclic group and heteroaryl group are independently selected from O, N or S, and the number of heteroatoms is 1, 2 or 3.

2. The compound according to claim 1 or its tautomer, stereoisomer or pharmaceutically acceptable salt thereof, characterized in that: Ring A is selected from C 5-10 Cycloalkyl, C 6-10 Aryl, 5-10 membered heteroaryl, 5-10 membered heterocyclic group; preferably, ring A is selected from C 5-10 Cycloalkyl, C6 aryl, 5-8 membered heteroaryl, 5-10 membered heterocyclic group; preferably, ring A is selected from C 5-10 Cycloalkyl, 5-10 membered heterocyclic group; preferably, ring A is selected from 5-10 membered heterocyclic group; preferably, ring A is selected from 5-8 membered heterocyclic group; preferably, ring A is selected from 5-7 membered heterocyclic group, heteroatoms are independently selected from O or N, and the number of heteroatoms is 1 or 2; preferably, ring A is selected from Preferably, ring A is selected from Preferably, ring A is selected from 3. The compound according to claim 1 or 2, or its tautomer, stereoisomer or pharmaceutically acceptable salt thereof, characterized in that: X is selected from N or CH; preferably, X is selected from N; preferably, X is selected from CH.

4. The compound according to any one of claims 1 to 3, or its tautomer, stereoisomer, or pharmaceutically acceptable salt thereof, characterized in that: R 1 Selected from optionally substituted C 3-10 Cycloalkyl, C 5-10 Bridged cycloalkyl, C 5-10 Condensed cycloalkyl, C 5-10 Spiroalkyl, C 6-10 Aryl, 5-10 membered heteroaryl, 5-10 membered monocyclic heterocyclic group, 5-10 membered bridged heterocyclic group, 5-10 membered fused heterocyclic group, 5-10 membered spiro heterocyclic group; the cycloalkyl, bridged cycloalkyl, fused cycloalkyl, spiro cycloalkyl, aryl, heteroaryl, monocyclic heterocyclic group, bridged heterocyclic group, fused heterocyclic group and spiro heterocyclic group are optionally replaced by one or more R a substituted; preferably, R 1 Selected from optionally substituted C 3-6 Cycloalkyl, C 5-10 Condensed cycloalkyl, C 5-10 Spiroalkyl, C 6-10 Aryl, 5-10 membered heteroaryl, 5-10 membered monocyclic heterocyclic group, 5-10 membered bridged heterocyclic group, 5-10 membered fused heterocyclic group, 5-10 membered spiro heterocyclic group; the cycloalkyl, fused cycloalkyl, spiroalkyl, aryl, heteroaryl, monocyclic heterocyclic group, bridged heterocyclic group, fused heterocyclic group and spiro heterocyclic group are optionally replaced by one or more R a substituted; preferably, R 1 Selected from optionally substituted C 6-10 Aryl, 5-10 membered heteroaryl, 5-10 membered monocyclic heterocyclic group, 5-10 membered bridged heterocyclic group, 5-10 membered fused heterocyclic group, 5-10 membered spiro heterocyclic group; the aryl, heteroaryl, monocyclic heterocyclic group, bridged heterocyclic group, fused heterocyclic group and spiro heterocyclic group are optionally substituted by one or more R a substituted; preferably, R 1 Selected from optionally substituted C 6-10 Aryl, 5-8 membered heteroaryl, 5-8 membered monocyclic heterocyclic group, 5-8 membered bridged heterocyclic group, 5-8 membered fused heterocyclic group, 5-8 membered spiro heterocyclic group; the aryl, heteroaryl, monocyclic heterocyclic group, bridged heterocyclic group, fused heterocyclic group and spiro heterocyclic group are optionally substituted by one or more R a substituted; preferably, R 1 is selected from an optionally substituted C6 aryl, a 5-8 membered heteroaryl, a 5-8 membered monocyclic heterocyclic group; the aryl, heteroaryl, monocyclic heterocyclic group is optionally substituted by one or more R a substituted; preferably, R 1 is selected from optionally substituted C6 aryl, 5-6 membered heteroaryl, 5-6 membered monocyclic heterocyclic group; the aryl, heteroaryl, monocyclic heterocyclic group is optionally substituted by one or more R a substituted; preferably, R 1 Selected from optionally substituted C6 aryl, 5-6 membered heteroaryl; the aryl, heteroaryl are optionally substituted by one or more R a substituted; preferably, R 1 Selected from optionally one or more R a substituted phenyl, pyridyl or imidazolyl; preferably, R 1 Selected from optionally one or more R a substituted pyridyl; preferably, R 1 Selected from Preferably, R 1 Selected from 5. The compound according to any one of claims 1 to 4, or a tautomer, stereoisomer, or a pharmaceutically acceptable salt thereof, characterized in that: L is selected from a bond, -O-, -S-, -C 1-4 Alkylene- or -OC 1-4 Alkylene-; the alkylene is optionally substituted by one or more substituents selected from deuterium, halogen, oxo, -CN, -OH, -NH2; preferably, L is selected from a bond, -O-, -S-, -C 1-2 Alkylene- or -OC 1-2 Alkylene-; the alkylene is optionally substituted with one or more substituents selected from deuterium, halogen, oxo, -CN, -OH, -NH2; preferably, L is selected from a bond, -O-, -S-, methylene or ethylene; the methylene or ethylene is optionally substituted with one or more substituents selected from deuterium, halogen, oxo, -CN, -OH, -NH2; preferably, L is selected from a bond, -O-, methylene or ethylene; preferably, L is selected from a bond or methylene; preferably, L is selected from a bond.

6. The compound according to any one of claims 1 to 5, or its tautomer, stereoisomer, or pharmaceutically acceptable salt thereof, characterized in that: R a Each occurrence is independently selected from deuterium, halogen, -CN, -OH, -SH, -NO2, -NH2, -W-OR a1 、-W-SR a1 、-WC(O)R a4 、-WC(O)OR a1 、-W-OC(O)R a1 、-WC(O)NR a2 R a3 、-W-OC(O)NR a2 R a3 、-W-NR a2 R a3 、-W-NR a2 C(O)R a4 、-WS(O)R a4 、-WS(O)2R a4 、-W-SO2NR a2 R a3 、-W-NR a2 S(O)2R a4 、-W-OS(O)2R a4 、C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-10 Cycloalkyl, 3-12 membered heterocyclic group, 5-16 membered heteroaryl; the alkyl, alkenyl, alkynyl, alkoxy, alkylthio, cycloalkyl, heterocyclic group, heteroaryl are optionally substituted by one or more selected from deuterium, halogen, oxo, oxime, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, phenyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Substituted by a halogenated alkoxy group or a halogenated phenyl group; preferably, R a Each occurrence is independently selected from deuterium, halogen, -CN, -OH, -SH, -NO2, -NH2, -W-OR a1 、-W-SR a1 、-WC(O)R a4 、-WC(O)OR a1 、-W-OC(O)R a1 、-WC(O)NR a2 R a3 、-W-NR a2 R a3 、-W-NR a2 C(O)R a4 、-WS(O)R a4 、-WS(O)2R a4 、-W-SO2NR a2 R a3 、-W-NR a2 S(O)2R a4 、C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-10 Cycloalkyl, 5-10 membered heterocyclic group, 5-10 membered heteroaryl; the alkyl, alkenyl, alkynyl, alkoxy, alkylthio, cycloalkyl, heterocyclic group, heteroaryl are optionally substituted by one or more selected from deuterium, halogen, oxo, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 substituted by a haloalkoxy substituent; preferably, R a Each occurrence is independently selected from deuterium, halogen, -CN, -OH, -SH, -NO2, -NH2, -W-OR a1 、-W-SR a1 、-WC(O)R a4 、-WC(O)OR a1 、-W-OC(O)R a1 、-WC(O)NR a2 R a3 、-W-NR a2 R a3 、-W-NR a2 C(O)R a4 、-WS(O)2R a4 、-W-SO2NR a2 R a3 、-W-NR a2 S(O)2R a4 、C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy; the alkyl, alkenyl, alkynyl, alkoxy may be optionally substituted with one or more selected from deuterium, halogen, oxo, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 substituted by a haloalkoxy substituent; preferably, R a Each occurrence is independently selected from deuterium, halogen, -CN, -OH, -NH2, -W-OR a1 、-W-SR a1 、-WC(O)R a4 、-WC(O)OR a1 、-W-OC(O)R a1 、-W-NR a2 C(O)R a4 、-C 1-4 Alkyl, C 1-4 Alkoxy; the alkyl and alkoxy groups are optionally substituted by one or more selected from deuterium, halogen, oxo, -CN, -OH, -NO2, -NH2, C 1-4 Alkyl, C 1-4 Alkoxy is substituted by a substituent; preferably, R a Each occurrence is independently selected from deuterium, halogen, -OH, -NH2, -W-NR a2 C(O)R a4 、C 1-4 Alkyl, C 1-4 Alkoxy; the alkyl and alkoxy groups are optionally substituted by one or more groups selected from deuterium, halogen, oxo, -OH, -NH2, C 1-4 Alkyl, C 1- 4 alkoxy, C 1-4 Halogenated alkyl, C 1-4 substituted by a haloalkoxy substituent; preferably, R a Each occurrence is independently selected from deuterium, halogen, C 1-4 Alkyl, -W-NR a2 C(O)R a4 、C 1-4 Haloalkyl; the alkyl or haloalkyl is optionally substituted with one or more deuterium; preferably, R a Each occurrence is independently selected from deuterium, halogen, C 1-4 Alkyl, C 1-4 Alkoxy, -W-NR a2 C(O)R a4 ; The alkyl or haloalkyl group is optionally substituted with one or more deuterium groups; preferably, R a Each occurrence is independently selected from deuterium, halogen, C 1-4 Alkyl, C 1-4 Alkoxy, -NHC(O)R a4 ; The alkyl group is optionally substituted with one or more deuterium groups; preferably, R a Each occurrence is independently selected from halogen, C 1-4 Alkyl, C 1-4 Alkoxy; preferably, R a Each occurrence is independently selected from deuterium, F, Cl, Br, methyl, ethyl, propyl, methoxy, ethoxy, trifluoromethyl, trifluoroethyl or -NHC(O)-phenyl; preferably, R a Each occurrence is independently selected from Cl, methyl, methoxy, or -NHC(O)-phenyl.

7. The compound according to any one of claims 1 to 6, or a tautomer, stereoisomer, or a pharmaceutically acceptable salt thereof, characterized in that: R a1 Each occurrence is independently hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 6-10 Aryl, 3-10 membered heterocyclic group, wherein alkyl, alkoxy, cycloalkyl, aryl, heterocyclic group is optionally substituted by one or more selected from halogen, deuterium, cyano, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 The heteroatoms are independently selected from O, N or S, and the number of heteroatoms is 1, 2 or 3; preferably, R a1 Each occurrence is independently hydrogen, deuterium, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 6-10 Aryl, 3-8 membered heterocyclic group, wherein alkyl, alkoxy, cycloalkyl, aryl, heterocyclic group is optionally substituted by one or more selected from halogen, deuterium, cyano, hydroxyl, amino, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl, C 1-4 substituted by a haloalkoxy substituent; preferably, R a1 Each occurrence is independently hydrogen, deuterium, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C6 aryl, 5-6 membered heterocyclic group, wherein alkyl, alkoxy, cycloalkyl, aryl, heterocyclic group is optionally substituted by one or more selected from halogen, deuterium, hydroxyl, amino, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl, C 1-4 substituted by a haloalkoxy substituent; preferably, R a1 Each occurrence is independently hydrogen, deuterium, methyl, ethyl, propyl, methoxy, ethoxy or propoxy, wherein methyl, ethyl, propyl, methoxy, ethoxy or propoxy is optionally replaced by one or more selected from halogen, deuterium, hydroxy, amino, C 1-4 Alkyl is substituted by a substituent; preferably, R a1 Each occurrence is independently hydrogen, methyl, ethyl, propyl, wherein methyl, ethyl, propyl is optionally substituted by one or more selected from halogen, deuterium, hydroxyl, amino, C 1-4 substituted by an alkyl substituent.

8. The compound according to any one of claims 1 to 7, or a tautomer, stereoisomer, or a pharmaceutically acceptable salt thereof, characterized in that: R a2 and R a3 Each occurrence is independently hydrogen, deuterium, C 1-4 Alkyl, C 1-4 Alkoxy, wherein alkyl, alkoxy is optionally substituted by one or more selected from halogen, deuterium, hydroxyl, amino, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl, C 1-4 substituted by a haloalkoxy substituent; preferably, R a2 and R a3 Each occurrence is independently hydrogen, deuterium, C 1-4 Alkyl, C 1-4 Alkoxy, wherein alkyl, alkoxy is optionally substituted by one or more selected from halogen, deuterium, hydroxyl, C 1- 4 alkyl, C 1-4 Alkoxy is substituted by a substituent; preferably, R a2 and R a3 Each occurrence is independently hydrogen, deuterium, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, wherein methyl, ethyl, propyl, methoxy, ethoxy, propoxy is optionally replaced by one or more selected from halogen, deuterium, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy is substituted by a substituent; preferably, R a2 and R a3 Each occurrence is independently hydrogen, methyl, ethyl, propyl, wherein methyl, ethyl, propyl is optionally substituted by one or more selected from halogen, deuterium, hydroxyl, amino, C 1-4 substituted by an alkyl substituent.

9. The compound according to any one of claims 1 to 8, or a tautomer, stereoisomer, or a pharmaceutically acceptable salt thereof, characterized in that: R a4 Each occurrence is independently hydrogen, deuterium, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-8 Cycloalkyl, C 6-10 Aryl, 3-10 membered heterocyclic group, wherein alkyl, alkoxy, cycloalkyl, aryl, heterocyclic group is optionally substituted by one or more selected from halogen, deuterium, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, phenyl, C 1-6 Halogenated alkyl, C 1-6 The heteroatoms are independently selected from O, N or S, and the number of heteroatoms is 1, 2 or 3; preferably, R a4 Each occurrence is independently hydrogen, deuterium, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C6 aryl, 3-8 membered heterocyclic group, wherein alkyl, alkoxy, cycloalkyl, aryl, heterocyclic group is optionally substituted by one or more selected from halogen, deuterium, hydroxyl, amino, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl, C 1-4 substituted by a haloalkoxy substituent; preferably, R a4 Each occurrence is independently hydrogen, deuterium, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C6 aryl, wherein alkyl, alkoxy, cycloalkyl, aryl are optionally substituted by one or more selected from halogen, deuterium, hydroxyl, amino, C 1-4 Alkyl, C 1-4 Alkoxy is substituted by a substituent; preferably, R a4 Each occurrence is independently hydrogen, deuterium, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, cyclopropane, cyclobutane or phenyl; wherein methyl, ethyl, propyl, methoxy, ethoxy, propoxy, cyclopropane, cyclobutane or phenyl is optionally replaced by one or more selected from halogen, deuterium, hydroxy, amino, C 1-4 Alkyl, C 1-4 Alkoxy is substituted by a substituent; preferably, R a4 Each occurrence is independently hydrogen, deuterium, methyl, ethyl, propyl, methoxy, ethoxy, propoxy or phenyl; wherein methyl, ethyl, propyl, methoxy, ethoxy, propoxy or phenyl is optionally replaced by one or more selected from halogen, deuterium, hydroxy, amino, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent.

10. The compound according to any one of claims 1 to 9, or a tautomer, stereoisomer, or a pharmaceutically acceptable salt thereof, characterized in that: R 2 Selected from hydrogen, deuterium, halogen, -CN, -OH, -SH, -NO2, -NH2, -W-OR b1 、-W-SR b1 、-WC(O)R b4 、-WC(O)OR b1 、-W-OC(O)R b1 、-W-OC(O)OR b1 、-WC(O)NR b2 R b3 、-WC(O)NR b2 OR b1 、-W-NR b2 R b3 、-W-NR b2 C(O)R b4 、-W-NR b2 C(O)NR b2 R b3 、-WS(O)R b4 、-WS(O)2R b4 、-W-SO2NR b2 R b3 、-W-NR b2 S(O)2R b4 、-W-OS(O)2R b4 、C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-6 Cycloalkyl, C 6-12 Aryl, 3-6 membered heterocyclic group, 5-12 membered heteroaryl; the alkyl, alkenyl, alkynyl, haloalkyl, haloalkoxy, alkoxy, alkylthio, cycloalkyl, aryl, heterocyclic group, heteroaryl are optionally substituted by one or more selected from deuterium, halogen, oxo, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 substituted by a haloalkoxy substituent; preferably, R 2 Selected from hydrogen, deuterium, halogen, -CN, -OH, -SH, -NO2, -NH2, -W-OR b1 、-W-SR b1 、-WC(O)R b4 、-WC(O)OR b1 、-W-OC(O)R b1 、-W-OC(O)OR b1 、-WC(O)NR b2 R b3 、-WC(O)NR b2 OR b1 、-W-NR b2 R b3 、-W-NR b2 C(O)R b4 、-W-NR b2 C(O)NR b2 R b3 、-WS(O)R b4 、-WS(O)2R b4 、-W-SO2NR b2 R b3 、-W-NR b2 S(O)2R b4 、-W-OS(O)2R b4 、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-6 Cycloalkyl, C 6-12 Aryl, 5-6 membered heterocyclic group, 5-6 membered heteroaryl; the alkyl, alkenyl, alkynyl, haloalkyl, haloalkoxy, alkoxy, alkylthio, cycloalkyl, aryl, heterocyclic group, heteroaryl are optionally substituted by one or more selected from deuterium, halogen, oxo, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 substituted by a haloalkoxy substituent; preferably, R 2 Selected from hydrogen, deuterium, halogen, -CN, -OH, -SH, -NO2, -NH2, -W-OR b1 、-W-SO2NR b2 R b3 、-W-NR b2 S(O)2R b4 、C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C6 aryl; the alkyl, alkoxy, cycloalkyl, aryl are optionally substituted by one or more selected from deuterium, halogen, oxo, -CN, -OH, -NO2, -NH2, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl, C 1-4 substituted by a haloalkoxy substituent; preferably, R 2 Selected from hydrogen, deuterium, halogen, -CN, -OH, -SH, -NO2, -NH2, methyl, ethyl, isopropyl, methoxy, ethoxy, propoxy, -W-SO2NR b2 R b3 、-W-NR b2 S(O)2R b4 The methyl, ethyl, isopropyl, methoxy, ethoxy, propoxy group may be replaced by one or more selected from deuterium, halogen, oxo, -CN, -OH, -NO2, -NH2, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl, C 1-4 substituted by a haloalkoxy substituent; preferably, R 2 is selected from hydrogen, deuterium, halogen, -CN, -OH, -NH2, methyl, ethyl, isopropyl, -SO2NH2, -NHSO2H; preferably, R 2 Selected from hydrogen.

11. The compound according to any one of claims 1 to 10, or a tautomer, stereoisomer, or a pharmaceutically acceptable salt thereof, characterized in that: R 3 Selected from hydrogen, deuterium, halogen, -CN, -OH, -SH, -NO2, -NH2, -W-OR b1 、-W-SR b1 、-WC(O)R b4 、-WC(O)OR b1 、-W-OC(O)R b1 、-W-OC(O)OR b1 、-WC(O)NR b2 R b3 、-WC(O)NR b2 OR b1 、-W-NR b2 R b3 、-W-NR b2 C(O)R b4 、-W-NR b2 C(O)NR b2 R b3 、-WS(O)R b4 、-WS(O)2R b4 、-W-SO2NR b2 R b3 、-W-NR b2 S(O)2R b4 、-W-OS(O)2R b4 、C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-6 Cycloalkyl, C 6-12 Aryl, 3-6 membered heterocyclic group, 5-10 membered heteroaryl; the alkyl, alkenyl, alkynyl, haloalkyl, haloalkoxy, alkoxy, alkylthio, cycloalkyl, aryl, heterocyclic group, heteroaryl are optionally substituted by one or more selected from deuterium, halogen, oxo, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 substituted by a haloalkoxy substituent; preferably, R 3 Selected from hydrogen, deuterium, halogen, -CN, -OH, -SH, -NO2, -NH2, -W-OR b1 、-W-SR b1 、-WC(O)R b4 、-WC(O)OR b1 、-W-OC(O)R b1 、-W-OC(O)OR b1 、-WC(O)NR b2 R b3 、-WC(O)NR b2 OR b1 、-W-NR b2 R b3 、-W-NR b2 C(O)R b4 、-W-NR b2 C(O)NR b2 R b3 、-WS(O)R b4 、-WS(O)2R b4 、-W-SO2NR b2 R b3 、-W-NR b2 S(O)2R b4 、-W-OS(O)2R b4 、C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkoxy, C 1-4 Alkylthio, C 3-6 Cycloalkyl, C 6- Aryl, 3-6 membered heterocyclic group, 5-6 membered heteroaryl; the alkyl, alkenyl, alkynyl, alkoxy, alkylthio, cycloalkyl, aryl, heterocyclic group, heteroaryl are optionally substituted by one or more selected from deuterium, halogen, oxo, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1- 6 haloalkoxy substituents; preferably, R 3 Selected from hydrogen, deuterium, halogen, -CN, -OH, -NH2, -W-OR b1 、-W-SR b1 、-WC(O)R b4 、-WC(O)OR b1 、-W-OC(O)R b1 、-WC(O)NR b2 R b3 、-W-NR b2 R b3 、-W-NR b2 C(O)R b4 、-W-NR b2 C(O)NR b2 R b3 、-WS(O)R b4 、-WS(O)2R b4 、C 1-4 Alkyl, C 1-4 Alkoxy, C 3- 6-cycloalkyl, C6-aryl, 3-6-membered heterocyclic group, 5-6-membered heteroaryl; the alkyl, alkoxy, cycloalkyl, aryl, heterocyclic group, heteroaryl are optionally substituted by one or more selected from deuterium, halogen, oxo, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 substituted by a haloalkoxy substituent; preferably, R 3 Selected from hydrogen, deuterium, halogen, -OH, -NH2, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, 5-6 membered heterocyclic group; the alkyl, alkoxy, cycloalkyl, heterocyclic group may be substituted by one or more selected from deuterium, halogen, oxo, -CN, -OH, -NO2, -NH2, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl, C 1-4 substituted by a haloalkoxy substituent; preferably, R 3 is selected from F, Cl, Br, -CF3, -CHF2-CH2, -CH2FCH3, -OCF3 or cyclopropane; preferably, R 3 Selected from Cl or -CF3; preferably, R 3 is selected from halogen, C optionally substituted by one or more halogens 1-4 Alkyl; preferably, R 3 Selected from halogen; preferably, R 3 Selected from Cl.

12. The compound according to any one of claims 1 to 11, or a tautomer, stereoisomer, or a pharmaceutically acceptable salt thereof, characterized in that: R b1 Each occurrence is independently hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Alkoxy, C 3- 6 cycloalkyl, C 6-10 Aryl, 3-10 membered heterocyclic group, wherein alkyl, alkoxy, cycloalkyl, aryl, heterocyclic group is optionally substituted by one or more selected from halogen, deuterium, cyano, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 substituted by a haloalkoxy substituent; preferably, R b1 Each occurrence is independently hydrogen, deuterium, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 6-10 Aryl, 3-8 membered heterocyclic group, wherein alkyl, alkoxy, cycloalkyl, aryl, heterocyclic group is optionally substituted by one or more selected from halogen, deuterium, cyano, hydroxyl, amino, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl, C 1-4 substituted by a haloalkoxy substituent; preferably, R b1 Each occurrence is independently hydrogen, deuterium, C 1-4 Alkyl, C 1- 4 alkoxy, C 3-6 Cycloalkyl, C6 aryl, 5-6 membered heterocyclic group, wherein alkyl, alkoxy, cycloalkyl, aryl, heterocyclic group is optionally substituted by one or more selected from halogen, deuterium, hydroxyl, amino, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl, C 1- 4 haloalkoxy substituents; preferably, R b1 Each occurrence is independently hydrogen, deuterium, methyl, ethyl, propyl, methoxy, ethoxy or propoxy, wherein methyl, ethyl, propyl, methoxy, ethoxy or propoxy is optionally replaced by one or more selected from halogen, deuterium, hydroxy, amino, C 1-4 Alkyl is substituted by a substituent; preferably, R b1 Each occurrence is independently hydrogen, methyl, ethyl, propyl, wherein methyl, ethyl, propyl is optionally substituted by one or more selected from halogen, deuterium, hydroxyl, amino, C 1-4 substituted by an alkyl substituent.

13. The compound according to any one of claims 1 to 12, or a tautomer, stereoisomer, or a pharmaceutically acceptable salt thereof, characterized in that: R b2 and R b3 Each occurrence is independently hydrogen, deuterium, C 1-4 Alkyl, C 1-4 Alkoxy, wherein alkyl, alkoxy is optionally substituted by one or more selected from halogen, deuterium, hydroxyl, amino, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl, C 1-4 substituted by a haloalkoxy substituent; preferably, R b2 and R b3 Each occurrence is independently hydrogen, deuterium, C 1-4 Alkyl, C 1-4 Alkoxy, wherein alkyl, alkoxy is optionally substituted by one or more selected from halogen, deuterium, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy is substituted by a substituent; preferably, R b2 and R b3 Each occurrence is independently hydrogen, deuterium, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, wherein methyl, ethyl, propyl, methoxy, ethoxy, propoxy is optionally replaced by one or more selected from halogen, deuterium, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy is substituted by a substituent; preferably, R b2 and R b3 Each occurrence is independently hydrogen, methyl, ethyl, propyl, wherein methyl, ethyl, propyl is optionally substituted by one or more selected from halogen, deuterium, hydroxyl, amino, C 1-4 substituted by an alkyl substituent.

14. The compound according to any one of claims 1 to 13, or a tautomer, stereoisomer, or a pharmaceutically acceptable salt thereof, characterized in that: R b4 Each occurrence is independently hydrogen, deuterium, C 1-4 Alkyl, C 1-4 Alkoxy, C 3- 8 cycloalkyl, C 6-10 Aryl, 3-10 membered heterocyclic group, wherein alkyl, alkoxy, cycloalkyl, aryl, heterocyclic group is optionally substituted by one or more selected from halogen, deuterium, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, phenyl, C 1-6 Halogenated alkyl, C 1-6 Substituted by a halogenated alkoxy group or a halogenated phenyl group; preferably, R b4 Each occurrence is independently hydrogen, deuterium, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C6 aryl, 3-8 membered heterocyclic group, wherein alkyl, alkoxy, cycloalkyl, aryl, heterocyclic group is optionally substituted by one or more selected from halogen, deuterium, hydroxyl, amino, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl, C 1-4 substituted by a haloalkoxy substituent; preferably, R b4 Each occurrence is independently hydrogen, deuterium, C 1-4 Alkyl, C 1- 4 alkoxy, C 3-6 Cycloalkyl, C6 aryl, wherein alkyl, alkoxy, cycloalkyl, aryl are optionally substituted by one or more selected from halogen, deuterium, hydroxyl, amino, C 1-4 Alkyl, C 1-4 Alkoxy is substituted by a substituent; preferably, R b4 Each occurrence is independently hydrogen, deuterium, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, cyclopropane, cyclobutane or phenyl; wherein methyl, ethyl, propyl, methoxy, ethoxy, propoxy, cyclopropane, cyclobutane or phenyl is optionally replaced by one or more selected from halogen, deuterium, hydroxy, amino, C 1-4 Alkyl, C 1-4 Alkoxy is substituted by a substituent; preferably, R b4 Each occurrence is independently hydrogen, deuterium, methyl, ethyl, propyl, methoxy, ethoxy or propoxy; wherein methyl, ethyl, propyl, methoxy, ethoxy, propoxy, optionally substituted by one or more selected from halogen, deuterium, hydroxy, amino, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent.

15. The compound according to any one of claims 1 to 14, or a tautomer, stereoisomer, or a pharmaceutically acceptable salt thereof, characterized in that: R 4 and R 5 Each independently selected from hydrogen, deuterium, halogen, -CN, -OH, -SH, -NO2, -NH2, -W-OR c1 、-W-SR c1 、-WC(O)R c4 、-WC(O)OR c1 、-W-OC(O)R c1 、-W-OC(O)OR c1 、-WC(O)NR c2 R c3 、-WC(O)NR c2 OR c1 、-W-OC(O)NR c2 R c3 、-W-NR c2 R c3 、-W-NR c2 C(O)R c4 、-W-NR c2 C(O)NR c2 R c3 、-WS(O)R c4 、-WS(O)2R c4 、-W-SO2NR c2 R c3 、-W-NR c2 S(O)2R c4 、-W-OS(O)2R c4 、C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-8 Cycloalkyl, C 3-8 Cycloalkenyl, C 6-12 Aryl, 4-12 membered heterocyclic group, 5-12 membered heteroaryl; the alkyl, alkoxy, alkylthio, cycloalkyl, cycloalkenyl, aryl, heterocyclic group, heteroaryl are optionally replaced by one or more R c replaced by; or R 4 and R 5 Attached to the same, adjacent or separated by one atom ring atoms, and the carbon or nitrogen atom to which it is attached together form an optionally substituted C 3-10 Cycloalkyl, C 6-12 Aryl, 5-12 membered heteroaryl, 5-12 membered heterocyclic group; the optional substitution means that the hydrogen on the substituted group is not replaced or one or more substitutable sites of the substituted group are independently selected from R c Preferably, R 4 and R 5 Each independently selected from hydrogen, deuterium, halogen, -CN, -OH, -SH, -NO2, -NH2, -W-OR c1 、-W-SR c1 、-WC(O)R c4 、-WC(O)OR c1 、-W-OC(O)R c1 、-W-OC(O)OR c1 、-WC(O)NR c2 R c3 、-WC(O)NR c2 OR c1 、-W-OC(O)NR c2 R c3 、-W-NR c2 R c3 、-W-NR c2 C(O)R c4 、-W-NR c2 C(O)NR c2 R c3 、-WS(O)R c4 、-WS(O)2R c4 、-W-SO2NR c2 R c3 、-W-NR c2 S(O)2R c4 、-W-OS(O)2R c4 、C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Alkylthio, C 3-6 Cycloalkyl, C 4-6 Cycloalkenyl, C 6-12 Aryl, 4-10 membered heterocyclic group, 5-12 membered heteroaryl; the alkyl, alkoxy, alkylthio, cycloalkyl, cycloalkenyl, aryl, heterocyclic group, heteroaryl are optionally replaced by one or more R c replaced by; or R 4 and R 5 Attached to the same, adjacent or separated by one atom ring atoms, and the carbon or nitrogen atom to which it is attached together form an optionally substituted C 3-10 Cycloalkyl, C 6-12 Aryl, 5-12 membered heteroaryl, 5-12 membered heterocyclic group; the optional substitution means that the hydrogen on the substituted group is not replaced or one or more substitutable sites of the substituted group are independently selected from R c Preferably, R 4 and R 5 Each independently selected from hydrogen, deuterium, halogen, -CN, -OH, -NH2, -W-OR c1 、-W-SR c1 、-WC(O)R c4 、-WC(O)OR c1 、-W-OC(O)R c1 、-WC(O)NR c2 R c3 、-W-OC(O)NR c2 R c3 、-W-NR c2 R c3 、-W-NR c2 C(O)R c4 、-WS(O)R c4 、-WS(O)2R c4 、-W-SO2NR c2 R c3 、-W-NR c2 S(O)2R c4 、-W-OS(O)2R c4 、C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Alkylthio, C 3-6 Cycloalkyl, C 4-6 Cycloalkenyl, C6 aryl, 4-10 membered heterocyclic group, 5-12 membered heteroaryl; the alkyl, alkoxy, alkylthio, cycloalkyl, cycloalkenyl, aryl, heterocyclic group, heteroaryl are optionally replaced by one or more R c substituted; heteroatoms are independently selected from O, N or S, the number of heteroatoms is 1, 2 or 3; preferably, R 4 and R 5 Each independently selected from hydrogen, deuterium, halogen, -OH, -WC(O)NR c2 R c3 、-W-NR c2 R c3 、-W-SO2NR c2 R c3 、-WC(O)R c4 、-WS(O)2R c4 、C 1-4 Alkyl, C 3-6 Cycloalkyl, 4-10 membered heterocyclic group, C 6-12 Aryl or 5-10 membered heteroaryl; the alkyl, cycloalkyl, heterocyclic, phenyl or heteroaryl group is optionally replaced by one or more R c replaced by; or R 4 and R 5 The carbon or nitrogen atom to which it is attached together forms an optionally substituted C 3-10 Cycloalkyl, 5-12 membered heterocyclic group; the optional substitution means that the hydrogen on the substituted group is not replaced or one or more substitutable sites of the substituted group are independently selected from R c substituted by a substituent; Preferably, R 4 For hydrogen, deuterium, halogen, -OH, C 1-4 Alkyl, C 1-4 Alkoxy, 4-6 membered heterocycloalkyl; the alkyl, alkoxy, azetidinyl or pyrrolidinyl are optionally substituted by one or more R c Replaced by; R 5 Selected from hydrogen, deuterium, halogen, -OH, -WC(O)NR c2 R c3 、-W-NR c2 R c3 、-W-SO2NR c2 R c3 、-WC(O)R c4 、-WS(O)2R c4 、C 1-4 Alkyl, C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, phenyl or 9-10 membered heteroaryl; the alkyl, cycloalkyl, heterocycloalkyl, phenyl or heteroaryl is optionally replaced by one or more R c replaced by; Preferably, R 4 is hydrogen, deuterium, halogen, -OH, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, azetidinyl or pyrrolidinyl; said methyl, ethyl, propyl, methoxy, ethoxy, propoxy, azetidinyl or pyrrolidinyl is optionally replaced by one or more R c Replaced by; R 5 Selected from hydrogen, deuterium, halogen, -OH, -WC(O)NR c2 R c3 、-W-NR c2 R c3 、-W-SO2NR c2 R c3 、-WC(O)R c4 、-WS(O)2R c4 , methyl, ethyl, propyl, methoxy, ethoxy, propoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, pyrrolidinyl, phenyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, benzopyrazolyl; the methyl, ethyl, propyl, methoxy, ethoxy, propoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, pyrrolidinyl, phenyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, benzopyrazolyl is optionally replaced by one or more R c replaced by; Preferably, R 4 is hydrogen, halogen, -OH, methyl, ethyl, propyl, methoxy, ethoxy, azetidinyl or pyrrolidinyl; said methyl, ethyl, propyl, methoxy, ethoxy, azetidinyl or pyrrolidinyl is optionally replaced by one or more R c Replaced by; R 5 Selected from hydrogen, halogen, -OH, -C 1-3 Alkylene-C(O)NR c2 R c3 、-C 1-3 Alkylene-NR c2 R c3 、-C 1-3 Alkylene-SO2NR c2 R c3 、-C(O)R c4 、-S(O)2R c4 , methyl, ethyl, phenyl, cyclopropyl, cyclobutyl, phenyl, pyridyl, benzopyrazolyl; the methyl, ethyl, phenyl, cyclopropyl, cyclobutyl, phenyl, pyridyl, benzopyrazolyl are optionally replaced by one or more R c replaced by; Preferably, R 4 For hydrogen, deuterium, halogen, -OH, methyl, R 5 Selected from hydrogen, methyl, phenyl, benzoyl, -SO2CH3, Preferably, R 4 is hydrogen, halogen, -OH or methyl; R 5 Selected from hydrogen, methyl, phenyl, benzoyl, -SO2CH3, Preferably, R 4 is hydrogen; R 5 Selected from hydrogen, C 1-6 Alkyl, optionally substituted by one or more R c substituted phenyl, 9-10 membered bicyclic heteroaryl; preferably, R 4 is hydrogen; R 5 Selected from hydrogen, C 1-4 Alkyl, optionally substituted by one or more halogen, -OH, C 1-4 phenyl optionally substituted by alkyl, 9-10 membered bicyclic heteroaryl; preferably, R 4 is hydrogen; R 5 Selected from hydrogen, C 1-4 Alkyl, phenyl optionally substituted by one or more -F, -Cl, -Br, -OH, methyl, ethyl, n-propyl, isopropyl, 9-10 membered bicyclic heteroaryl; the heteroatom in the heteroaryl is selected from N, and the number of heteroatoms is 1, 2, or 3.

16. The compound according to any one of claims 1 to 15, or a tautomer, stereoisomer, or a pharmaceutically acceptable salt thereof, characterized in that: R c independently selected from deuterium, halogen, oxime, -CN, -OH, -SH, -NO2, -NH2, -W-OR c1 、-W-SR c1 、-WC(O)R c4 、-WC(O)OR c1 、-W-OC(O)R c1 、-W-OC(O)OR c1 、-WC(O)NR c2 R c3 、-WC(O)NR c2 OR c1 、-W-OC(O)NR c2 R c3 、-W-NR c2 R c3 、-W-NR c2 C(O)R c4 、-W-NR c2 C(O)OR c1 、-W-NR c2 C(O)NR c2 R c3 、-WS(O)R c4 、-WS(O)2R c4 、-W-SO2NR c2 R c3 、-W-NR c2 S(O)2R c4 、-W-OS(O)2R c4 、-W-NR c2 S(O)2NR c2 R c3 、-W-OS(O)2NR c2 R c3 、C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-10 Cycloalkyl, C 3- 10 Cycloalkenyl, C 6-12 Aryl, 3-12 membered heterocyclic group, 5-16 membered heteroaryl; the alkyl, alkenyl, alkynyl, haloalkyl, haloalkoxy, alkoxy, alkylthio, cycloalkyl, cycloalkenyl, heterocyclic group, heteroaryl are optionally substituted by one or more selected from deuterium, halogen, oxo, oxime, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, C 6-14 Aryl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Substituted by a halogenated alkoxy group or a halogenated phenyl group; Preferably, R c independently selected from deuterium, halogen, oxime, -CN, -OH, -SH, -NO2, -NH2, -W-OR c1 、-W-SR c1 、-WC(O)R c4 、-WC(O)OR c1 、-W-OC(O)R c1 、-W-OC(O)OR c1 、-WC(O)NR c2 R c3 、-WC(O)NR c2 OR c1 、-W-OC(O)NR c2 R c3 、-W-NR c2 R c3 、-W-NR c2 C(O)R c4 、-W-NR c2 C(O)OR c1 、-W-NR c2 C(O)NR c2 R c3 、-WS(O)R c4 、-WS(O)2R c4 、-W-SO2NR c2 R c3 、-W-NR c2 S(O)2R c4 、-W-OS(O)2R c4 、-W-NR c2 S(O)2NR c2 R c3 、-W-OS(O)2NR c2 R c3 、C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1- 6 haloalkyl, C 1-6 Halogenated alkoxy, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-10 Cycloalkyl, C 3-10 Cycloalkenyl, C 6-12 Aryl, 3-12 membered heterocyclic group, 5-16 membered heteroaryl; the alkyl, alkenyl, alkynyl, haloalkyl, haloalkoxy, alkoxy, alkylthio, cycloalkyl, cycloalkenyl, heterocyclic group, heteroaryl are optionally substituted by one or more selected from deuterium, halogen, oxo, oxime, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, C 6-14 Aryl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Substituted by a halogenated alkoxy group or a halogenated phenyl group; Preferably, R c independently selected from deuterium, halogen, oxime, -CN, -OH, -SH, -NO2, -NH2, -W-OR c1 、-W-SR c1 、-WC(O)R c4 、-WC(O)OR c1 、-W-OC(O)R c1 、-W-OC(O)OR c1 、-WC(O)NR c2 R c3 、-WC(O)NR c2 OR c1 、-W-OC(O)NR c2 R c3 、-W-NR c2 R c3 、-W-NR c2 C(O)R c4 、-W-NR c2 C(O)OR c1 、-W-NR c2 C(O)NR c2 R c3 、-WS(O)R c4 、-WS(O)2R c4 、-W-SO2NR c2 R c3 、-W-NR c2 S(O)2R c4 、-W-OS(O)2R c4 、-W-NR c2 S(O)2NR c2 R c3 、-W-OS(O)2NR c2 R c3 、C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1- 6 haloalkyl, C 1-6 Halogenated alkoxy, C 1-6 Alkoxy, C 1-6 Alkylthio, C 3-10 Cycloalkyl, C 3-10 Cycloalkenyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl; the alkyl, alkenyl, alkynyl, haloalkyl, haloalkoxy, alkoxy, alkylthio, cycloalkyl, cycloalkenyl, heterocyclic, heteroaryl may be substituted with one or more selected from deuterium, halogen, oxo, oxime, -CN, -OH, -NO2, -NH2, C 1-6 Alkyl, C 6-14 Aryl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Substituted by a halogenated alkoxy group or a halogenated phenyl group; Preferably, R c Independently selected from deuterium, halogen, -CN, -OH, -SH, -NH2, -W-OR c1 、-W-SR c1 、-WC(O)R c4 、-WC(O)OR c1 、-W-OC(O)R c1 、-WC(O)NR c2 R c3 、-W-NR c2 R c3 、-W-NR c2 C(O)R c4 、-WS(O)2R c4 、-W-SO2NR c2 R c3 、-W-NR c2 S(O)2R c4 、C 1-4 Alkyl, C 1-4 Alkoxy, C 3-8 Cycloalkyl, 4-8 membered heterocyclic group, C 6- 12 Aryl, 5-8 membered heteroaryl; the alkyl, alkenyl, alkynyl, alkoxy, alkylthio, cycloalkyl, cycloalkenyl, hetero Cyclic group, heteroaryl group is optionally substituted by one or more selected from deuterium, halogen, oxo, oxime, -CN, -OH, -NO2, -NH2, C 1- 4 alkyl, C 6-12 Aryl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl, C 1-4 substituted by a haloalkoxy substituent; Preferably, R c Independently selected from deuterium, halogen, -CN, -OH, -SH, -NH2, -W-OR c1 、-W-SR c1 、-WC(O)R c4 、-WC(O)OR c1 、-W-OC(O)R c1 、-WC(O)NR c2 R c3 、-W-NR c2 R c3 、-W-NR c2 C(O)R c4 、-WS(O)2R c4 、-W-SO2NR c2 R c3 、-W-NR c2 S(O)2R c4 、C 1-4 Alkyl, C 1-4 Alkoxy, C 3-8 Cycloalkyl, 4-8 membered heterocyclyl, C6 aryl, 5-6 membered heteroaryl; the alkyl, alkenyl, alkynyl, alkoxy, alkylthio, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl are optionally substituted by one or more selected from deuterium, halogen, oxo, oxime, -CN, -OH, -NO2, -NH2, C 1-4 Alkyl, C 6-12 Aryl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl, C 1-4 substituted by a haloalkoxy substituent; Preferably, R c Independently selected from deuterium, halogen, -CN, -OH, -W-OR c1 、-WC(O)NR c2 R c3 、-W-NR c2 R c3 、-W-SO2NR c2 R c3 、C 1-4 Alkyl, 4-8 membered heterocyclic group; the heterocyclic group is optionally substituted by one or more selected from deuterium, halogen, -OH, C 1-4 Alkyl C 1-4 Halogenated alkyl, C 1-4 substituted by a haloalkoxy substituent; Preferably, R c Independently selected from -F, -Cl, -Br, -CH2-OH, -OH, -C(O)NH-CH3, -N(CH3)2, -SO2CH3, -SO2N(CH3)2, morpholinyl, methyl, ethyl, n-propyl, isopropyl.

17. The compound according to any one of claims 1 to 16, or a tautomer, stereoisomer, or a pharmaceutically acceptable salt thereof, characterized in that: R c1 Each occurrence is independently hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 6-10 Aryl, 3-10 membered heterocyclic group, wherein alkyl, alkoxy, cycloalkyl, aryl, heterocyclic group is optionally substituted by one or more selected from halogen, deuterium, cyano, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 substituted by a haloalkoxy substituent; preferably, R c1 Each occurrence is independently hydrogen, deuterium, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 6-10 Aryl, 3-8 membered heterocyclic group, wherein alkyl, alkoxy, cycloalkyl, aryl, heterocyclic group is optionally substituted by one or more selected from halogen, deuterium, cyano, hydroxyl, amino, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl, C 1- 4 haloalkoxy substituents; preferably, R c1 Each occurrence is independently hydrogen, deuterium, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C6 aryl, 5-6 membered heterocyclic group, wherein alkyl, alkoxy, cycloalkyl, aryl, heterocyclic group is optionally substituted by one or more selected from halogen, deuterium, hydroxyl, amino, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl, C 1-4 substituted by a haloalkoxy substituent; preferably, R c1 Each occurrence is independently hydrogen, deuterium, methyl, ethyl, propyl, methoxy, ethoxy or propoxy, wherein methyl, ethyl, propyl, methoxy, ethoxy or propoxy is optionally replaced by one or more selected from halogen, deuterium, hydroxy, amino, C 1-4 Alkyl is substituted by a substituent; preferably, R c1 Each occurrence is independently hydrogen, methyl, ethyl, propyl, wherein methyl, ethyl, propyl is optionally substituted by one or more selected from halogen, deuterium, hydroxyl, amino, C 1-4 substituted by an alkyl substituent.

18. The compound according to any one of claims 1 to 17, or a tautomer, stereoisomer, or a pharmaceutically acceptable salt thereof, characterized in that R c4 Each occurrence is independently hydrogen, deuterium, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-8 Cycloalkyl, C 6-10 Aryl, 3-10 membered heterocyclic group, wherein alkyl, alkoxy, cycloalkyl, aryl, heterocyclic group is optionally substituted by one or more selected from halogen, deuterium, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, phenyl, C 1-6 Halogenated alkyl, C 1-6 Substituted by a halogenated alkoxy group or a halogenated phenyl group; preferably, R c4 Each occurrence is independently hydrogen, deuterium, C 1-4 Alkyl, C 1- 4 alkoxy, C 3-6 Cycloalkyl, C6 aryl, 3-8 membered heterocyclic group, wherein alkyl, alkoxy, cycloalkyl, aryl, heterocyclic group is optionally substituted by one or more selected from halogen, deuterium, hydroxyl, amino, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl, C 1- 4 haloalkoxy substituents; preferably, R c4 Each occurrence is independently hydrogen, deuterium, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C6 aryl, wherein alkyl, alkoxy, cycloalkyl, aryl are optionally substituted by one or more selected from halogen, deuterium, hydroxyl, amino, C 1-4 Alkyl, C 1-4 Alkoxy is substituted by a substituent; preferably, R c4 Each occurrence is independently hydrogen, deuterium, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, cyclopropane, cyclobutane or phenyl; wherein methyl, ethyl, propyl, methoxy, ethoxy, propoxy, cyclopropane, cyclobutane or phenyl is optionally replaced by one or more selected from halogen, deuterium, hydroxy, amino, C 1-4 Alkyl, C 1-4 Alkoxy is substituted by a substituent; preferably, R c4 Each occurrence is independently hydrogen, deuterium, methyl, ethyl, propyl, methoxy, ethoxy or propoxy; wherein methyl, ethyl, propyl, methoxy, ethoxy, propoxy, optionally substituted by one or more selected from halogen, deuterium, hydroxy, amino, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent.

19. The compound according to any one of claims 1 to 18, or a tautomer, stereoisomer, or a pharmaceutically acceptable salt thereof, characterized in that: W is selected from a bond, C 1-3 Alkylene, wherein the alkylene is optionally substituted by one or more substituents selected from deuterium, halogen, oxo, -CN, -OH, -NH2; preferably, W is selected from a bond, C 1-3 Alkylene, wherein the alkylene is optionally substituted with one or more substituents selected from deuterium, halogen, oxo, -CN, -OH, -NH2; preferably, W is selected from a bond, methylene or ethylene, wherein the methylene or ethylene is optionally substituted with one or more substituents selected from deuterium, halogen, oxo, -CN, -OH, -NH2.

20. An atropisomer of a compound represented by formula (III-a), (III-b), (III-c), (III-d) or (III-e) or a pharmaceutically acceptable salt of the atropisomer: where R 1 、R 2 、R 3 、R 4 、R 5 、R 6 and X is as described in the compound shown in claim 1-18 formula (I), wherein L is a bond, R 1 At least one R a replaced.

21. The atropisomer of the compound according to claim 20 or a pharmaceutically acceptable salt thereof: preferably, R 1 Selected from optionally one or more R a substituted pyridyl; preferably, R a Each occurrence is independently selected from Cl, methyl, methoxy; further preferably, R 1 Selected from 22. A compound selected from the group consisting of:

23. A pharmaceutical composition, characterized in that: Comprising the compound according to any one of claims 1 to 22 or its tautomer, stereoisomer or pharmaceutically acceptable salt, and optional pharmaceutically acceptable excipients.

24. Use of the compound according to any one of claims 1 to 22, or its tautomer, stereoisomer or pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 23, in the preparation of a medicament for preventing and / or treating diseases, disorders and conditions mediated by MAT2A, preferably, the diseases, disorders and conditions are tumors with MTAP deficiency, further preferably, the tumors include solid tumors and hematological tumors; the solid tumors include colorectal cancer.

25. Use of the compound according to any one of claims 1 to 22, or its tautomer, stereoisomer, or pharmaceutically acceptable salt, or the pharmaceutical composition according to claim 23, in the preparation of a medicament for preventing and / or treating tumors.

26. A pharmaceutical composition, characterized in that: The invention comprises the compound according to any one of claims 1 to 22 or its tautomer, stereoisomer or pharmaceutically acceptable salt, or the pharmaceutical composition according to claim 23 and another, two or more drugs having tumor-suppressing activity.